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Abstract 
Mono-ADP-ribosylation is a reversible post-translational protein modification that 
modulates the function of proteins involved in different cellular processes, 
including signal transduction, protein transport, transcription, cell cycle regulation, 
DNA (deoxyribonucleic acid) repair and apoptosis. In mammals, mono-ADP-
ribosylation is catalyzed by three different classes of enzymes: ARTCs, ARTDs, and 
members of the sirtuin family.  
In the present study, hARTC1-mediated mono-ADP-ribosylation was investigated 
in terms of the cellular compartments involved, target(s) and roles. The collected 
results demonstrated that hARTC1 protein and enzymatic activity is mainly 
localized to the endoplasmic reticulum (ER), in contrast to other ARTCs, which are 
either typically GPI-anchored enzymes in the plasma membrane, or secreted 
enzymes. Previous studies in my laboratory demonstrated that a protein macro 
domain was useful for the study of APD-ribosylation. The data reported here 
indicate, for the first time, that the macro domain can be used for 
immunofluorescence, allowing visualization of ADP-ribosylated proteins in intact 
cells, and in far-Western Blotting, allowing the detection of specific ADP-
ribosylated targets. These methodologies were employed to demonstrate that the 
ER-localized chaperone, GRP78/BiP, was a prime target of hARTC1. A doubly 
mutated hARTC1 mutant was designed, and used as a specific control for hARTC1 
expression. The mutant enzyme localized to the ER, but did not catalyze 
GRP78/BiP ADP-ribosylation.   
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The demonstration that GRP78/BiP was mono-ADP-ribosylated by hARTC1 
suggested that hARTC1 could be a key regulator of GRP78/BiP-mediated 
functions. Consistent with the key role of GRP78/BiP in the ER stress response, it 
was found that hARTC1 was activated during short-term cell treatment with ER 
stressors, resulting in acute GRP78/BiP ADP-ribosylation. However, the mono-
ADP-ribosylation of the chaperone did not trigger an unfolded protein response. 
Recently, hARTC1 has been associated with cancer, suggesting a possible role in 
cell proliferation. In line with these findings, the results presented here 
demonstrated that hARTC1 over-expression inhibited cell proliferation.  
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Chapter 1 
Introduction 
The function of proteins is frequently modulated by covalent modifications 
introduced after translation from RNA (ribonucleic acid). These covalent 
modifications are defined as post-translational modifications (PTMs), and they 
represent an essential mechanism used by cells to diversify protein functions and 
dynamically coordinate their signaling networks (Figure 1.1; Khoury, G.A. et al., 
2011). Defects in PTMs have been linked to numerous developmental disorders 
and human diseases, highlighting the importance of PTMs in maintaining normal 
cellular states.  
PTMs generally refers to the covalent addition of a functional group, or groups, to 
a protein, as in the most extensively studied case of phosphorylation, but proteins 
can also be modified by acetylation, glycosylation and nitrosylation. However, 
other frequently encountered PTMs consist of the conjugation of other proteins 
or peptides (e.g., ubiquitination, SUMOylation), changing of the chemical nature 
(e.g., deamidation, citrullination), or alterations in the structure (e.g., disulfide bond 
formation) of proteins (Figure 1.1; Khoury, G.A. et al., 2011).  
17 
 
 
Taken from Ribet, D. and Cossart, P., 2010 
Figure 1.1 The most common and important post-translational modifications (PTMs). PTMs 
can be distinguished based on the modification of the chemical structure of amino acid 
side chains, addition of chemical groups or complex molecules to specific amino acids, 
covalent linkage of polypeptides, and cleavage of the peptide bond between two amino 
acids. 
Among the other PTMs, adenosine diphosphate (ADP)-ribosylation is receiving 
increasing attention due to its involvement in both physiological and 
pathophysiological processes, such as signal transduction, protein transport, 
transcription, DNA repair pathways, cell cycle regulation, apoptosis and necrosis. 
There are also increasing numbers of reports that link ADP-ribosylation to human 
diseases, including inflammation, neurodegeneration and cancer metastasis 
(Butepage, M. et al., 2015; Fabrizio, G. et al., 2015a; Gupte, R. et al., 2017).  
ADP-ribosylation was discovered more than five decades ago and during the 
intervening years of research numerous enzymes, and some of their targets, have 
been isolated and characterized. The reaction, catalyzed by enzymes found in 
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organisms ranging from prokaryotes to mammals, consists of the enzymatic 
transfer of ADP-ribose from nicotinamide adenine dinucleotide (NAD+) to 
acceptor proteins. In viruses and prokaryotes, ADP-ribosylation is mainly, but not 
exclusively, a mechanism used to take control of the host cell. In mammals, ADP-
ribosylation serves to regulate protein functions, including cell-surface, nuclear 
and cytosolic proteins. 
The effects of ADP-ribosylation are counteracted via enzymes that can reverse this 
PTM. By cleaving the covalent bond and releasing the ADP-ribose moiety the 
target protein is de-modified, but may also be subject to further modification. 
Three classes of proteins have been demonstrated to perform the reverse reaction: 
the ADP-ribosyl-hydrolases (ARHs), the poly-ADP-ribose-glycohydrolases 
(PARGs) and the macro-domain–containing proteins (Verheugd, P. et al., 2016). 
Some of the members of this last class have been only recently described as 
enzymes able to remove ADP-ribose modifications (Jankevicius, G. et al., 2013; 
Rosenthal, F. et al., 2013).  
1.1 The ADP-ribosylation reactions 
The transfer of ADP-ribose to a target protein can occur by non-enzymatic or 
enzymatic mechanism. In the first case, the reaction is known as glycation and it 
involves the covalent binding of ADP-ribose to reactive nucleophilic amino acid 
residues, primarily lysines and cysteines. Specifically, the ADP-ribose moiety can 
be non-enzymatically attached to a lysine residue through a keto-amine bond, or 
to a cysteine residue through either a thiazolidine or S-glycosidic bond 
19 
 
(Cervantes–Laurean, D. et al., 1996; McDonald, L.J. et al., 1992; McDonald, L.J. and 
Moss, J., 1993). The free ADP-ribose required for the reaction is produced as part 
of the turnover of either cyclic ADP-ribose or ADP-ribose polymers, or by 
hydrolysis of pre-existing ADP-ribosylated proteins. An example of physiologically 
relevant in vivo glycation is that of histone H1, which has been associated with 
various disease conditions (Cervantes–Laurean, D. et al., 1996; Rouf Mir, A. and 
Bashir, Y., 2015). 
In the second case, the reaction is catalyzed by specific enzymes known as ADP-
ribosyl-transferases (ARTs). ARTs cleave the N-glyosidic bond of β-NAD+ 
producing a positively charged oxocarbenium intermediate which is subjected to 
a nucleophilic attack by either a single (mono-ADP-ribosylation) or multiple (poly-
ADP-ribosylation) ADP-ribose moieties (Figure 1.2; Sung, V.M., 2015; Verheugd, P. 
et al., 2016). Besides the difference in the length of the ADP-ribose chain that they 
form, enzymatic ADP-ribosylation reactions differ also for the chemical nature of 
the ADP-ribosyl-protein bond. Ueda and Hayaishi were the first that distinguished 
between the nucleophilic attack by the guanidine group of arginine and that by 
the hydroxyl group of glutamic acid. The nucleophilic attack by the guanidine 
group of arginine leads to the formation of an N-glycosidic bond and is catalyzed 
by NAD-arginine ARTs. The nucleophilic attack by the hydroxyl group of glutamic 
acid, instead, leads to the formation of an O-glycosidic bond and is catalyzed by 
NAD-glutamate ARTs (Ueda, K. and Hayaishi, O., 1985). Moreover, the enzymatic 
ADP-ribosylation reactions differ also for the cell compartment in which they take 
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place, as initially reported by Shall (cytoplasm and cell membrane versus nucleus; 
Shall, S., 1995).  
 
Figure 1.2 Cellular enzymatic ADP-ribosylation reactions. Cellular transferase enzymes can use 
NAD to catalyze either mono-ADP-ribosylation, attaching a single ADP-ribose molecule to 
target protein, or poly-ADP-ribosylation, catalyzing a multiple ADP-ribose chain elongation 
and branching. 
Currently, 22 human genes encoding proteins with ADP-ribosyl-transferase 
activity have been discovered, but recent structural and enzymological evidences 
demonstrate that earlier proposed names and classifications of ARTs are no longer 
accurate. This earlier classification distinguished ADP-ribosylating enzymes as 
ADP-ribosyl-transferases (ARTs) or poly-ADP-ribose-polymerases (PARPs). For this 
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reason, a new nomenclature has been suggested for all ART enzymes. This new 
classification distinguishes clostridia-toxin-like ARTs (mono-ARTs; see Chapter 1.2) 
and diphtheria-toxin-like ARTs (mono- and poly-ARTs; see Chapter 1.3), with 
acronyms respectively ARTC and ARTD and numbers specifying the different 
proteins of the family (Table 1.1; Hottiger, M.O. et al., 2010).  
 
Table 1.1 The new proposed classification of human ARTs.  
Example of the new classification of human ARTD and ARTC enzymes, compared to the old 
protein classification. Family members are numbered on the basis of similarities in amino acid 
sequence, structure of the catalytic domain and postulated catalytic reaction. Several accession 
numbers denote individual isoforms. b Pseudogene in humans; Art2 is duplicated in the mouse. 
Modified from Hottiger, M.O. et al., 2010. 
The ARTC family is composed of a relatively small group of structurally related 
ecto-mono-ARTs, expressed at the cell surface or secreted into the extracellular 
compartment (Glowacki, G. et al., 2002; Koch-Nolte, F. et al., 2008). The ARTD is a 
large family of 17 proteins that comprises both poly-ARTs and mono-ARTs (Ame, 
J.C. et al., 2004; Hassa, P.O. et al., 2006; Hassa and Hottiger, 2008; Otto, H. et al., 
2005; Schreiber, V. et al., 2006). Additionally, some members of the sirtuin family 
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have also been reported to catalyze ADP-ribosylation reactions under certain 
conditions, even though sirtuins are structurally distinct from ARTs and their 
predominant enzymatic activity is NAD+-dependent protein deacetylation (Hawse, 
W.F. and Wolberger, C., 2009). 
From a functional point of view, ADP-ribosylation reactions were originally 
identified as the mechanism of action of various bacterial toxins (Honjo, T. et al., 
1968). Subsequently, they have also been discovered in bacteriophages and in 
eukaryotic cells. Viruses, like bacteriophage T4, use mono-ADP-ribosylation to 
regulate transcription and impose their genetic program over infected host cells 
(Alawneh, A.M. et al., 2016; Fabrizio, G. et al., 2015a; Goff, C.G., 1974; Laing, S. et 
al., 2011).  
Diphtheria, cholera, pertussis, clostridia and many other bacterial toxins are mono-
ARTs that can modify specific host proteins after their translocation into the 
mammalian host cell, resulting in pathological situations (Corda, D. and Di 
Girolamo, M., 2003; Di Girolamo, M. et al., 2005; Fabrizio, G. et al., 2015a; Holbourn, 
K.P. et al., 2006). However, bacteria use mono-ADP-ribosylation not only as a 
pathogenic mechanism, but also as a physiological mechanism to regulate certain 
own cellular functions. A well-known example is the mono-ADP-ribosylation of the 
enzyme dinitrogenase reductase involved in the nitrogen fixation of the 
photosynthetic bacterium Rodospirillum rubrum (Ludden, P.W. and Burris, R.H., 
1976; Ludden, P.W., 1994; Nordlund, S. and Hogbom, M., 2013).  
The finding that bacteria use mono-ADP-ribosylation to mimic eukaryotic cellular 
functions prompted investigators to looking for endogenous relatives of bacterial 
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toxins in animal cells. The first researchers who described mono-ADP-ribosylation 
in animals were Moss and colleagues, who were successful in purifying an ART 
from turkey erythrocytes (Moss, J. and Vaughan, M., 1978). Subsequently, other 
mono-ARTs were isolated from different vertebrate tissues. Particularly, proteins 
with ADP-ribosylation activity were purified from rabbit skeletal muscle and 
chicken bone marrow cells (Peterson, J.E. et al., 1990; Tsuchiya, M. et al., 1994; 
Zolkiewska, A. et al., 1992).   
1.2 The ADP-ribosyl-transferases clostridia toxin-like (ARTCs) 
The eukaryotic mono-ARTs family comprises seven members (ART1-7). In 
mammals only six mono-ARTs have been found (ART1, ART2.1 and ART2.2, ART3, 
ART4 and ART5), whereas three further forms have been described in birds 
(ART6A, ART6B and ART7; Okazaki, I.J. and Moss, J., 1999). According to the new 
nomenclature, the mammalian ecto-mono-ART family has been categorized as 
ARTCs (Hottiger, M.O. et al., 2010). The small group of proteins that composed the 
ARTC family has been numbered on the basis of similarities in amino acid 
sequence, structure of the catalytic domain and postulated catalytic reaction 
(Hottiger, M.O. et al., 2010). In humans, there are only four ARTCs, that are either 
active mono-ARTs (human [h]ARTC1, hARTC5) or inactive proteins (hARTC3, 
hARTC4). The gene encoding for ARTC2, which is duplicated in mouse and rat, is 
a pseudogene in humans that arises from three premature exonic stop codons 
(Koch-Nolte, F. et al., 1997; Prochazka, M., et al., 1991; Haag, F. et al., 1994).  
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The exon/intron structures of all human ARTCs, determined by comparative 
sequencing of full-length cDNA and genomic DNA clones, revealed that artc 
genes are composed of 3 to 11 exons. In each gene, a single long exon encodes 
most of the native protein, including the catalytic domain (Figure 1.3). Separate 
exons encode the N- and the C-terminal signal peptides. The gene for hARTC4 
does not contain any additional coding exons, whereas the genes for hARTC1 and 
hARTC5 possess one additional small exon encoding the C-terminal end, and the 
gene for hARTC3 contains several small exons in this region. Moreover, the 5’ 
untranslated region of hARTC1, hARTC3 and hARTC5 is split into several distinct 
exons (Glowacki, G. et al., 2002). The last 3’ exons of hARTC1, hARTC3 and hARTC4 
end in a stretch of hydrophobic amino acids that is a typical feature of GPI 
(glycosylphosphatidylinisotol)-anchored membrane proteins. These findings 
suggest that these enzymes are all ecto-enzymes anchored to the cell membrane. 
The only exception is that of hARTC5, which lacks this region and thus represents 
the only secreted enzyme (Glowacki, G. et al., 2002; Okazaki, I.J. and Moss, J., 1999; 
Stilla, A. et al., 2011).  
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Modified from Glowacki, G. et al., 2002 
Figure 1.3 Exon-intron structures of human and mouse ART genes. Introns are shown as 
lines and exons as boxes; the coding regions are depicted in red. The numbers indicate 
lengths of exons and introns in base pairs. Corresponding exons in ART orthologs are 
indicated by arrows.  
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From a topological point of view, the C-terminal region of ARTCs is folded into β-
sheets, which is characteristic of GPI-anchored membrane proteins, whereas their 
N-terminus is an α-helix–rich region, a feature that represents a typical signal 
sequence for extracellular proteins. The catalytic domain of ARTCs can be divided 
into three different regions: an N-terminal region, which contains a conserved 
arginine residue; a central region, which is characterized by the serine-x-serine 
motif (where x can be threonine, serine or alanine) and is involved in the binding 
of NAD, and a C-terminal highly acidic region, which contains the catalytically 
crucial glutamate residue (Domenighini, M. et al., 1994; Domenighini, M., and 
Rappuoli, R., 1996). The crystal structure of rat ART2.2 has been determined and 
its comparison with several bacterial ARTs and chicken PARP crystal structures, 
revealed a common topology of the catalytic domain (Mueller-Dieckmann, C. et 
al., 2002). The catalytic domain is composed of a central six-stranded β-sheet and 
an α-helix that form the upper and the lower parts of the active sites (Choe, S. et 
al., 1992; Han, S. et al., 1999; Mueller-Dieckmann, C. et al., 2002). The strictly 
conserved glutamic acid is positioned in the fifth β-strand, whereas the other two 
residues that compose the conserved triad (arginine and serine) are positioned in 
the first and in the second β-strand, respectively (Bazan, J.F. and Koch-Nolte, F., 
1997; Carrol, S.F. and Collier, R.J., 1984; Domenighini, M., and Rappuoli, R., 1996; 
Koch-Nolte, F. et al, 1996). Furthermore, a second important glutamic acid was 
found two residues upstream of the catalytic glutamate, in the loop connecting 
the fourth and fifth β-strands.  
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The loop preceding the glutamic acid is likely to be involved in the contact of the 
ARTs with target proteins and, therefore, in the control of target specificity (Han, 
S. et al., 2001). Mutational studies in ARTC1 from rabbit demonstrated that the 
conserved catalytic glutamate is necessary for the transfer of ADP-ribose on the 
arginine within the target protein, and that the neighbouring glutamate is equally 
important for the transfer (Hara, N. et al., 1996). Substitution of this second 
glutamic acid determines the abrogation of ADP-ribose transfer on arginine in 
several ARTCs. As shown by Stilla et al., the single mutation of the catalytic 
glutamate in ARTC2.1 of hamster (cARTC2.1) still resulted in a partial ADP-ribosyl-
transferase activity (Stilla, A. et al., 2011). However, it was completely abolished with 
the additional mutation of the neighbouring glutamate, by which both the 
glutamate residues of the R-S-EXE motif were mutated (Stilla, A. et al., 2011). These 
findings support the hypothesis that this region is important for substrate 
recognition.   
The sequence arginine-serine-glutamate (R-S-EXE) is typical of the arginine-
specific ARTs. It was found in all the active ARTC enzymes: ARTC1, ARTC2 and 
ARTC5, whereas the motif is missing in ARTC3 and ARTC4 (Table 1.2; Friedrich, M. 
et al., 2006; Koch-Nolte, F. et al., 1997). Thus, they do not have measurable activities 
and their roles in cell biology are independent of ART activity, a situation that is 
also seen in the ARTD family and in the sirtuin family.  
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Table 1.2 Mammalian ARTC family.  
 
 
* secreted enzyme 
1.2.1 The active ARTCs 
1.2.1.1 ARTC1  
ARTC1 was the first mammalian arginine-specific ART to have been discovered. It 
is a 36 kDa (kilodalton) protein that was initially isolated and characterized from 
rabbit skeletal muscle microsomal membranes (Peterson, J.E. et al., 1990; 
Zolkiewska, A. et al., 1992). Subsequent studies revealed the protein was conserved 
among different species such as human, rabbit and mouse and that it was 
preferentially expressed at high level in cardiac and skeletal muscle (Okazaki, I.J. et 
al., 1996a).  
The ARTC1 mono-ART activity has been fully described in myogenically 
differentiated cultured mouse skeletal muscle (C2C12) cells. As reported by 
Zolkiewska and Moss, the substrate of ARTC1 was the cell surface adhesion 
molecule integrin α7, whose ADP-ribosylation was suggested to have a role in 
myogenesis. Increased levels of ADP-ribosylation were observed during the 
differentiation of these cells into myotubes (Zolkiewska, A. and Moss, J., 1993). 
Integrins are integral membrane proteins with a role as receptors in mediating 
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cell-substratum and cell-cell adhesion. Signals from the extracellular matrix 
transduced by integrins control cell growth, shape, migration and differentiation. 
The selective expression of ARTC1 and integrin α7 in both cardiac and skeletal 
muscle, their similar developmental appearance, and the specific ADP-
ribosylation, are consistent with the regulatory association between these two 
proteins. It has been suggested that mono-ADP-ribosylation of integrin α7 may 
modulate receptor signaling and could play a significant role in cell adhesion and 
in outside-insight cell signaling (Zolkiewska, A. and Moss, J., 1993). 
Another identified substrate of ARTC1 is the human defensin human neutrophil 
peptide 1, (HNP-1), an arginine-rich peptide that is considered to be the major 
component of innate antimicrobial immunity (Paone, G. et al., 2002). It is also 
involved in adaptive immunity, since cytokine stimulation of human natural killer 
cells and T- and B-lymphocytes leads to the production of defensins. HNP-1 is 
mono-ADP-ribosylated by ARTC1 on arginine 14, as demonstrated by in vitro 
assays (Paone, G. et al., 2002). ADP-ribosylation alters its biological properties, 
decreasing cytotoxic and antimicrobial activity, whereas its ability to release 
interleukin 8 (IL-8) from epithelial cells is significantly increased. However, ADP-
ribosylated HNP-1 retains its function as chemoattractant for recruiting leukocytes, 
similarly to the unmodified protein (Stevens, L.A. et al., 2009). It is possible that, 
once modified, HNP-1 acquires specific biological properties that can still result in 
the recruitment of neutrophils (after the release of IL-8 from epithelial cells), but 
also in the modulation of its own antimicrobial and cytotoxic activities (Paone, G. 
et al., 2002). This last aspect is extremely important considering the identification 
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of ADP-ribosylated HNP-1 also in vivo, in bronchoalveolar lavage fluids (BALF) of 
some smoker patients. This observation supports the idea that ADP-ribosylated 
HNP-1 is produced during the inflammatory response when it loses its 
antimicrobial activity (Paone, G. et al., 2002). 
Additional substrates of ARTC1 have been identified in various different cell lines 
overexpressing this enzyme, and these include growth factors and membrane 
receptors. The basic fibroblast growth factor 2 (FGF-2) was demonstrated to 
undergo ADP-ribosylation in ARTC1-transfected rat mammary adenocarcinoma 
(NMU) cells (Boulle, N. et al., 1995; Jones, E.M. and Baird, A., 1997). FGF-2 has a 
specific extracellular receptor (FGFR), which was initially detected on the surface of 
adult bovine aortic endothelial and human hepatoma cells. As FGF-2 has a high 
affinity for heparin, it is localized and possibly sequestered by the heparin sulfates 
on the cell surface and in the extracellular matrix. Because heparin is an inhibitor 
of the ADP-ribosylation reaction, the heparin binding of FGF-2 and its ADP-
ribosylation are mutually exclusive. Moreover, the ADP-ribosylated site of FGF-2 is 
located in its receptor-binding domain and, thus, it is possible that ADP-
ribosylation modulates the binding of FGF-2 to its receptor and to heparin, 
regulating its availability to the cell (Boulle, N. et al., 1995; Jones, E.M. and Baird, 
A., 1997). 
Another example of a characterized ARTC1 substrate is the platelet-derived 
growth factor-BB (PDGF-BB), whereas its structural homolog PDGF-AA is not 
modified by this reaction (Saxty, B.A. et al., 2001). ADP-ribosylated PDGF-BB loses 
its ability to stimulate mitogenic and chemotactic responses in human pulmonary 
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smooth muscle cells (SMCs). Furthermore, it shows a reduced capacity of binding 
to PDGF receptors in competition-binding experiments, as compared to the 
unmodified PDGF-BB (Saxty, B.A. et al., 2001). This suggests that PDGF-BB- 
dependent signaling can be regulated by ARTC1 at the cell surface. 
Finally, in murine T-cell lymphoma EL4 cells, overexpressed ARTC1 ADP-ribosylates 
distinct cell surface molecules, such as lymphocyte-function-associated antigen 1 
(LFA-1), cluster of differentiation (CD) 45, CD43 and CD44, resulting in the inhibition 
of the T-cell receptor trans-membrane signaling (Liu, Z.X. et al., 1999). These effects 
have been proposed to result from a failure of the T-cell receptors and co-
receptors to associate into a functional receptor cluster. Thus, these T-cell 
responses would be modulated by mono ADP-ribosylation of cell surface proteins 
(Liu, Z.X. et al.,1999; Nemoto, E. et al.,1996).  
All these data suggest that ARTC1 is involved in different processes and, thus, it 
could assume a role of particular therapeutic relevance. However, with the only 
exception being HNP-1, all the data reported have been generated using in vitro 
cellular models. Therefore, experimental observation on animal and human 
models will be crucial for future studies.  
1.2.1.2 ARTC2 
ARTC2 was originally identified in rat cells as a cell surface alloantigen and was 
initially indicated as RT6. Its expression is restricted to mature peripheral T-cells, 
whereas it is expressed only as a small population in mature thymocytes, 
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appearing to be developmentally regulated (Haag, F. et al., 1990; Koch-Nolte, F. et 
al., 1999; Koch-Nolte, F. et al., 1996; Koch-Nolte, F. et al., 2008).  
The rat Art2 gene has a single copy composed of eight exons located on 
chromosome 1. The entire mature protein, composed of 226 amino acids, is 
encoded by exon 7 (Haag, F.A. et al., 1996). Two allelic variants have been found 
in rat, Artc2a and Artc2b, which respectively encodes for ARTC2.1 and ARTC2.2. 
These two allelic variants differ by less than 5% of their amino acid sequences and 
eight of the ten different amino acids represent a non-conservative change (Haag, 
F. et al., 1990). The variation of these ten amino acids alters the enzymatic 
properties of the two proteins: both of them catalyze the hydrolysis of NAD+ to 
ADP-ribose and nicotinamide, but only ARTC2.2 can ADP-ribosylate itself.  
While the rat carries two strongly divergent alleles of a single copy gene, the 
mouse Art2 locus is duplicated, giving rise to the tandem associated gene Art2a 
and Art2b, which approximatively differ in 25% in their amino acid sequences 
(Prochazka, M. et al., 1991). In mice, the two closely related tandem genes are 
located on chromosome 7 and their products are co-expressed by T-cells and 
show similar enzymatic activities. My laboratory has reported the molecular 
cloning and the functional characterization of the first ARTC2 sequence from 
Chinese hamster ovary (CHO) cells, named (Cricetinae) cARTC2.1 (Stilla, A. et al., 
2011). cARTC2.1 has the R-S-EXE active-site motif that is typical of arginine-specific 
ARTs, with glutamate 209 as the predicted catalytic amino acid. However, cARTC2.1 
requires both of the glutamate residues 207 and 209 of the EXE sequence for its 
activity: although mutation of the catalytic glutamate 209 is enough to strongly 
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reduce ART activity, only the double mutation, involving both glutamate 207 and 
glutamate 209, led to the complete loss of activity (Stilla, A. et al., 2011). 
Unexpectedly, in human and chimpanzee the Art2 gene contains three premature 
in-frame stop codons that preclude the expression of the single copy Art2 gene 
as a cell surface protein (Haag, F. et al., 1994). 
ARTC2 is expressed in resting T-cells and in natural killer cells (Glowacki, G. et al., 
2002; Thiele, H.G. and Haag, F., 2001). The presence of ARTC2 on the surface of 
immune cells would suggest an immunomodulatory activity (Greiner, D.L. et al., 
1987). The first relationship between ARTC2 and inflammation was shown for the 
two murine ARTC2 isoforms that are expressed in T-cells and macrophages (Hong, 
S. et al., 2009). When activated by NAD+, ARTC2 catalyses mono-ADP-ribosylation 
of the purinergic receptor P2X7, that is a member of the P2X family of adenosine 
triphosphate (ATP)-gated ion channels. Once P2X7 is activated, it causes calcium 
flux, formation of large membrane pores and exposure of phosphatidylserine (PS), 
resulting in cell death, which is a crucial component in immune/inflammatory 
responses. P2X7 could be activated by millimolar concentrations of ATP (Di 
Virgilio, F. et al., 2001). Interestingly, the same effects can be triggered by much 
lower (micromolar) concentration of NAD+ (Seman, M. et al., 2003).  
Usually the concentration of extracellular NAD+ in serum is low (0.1-0.3 μM) and, 
under basal conditions, ARTC2 is inactive. It activation can only occur when the 
levels of extracellular NAD+ increase. Of relevance to the action of ARTC2, 
intracellular NAD+ (ca. 500 μM) can be released into the extracellular space under 
physiopathological conditions caused by tissue injuries, like acute inflammation.  
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In addition to ARTC2 being prevalently expressed in peripheral lymphoid tissues, 
Stilla and co-workers first reported that ARTC2 is also expressed and active in the 
ovarian system, thus demonstrating that the expression of these enzymes is wider 
than previously believed (Stilla, A. et al., 2011). Moreover, considering the role of 
ARTC2 in inducing apoptosis in mouse T-cells, it has been investigated whether 
this was also the case of ovarian cells (Adriouch, S. et al., 2001; Scheuplein, F. et al., 
2003). However, experiments on CHO and SKOV-3 cells indicated that cARTC2.1 
protein was not involved in apoptosis, since the sensitivity to anisomycin-induced 
apoptosis was not modified when the cells were transfected with cARTC2.1 (Stilla, 
A. et al., 2011). Thus, ARTC2’s role in apoptosis, which had been well established in 
mouse T-cells, cannot be extended to the ovarian system.  
1.2.1.3 ARTC5 
ARTC5 was first cloned from Yac-1 murine lymphoma cells (Okazaki, I.J. et al., 
1996b). It is a single copy gene, which maps to mouse chromosome 7 in close 
proximity to the Art1, Art2a and Art2b genes. Differently from other ARTCs, Art5 
gene lacks the C-terminal hydrophobic GPI-anchor signal and, thus, ARTC5 exists 
as a secreted protein (Glowacki, G. et al., 2001). The gene transcript is most 
abundant in testis, but it is also present in cardiac and skeletal muscle. The deduced 
amino acid sequence is 32% identical to that of mARTC1. hARTC5 has been 
reported to be an arginine-specific ART, differently from mARTC5, which instead 
possesses a prominent NAD-glycohydrolase activity (Glowacki, G. et al., 2002).  
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Even though mARTC5 was found to be primarily a NAD-glycohydrolase enzyme, 
at a high NAD+ concentration (1 mM) its ADP-ribosyl-transferase activity increases. 
The changes in its catalytic activity correlate with auto-ADP-ribosylation of ARTC5, 
which may suggest that the modification occurs at a critical active site residue 
(Glowacki, G. et al., 2002). This could be a mechanism for regulating its enzymatic 
activity.  
Furthermore, recent studies have demonstrated that the defensin HNP-1 inhibits 
hARTC5 auto-ADP-ribosylation and that, even under conditions that promote 
ART5 activity (e.g. high NAD+ concentrations), HNP-1 is not significantly modified 
(Paone, G. et al., 2006). 
Despite ARTC5’s ability to catalyze auto-ADP-ribosylation, its ADP-ribosylation of 
other protein substrates remains relatively poor. However, regardless of the lack 
of identified ARTC5 targets, this enzyme can be responsible for protein ADP-
ribosylation in the extracellular environment.   
1.2.2 The inactive ARTCs: ARTC3 and ARTC4  
ARTC3 and ARTC4 were firstly cloned in human testis and spleen, respectively. 
Their deduced amino acid sequences show 28% sequence identity to one another, 
and, with respect to the other gene family members, the highest sequence 
similarity to ARTC3 is ARTC2 (41%), that of ARTC4 is ARTC1 (39%; Koch-Nolte, F. 
et al., 1997). The ARTC3 transcript has been found in testis and, at low levels, in 
intestine, spleen and skeletal muscle (Koch-Nolte, F. et al., 1997). ARTC4 is, instead, 
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prominently expressed on erythrocytes and, less strongly, on monocytes, splenic 
macrophages and human umbilical vein endothelial cells (Parusel, I. et al., 2005).  
The biological functions of both ARTC3 and ARTC4 are still to be elucidated. ART 
activity on the surface of human monocytes correlates with the presence of ARTC3 
in unstimulated monocytes, whereas ARTC4 is expressed only in response to 
lipopolysaccharide stimulation, as during bacterial infection (Grahnert, A. et al., 
2002).     
Cell surface ADP-ribosylated proteins on human monocytes are modified on 
cysteine residues, suggesting that ARTC3 and ARTC4 could be cysteine-specific 
enzymes (Grahnert, A. et al., 2002). This is consistent with the finding that neither 
mouse nor human ARTC3 and ARTC4 showed any detectable arginine-specific 
enzymatic activity, as reported by Glowacki et al. using in vitro assays. Indeed, in 
accordance with this, and in contrast to the other members of the ARTC family, 
both ARTC3 and ARTC4 lack the motif R-S-EXE in their catalytic site, which is typical 
of arginine-specific ARTs (Glowacki, G. et al., 2002). Thus, it is possible that these 
family members may have lost their enzymatic activity or have acquired a different 
target specificity. Nevertheless, they still maintain some features and functions of 
the family, similarly to what happens in the largest ARTD family. 
1.3 The ADP-ribosyl-transferases diphtheria toxin-like (ARTDs) 
The human ARTD enzyme family consists of 17 multidomain proteins that can be 
divided on the basis of their catalytic activity into polymerases (ARTD1–6), mono-
ADP-ribosyl-transferases (ARTD7–17) and the inactives ARTD9 and ARTD13. Poly-
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ADP-ribosylation is a PTM that occurs in multicellular organisms, including plants 
and some lower unicellular eukaryotes, but it is not seen in prokaryotes and yeast 
(Perina D. et al., 2014). The reaction consists of the addition of multiple ADP-ribose 
groups on proteins. The first description of poly-ADP-ribosylation dates back to 
1963, when Chambon et al reported the formation of a nucleic acid-like polymer 
from NAD+. In the following years poly-ADP-ribosylation was intensively studied 
and research was dominated by studies focusing on the role of this modification 
and its implication on various cellular processes.  
Poly-ADP-ribose (PAR) is a homo-polymer of ADP-ribose units synthesized with 
β-NAD+ as a substrate. The chain length of the polymer is heterogeneous and in 
vitro it can reach 200 units. ADP-ribose chains that are shorter in length than 11 
units are referred to as oligo-ADP-ribose (Burkle, A., 2005; Diefenbach, J. and 
Burkle, A., 2005). PAR is irregularly branched with the number of branches 
increasing with the length of polymer. The average branching frequency is 
approximately one branch for every 20-50 units of ADP-ribose. Formation of the 
polymer is obtained through three different steps: initiation reaction (or mono-
ADP-ribosylation of the substrate), elongation of the polymer and branching 
(D’Amours, D. et al., 1999).  
The fact that some members of the ARTDs were involved in several critical cellular 
functions had made these enzymes really attractive as therapeutic targets. So far, 
a wide range of ARTD inhibitors have been developed in different research areas 
such as cancer therapy, ischemia, stress response and neurodegenerative diseases 
(Luo, X. and Kraus, W.L., 2012; Wahlberg, E. et al., 2012). Moreover, the availability 
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of the crystal structure of the catalytic domain of some ARTDs further improved 
studies on ARTDs inhibitors (Thorsell, A.G. et al., 2017; Wahlberg, E. et al., 2012).  
PARP1 is the founding member of the PARP family and, for many years, it was the 
only PARP enzyme known. PARP1 is activated by DNA strand breaks and its role 
in the cellular response to genotoxic and oxidative stress has been widely 
recognized and studied, with some PARP inhibitors being evaluated in several 
clinical trials as anticancer therapeutics (Ali, A.A. et al., 2012; Brown, J.S. et al., 2017; 
Curtin, N.J., 2012; Dulaney, C. et al., 2017; Jungmichel, S. et al., 2013; Kumar, C. et 
al., 2017; Langelier, M.F. et al., 2012; Martin-Hernandez, K. et al., 2016; Miwa, M. 
and Masutani, M., 2007; Peralta-Leal, A. et al., 2009). Olaparib was the first PARP 
inhibitor to be used for the therapy of patients with ovarian tumors and, more 
recently, it has been approved by US Food and Drug Administration (FDA) for the 
treatments of this type of cancer (Kim, G., et al., 2015). Moreover, two other PARP 
inhibitors such as rucaparib and niraparib have recently been approved by FDA 
for the therapy of patients with ovarian tumors and there are other PARP inhibitors 
such as talazoparib and veliparib that are currently under clinical trials 
(Balasubramaniam, S. et al., 2017; Brown, J.S. et al., 2016; Brown, J.S. et al., 2017; 
Dulaney, C. et al., 2017; Scott, L.J., 2017). 
The observation of PARP activity in PARP1-/- mice accelerated the discovery of 
other PARPs. Firstly, four similar enzymes (PARP2-5) were identified and 
characterized, and along with PARP1 they constitute the classical bona fide PARP 
family (Jacobson, M.K. and Jacobson, E.L., 1999; Smith, S., 2001). Then, an in-silico 
analysis of the human genome suggested the existence of other proteins that 
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share similarities with PARP1 catalytic domains (Otto, H. et al, 2005). To date, 17 
members of the PARP family have been identified, which differ from each other in 
terms of domain organization, transmodification targets, cellular localization, and 
biological functions (Ame, J.C. et al., 2004; Otto, H. et al. 2005; Schreiber, V. et al., 
2006).  
However, recent enzymatic data support the view that the earlier proposed name 
“PARP” and the provided numbering are no longer accurate. Firstly, the term 
polymerase is commonly used for template-dependent DNA or RNA synthesizing 
enzymes, but not for enzymes that modify proteins at a defined amino acid (Otto, 
H. et al., 2005). Moreover, some of the recently identified PARP members were 
reported to catalyze mono-ADP-ribosylation, and thus do not comply with the 
name polymerase (Kleine, H. et al., 2008; Otto, H. et al., 2005). Furthermore, some 
PARP members (e.g. PARP5a and PARP5b) have been shown to be distinct 
proteins encoded by different genes, rather than splice variants, and therefore 
should be numbered individually (Hottiger, M.O. et al., 2010). 
Thus, for all these reasons, a new classification has been proposed, based on 
structural and biochemical features of all ARTs. In line with this new nomenclature, 
enzymes firstly classified as PARP are now named diphtheria-toxin-like ARTs, 
abbreviated ARTDs, in accordance with the prototype bacterial toxin that their 
structural aspects resemble, with numbers indicating the different proteins of the 
family (Hottiger, M.O. et al., 2010). 
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1.3.1 The ARTDs domains  
All ARTDs share a conserved ADP-ribosyl-transferase (ART) domain, which is 
usually located at the C-terminus of the protein (except in ARTD4). This ART 
domain represents the catalytic core required for ART activity (Otto, H. et al., 2005; 
Verheugd, P. et al., 2016).  
Besides the ART domain, ARTDs contain many other motifs and domains that 
differ between all the enzymes and are involved in different functions, such as DNA 
or RNA binding, protein-protein interactions, cell signaling or enzyme localization 
(Hottiger, M.O., 2015). The key functional ARTDs motifs and domains are reported 
in Figure 1.4 and are discussed below. 
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Modified from Hottiger, M.O. et al., 2010 
Figure 1.4 The human ARTD family. Schematic comparison of ARTDs based on their domain 
architecture and their enzymatic activity. The following domains are indicated. ART: ADP-ribosyl-
transferase; PRD: PARP regulatory domain; WGR: conserved motif containing W-G-R; BRCT: BRCA1 
carboxy-terminal domain; AMD: automodification Domain; ZF: zinc finger; ZF/THP: zinc 
finger/TiPARP homologous domain; SAP: SAF/Acinus/PIAS-DNA-binding domain; RRM: RNA-
binding/recognition motif; SAM: sterile alpha motif; ARD: ankyrin repeat domain; HPS: histidine-
proline-serine region; VIT: vault protein inter-alpha-trypsin domain; vWA: von Willebrand type A 
domain; MVP-ID: Major-vault particle interaction domain; A1pp/macro: A1pp or macro domain; 
WWE; conserved motif containing W-W-E residues; UIM: ubiquitin interaction motif; GRD: glycine-
rich domain; CBD: central binding domain; TMD: trans-membrane domain. Depicted in black within 
the ART domains are the catalytic glutamates of ARTD1-6. * inactive enzymes 
ARTD1-3 are characterized by PRD and WGR domains. The PRD is the PARP 
regulatory domain and it is thought to be involved in the modulation of the PAR 
chain branching (Citarelli, M. et al., 2010; Hottiger, M.O. et al., 2010; Langelier, M.F. 
et al., 2014). The WGR domain represents a motif characterized by the presence of 
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the conserved amino acid residues tryptophan (W), glycine (G) and arginine (R). It 
has high affinity for PAR polymers and it has been described as a nucleic acid 
binding domain (Barkauskaite, E. et al., 2015; Langelier, M.F. et al., 2012). It 
participates in DNA binding and mediates domain–domain contacts that are 
essential for DNA-dependent activity (Langelier, M.F. et al., 2014). 
ARTD1 also contains three zinc finger (ZF) and one breast cancer type 1 
susceptibility protein (BRCA1) carboxy-terminal (BRCT) domains. The ZF domain is 
a small structural motif usually involved in a wide range of functions, including 
DNA- or RNA-binding, protein-protein interactions and membrane association 
(Krishna, S.S. et al., 2003). Specifically, two of the three ZF domains of ARTD1, 
indicated as ZF-1 and ZF-2, are involved in DNA-binding, acting as DNA nick 
sensor (Ali, A.A. et al., 2012; Barkauskaite, E. et al., 2015; Langelier, M.F. et al., 2011). 
The third ZF domain, referred to as ZF-3, is unrelated to ZF-1 and ZF-2, since it is 
not involved in DNA binding. Instead, it has a role in protein-protein interactions 
and is crucial for ARTD1 activation and for its DNA-dependent stimulation 
(Karlberg, T. et al., 2013; Langelier, M.F. et al., 2008; Tao, Z. et al., 2008). In addition 
to ARTD1, also ARTD12 and ARTD13 contain typical ZF motifs in their N-terminal 
domains and they have been implicated in RNA-binding (see Chapters 1.3.3.4 and 
1.3.4; Barkauskaite, E. et al., 2015; Guo, X. et al., 2004).  
The BRCT domain, also present in ARTD4, is a domain predominantly found in cell 
cycle checkpoint proteins with a role in the DNA damage response (Yu, X. et al., 
2003) Studies on ARTD1 BRCT domain suggest it is important for protein-protein 
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interaction in both DNA repair and cell signaling pathways (Langelier, M.F. and 
Pascal, J.M., 2013; Loeffler, P.A. et al., 2011; Li, M. et al., 2013).  
The vault protein inter-alpha-trypsin (VIT) and the von Willebrand type A (vWA) 
domains are distinctive features of ARTD4, with probably function in mediating 
protein-protein interactions (Barkauskaite, E. et al., 2015; Hassa, P.O. and Hottiger, 
M.O., 2008). Also the major-vault particle interaction domain (MVP-ID) is a unique 
characteristic of ARTD4, and it is involved in the interaction with the major vault 
protein, as suggested by name (Kickhoefer, V.A. et al., 1999).  
ARTD5 and ARTD6, also known as tankyrases, are characterized by the presence 
of the sterile alpha motif (SAM) and the ankyrin repeat domains (ARD). SAM is a 
domain important for mediating multimerization of tankyrases, while ARD is 
involved in protein-protein interactions (De Rycker, M. et al., 2003; Eisemann, T. et 
al., 2016; Mariotti, L. et al., 2016; Riccio, A.A. et al., 2016b). Both ARTD5 and ARTD6 
contain five ARD in their N-terminal region (Barkauskaite, E. et al., 2015; Eisemann, 
T. et al., 2016; Smith, S. et al., 1998; Seimiya, H. et al., 2004). Additionally, ARTD5 is 
characterized by the presence of the HPS domain, a N-terminal domain containing 
histidine, proline and serine, with a hitherto unclear function (Kaminker, P.G. et al., 
2001). 
The a1pp or macro domain (A1pp/macro) is specifically found in ARTD7, ARTD8 
and ARTD9, which are also known as macro domain containing-mono-ARTDs. 
Multiple macro domains have been found in these ARTDs, with two in ARTD9 and 
ARTD7, and three in ARTD8 (Aguiar, R.C. et al., 2005; Barkauskaite, E. et al., 2015). 
Macro domains have been described as binding modules able to recognize ADP-
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ribosylated target, either those mono-ADP-ribosylated or the poly-ADP-
ribosylated one, through the binding of the last residue of the poly-ADP-ribose 
chain (Feijs, K.L. et al., 2013c; Gottschalk, A.J. et al., 2009; Timinszky, G. et al., 2009; 
see Chapter 1.6.1). Macro domains 2 and 3 of ARTD8 have been shown to 
recognize mono-ADP-ribosylated substrates (Forst, A.H. et al., 2013). Macro 
domain 2 of ARTD9 has reported to bind ARTD1‑generated poly-ADP-ribose 
chain at DNA damage sites (Karras, G. I. et al., 2005; Yan, Q. et al., 2013). The 
function of ARTD9 macro domain 1 of both ARTD8 and ARTD9 still remains to be 
defined, since they do not bind either poly- or mono-ADP-ribose.  
Uniquely among the macro domain containing-mono-ARTDs, but together with 
ARTD11, ARTD12, ARTD13 and ARTD14, ARTD8 is characterized by the WWE 
domain (Barkauskaite, E. et al., 2015). It is a domain containing the conserved 
amino acid sequence tryptophan-tryptophan-glutamate (W-W-E) that has been 
described to be able to recognize iso-ADPR (Wang, Z. et al., 2012). Structural 
information about the WWE domain were initially obtained studying 
ubiquitination-related proteins, another family of proteins characterized by this 
domain (Zweifel, M.E et al., 2005). However, the determination of the solution 
structures of ARTD8 and ARTD11 WWE domains demonstrated they have some 
features resembling that of the ubiquitination-related proteins, but also showing 
several unique structural features (He, F. et al., 2012; Wei, H. and Yu, X., 2016).  
The ubiquitin interaction motif (UIM) is characteristic of ARTD10. This enzyme 
contains two UIMs that have been reported to interact with K63-poly-ubiquitin 
chains, promoting mono-ADP-ribosylation of NF-κB (Nuclear Factor-κappaB) 
45 
 
essential modulator (NEMO) and preventing its poly-ubiquitination (Verheugd, P. 
et al., 2013). As a consequence, NF-κB nuclear translocation is inhibited and this 
results in impairing the expression of target genes (Verheugd, P. et al., 2013). In 
addition to this role in inflammation, ARTD10 is also involved in the S-phase repair 
(Butepage, M. et al., 2015). Indeed, ARTD10’s UIMs have been shown to interact 
with ubiquitinated PCNA (Proliferating Cell Nuclear Antigen) and to be important 
in maintaining PCNA ubiquitination levels (Nicolae, C.M. et al., 2014).  
Comparison of the ART domain of all the ARTDs shows that six diphtheria-toxin-
like enzymes are characterized by the presence of a glutamate in the histidine-
tyrosine-glutamate (H-Y-E) triad motif (ARTD1–6), the remaining 11 members are 
characterized by the lack of this glutamate residue, that is replaced by isoleucine 
(I), leucine (L), threonine (T), valine (V) or tyrosine (Y; ARTD7–17). This glutamate 
has been demonstrated to be crucial for polymer elongation and, based on its 
presence, ARTDs have been classified as poly-ARTDs (ARTD1–6), mono-ARTDs 
(ARTD7,8; ARTD10-12; ARTD14-17) or inactive enzymes (ARTD9 and ARTD13; 
Figure 1.4; Hottiger, M.O. et al., 2010; Kleine, H. et al., 2008; Otto, H. et al., 2005; 
Verheugd, P. et al, 2016).  
1.3.2 The poly-ARTDs: (ARTD1 to ARTD6) 
ARTD1-6 are members of the ARTDs that are typical PARPs, as they all possess the 
conserved glutamate residue of the H-Y-E triad, which is crucial for polymer 
elongation (Barkauskaite, E. et al., 2015; Gibson, B.A. and Kraus, W.L., 2012; 
Hottiger, M.O. et al., 2010; Perina, D. et al., 2014; Verheugd, P. et al., 2016). 
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ARTD1/PARP1 is the best studied member of this ARTDs group, with a well-defined 
and detailed structural basis for its DNA damage-dependent activity (Beck, C. et 
al., 2014; Bock, F.J. and Chang, P., 2016; Langelier, M.F et al., 2012). It is a nuclear 
protein but there are studies suggesting that ARTD1 could also be present in the 
mitochondria (Barth, E. et al, 2006; Druzhyna, N. et al, 2000; Scovassi, A.I., 2004).  
This protein consists of three modular domains: a N-terminal DNA binding domain 
consisting of three ZF domains, an automodification domain and a C-terminal ART 
domain containing the conserved H-Y-E motif (Figure 1.4; Barkauskaite, E. et al., 
2015; D'Amours, D. et al., 1999; Hassa, P.O. and Hottiger, M.O., 2008; Karlberg, T. 
et al., 2013). The DNA binding domain plays a critical role in the recognition of 
DNA strand aberrations and concurrent activation of ARTD1 (Ali, A.A. et al., 2012; 
Liu, C. and Yu, X., 2015; Karlberg, T. et al., 2013). The automodification domain is 
comprised of a BRCA1-carboxy terminus-like module that mediates several 
protein-ARTD1 and DNA-ARTD1 interactions (Altmeyer, M. et al., 2009; Ciccarone, 
F. et al., 2017; Langelier, M.F. et al., 2010; Karlberg, T. et al., 2013; Tao, Z et al., 2009). 
ARTD1 is responsible for the majority of PARP activity in the cell, and it accounts 
for approximately 85-90% of mammalian cell poly-ADP-ribosylation activity 
(Brunyanszki, A. et al., 2016; Karlberg, T. et al., 2013).  
ARTD1 is best known for its function in the base excision repair pathway during 
DNA damage (D'Amours, D. et al., 1999; de Murcia, G. and Menissier de Murcia, J., 
1994; Ko, H.L. and Ren, E.C., 2012; Swindall, A.F. et al., 2013; Wei, H. and Yu, X., 
2016). It acts as a DNA damage sensor and a signaling molecule binding to both 
single and double-stranded DNA breaks (Hassa, P.O. and Hottiger, M.O., 2008; 
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Langelier, M.F. et al, 2011). ARTD1-DNA binding leads to a conformational change 
of the enzyme, followed by extensive auto-ADP-ribosylation and hetero-ADP-
ribosylation of different forms of histones, such as H1, H2B, H3 and H4 (Altmeyer, 
M. et al., 2009; Hottiger, M.O., 2011; Kim, M.Y. et al., 2005; Liu, C. and Yu, X., 2015; 
Messner, S. et al., 2010). This causes a complete decondensation of the chromatin 
structure, allowing access to DNA regions that are normally weakly accessible (Kim, 
M.Y. et al., 2005; Kraus, W.L. and Hottiger, M.O., 2013).  
Apart from its role in DNA repair, ARTD1 is also involved in other complex 
biological processes such as apoptosis, maintenance of genomic integrity, 
regulation of replication and differentiation, inflammation and transcriptional 
regulation (Bock, F.J. and Chang, P., 2016; Hassa, P.O. and Hottiger, M.O., 2008; 
Kraus, W.L. and Hottiger, M.O., 2013; Malanga, M. and Althaus, F.R., 2005; Koh, 
D.W. et al., 2005; Schreiber, V. et al., 2006; Yang, Y.G. et al., 2004).  
Because of its crucial role in mitosis and cancer, ARTD1 has been at the front line 
of drug discovery since the 1980s, and the first clinical trial for an ARTD1 inhibitor 
was initiated in 2003 with rucaparib (Plummer, R. et al., 2008). Since then, other 
further inhibitors have entered clinical trials with the aim of blocking the 
mechanism of repair of damaged DNA through ARTD1 inhibition, and thus 
enhancing the DNA damage caused by chemotherapy and radiotherapy (Brown, 
J.S. et al., 2017; Curtin, N.J., 2012; Dulaney, C. et al., 2017; Kumar, C. et al., 2017). 
Currently, several PARP inhibitors such as olaparib, niraparib, talazoparib, veliparib 
and the same rucaparib are under clinical trials (Brown, J.S. et al., 2016). Some of 
them are in the last steps of these trials, while olaparib, rucaparib and niraparib 
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have been recently approved by FDA for the treatment of relapsed ovarian cancer 
(Balasubramaniam, S. et al., 2017; Scott, L.J., 2017; Kim, G., et al., 2015). 
ARTD2/PARP2 is a DNA-dependent nuclear protein which, among all the ARTD 
members, is the closest relative of ARTD1, since they display the highest sequence 
homology (69% similarity; Ame, J.C. et al., 2004). Like ARTD1, ARTD2 contains a 
WGR domain, that is required for DNA-dependent activity, and has the catalytic 
domain located at the carboxy terminus (Hottiger, M.O. et al., 2010). However, its 
DNA binding domain is different from that of ARTD1 and, considering that the 
DNA binding domain of ARTD2 shows no homology to any other ARTDs reported, 
it may be responsible for the different substrate specificity (Kutuzov, M.M. et al., 
2013; Oliver, A.W. et al., 2004).  
The main role of ARTD2 is the same of ARTD1 as it acts as a sensor and signaling 
molecule in response to DNA damage (Beck, C. et al., 2014). Similarly to ARTD1, 
ARTD2 is activated by DNA nicks and this leads to its auto-ADP-ribosylation and 
synthesis of long branched chains of PAR (Ame, J.C. et al., 1999; Beck, C. et al., 
2014; Ghosh, R. et al., 2016; Langelier, M.F. et al., 2014; Riccio, A.A. et al., 2016a; 
Schreiber, V. et al., 2002). In addition to its role DNA repair, ARTD2 has other 
proposed functions in genome integrity, spermatogenesis, adipogenesis and 
immune cell development (Ali, S.O. et al, 2016; Bai, P. et al., 2007; Dantzer, F. et al., 
2006; Robert, I. et al., 2009; Yelamos, J. et al., 2006).  
ARTD3/PARP3 is a poly-ARTDs sharing high degree of structural similarity of ARTD 
catalytic domain and with a conserved glutamate residue as compared to ARTD1 
and ARTD2 (Barkauskaite, E. et al., 2015; Hottiger, M.O. et al., 2010). It has been 
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firstly identified as a core component of the centrosome preferentially located at 
the daughter centriole throughout all stages of the cell cycle (Augustin, A. et al., 
2003). ARTD3 overexpression interfered with the G1/S phase cell cycle progression 
and it was described to interact with ARTD1 at the centrosome (Augustin, A. et al., 
2003). Nevertheless, further studies disputed the centrosomal localization of 
ARTD3 and suggested that ARTD3 localized to the nucleus and associated with 
polycomb group proteins involved in gene silencing and DNA repair networks 
including DNA protein kinases, DNA ligase III and IV, Ku70 and Ku80 and ARTD1 
(Boehler, C. et al., 2011; Rouleau, M. et al., 2007). Boehler and colleagues 
demonstrated ARTD3 cooperates with ARTD1 during the cellular response to DNA 
double-strand breaks, pertinent to association with Ku and Ligase IV (Boehler, C. 
et al., 2011). 
Initially, auto-ADP-ribosylation and hetero-ADP-ribosylation activities of ARTD3 
were described as mono-ADP-ribosyl-transferase activity (Loseva, O. et al., 2010). 
However, a later report has suggested that ARTD3 possessed poly-ADP-ribosyl-
transferase activity (Boehler, C. et al., 2011). In particular, ARTD3 was described to 
poly-ADP-ribosylate the nuclear mitotic apparatus protein (NuMA) directly and 
indirectly through ARTD5, suggesting that ARTD3 was required for mitotic spindle 
integrity during mitosis (Boehler, C. et al., 2011). Collectively, these reports 
implicate ARTD3 in the maintenance of genomic integrity, mitotic spindle integrity 
and transcriptional repression.  
ARTD4/PARP4/vPARP is the largest member of the ARTD family and has originally 
been identified as a component of mammalian cytoplasmic ribonucleoprotein 
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complexes called vault particles that have been proposed to be involved in 
multidrug resistance of human tumors and to function in intracellular transport 
(Kickhoefer, V.A. et al., 1999). ARTD4 associates with two essential proteins of the 
vault particle, major vault protein (MVP) and telomerase-associated protein (TEP1; 
Kickhoefer, V.A. et al., 1999). ARTD4 is also present in the nucleus where it is not 
attached to the vault components, and at the mitotic spindle, suggesting that it 
may play multiple roles not yet identified (Kickhoefer, V.A. et al., 1999).  
The structure of ARTD4 is unusual, since it is the only ARTD member to have its 
catalytic domain located at the N-terminal portion of the protein (Barkauskaite, E. 
et al., 2015; Hottiger, M.O. et al., 2010; Schreiber, V. et al., 2006). It comprises of 
five major domains, which are the BRCT motif, the catalytic ARTD domain, the 
breast cancer vault protein inter-α-trypsin (VIT) domain, the von Willebrand type 
A (vWA) domain and finally the major vault protein particle interacting domain 
(MVP-ID; Hottiger, M.O. et al., 2010). BRCT domain is thought to bind 
phosphorylated DNA damage-sensing proteins (Manke, I.A. et al., 2003). VIT and 
vWA domains are presumed to mediate protein-protein interactions (Hassa, P.O. 
and Hottiger, M.O., 2008). MVP-ID is involved in the interaction with the major 
vault protein, as suggested by its name. MVP mRNA (messenger RNA) levels are 
shown to be an indicator of the multidrug resistance (MDR), which is a major cause 
of chemotherapy failure in the cancer patients (Laurencot, C.M. et al., 1997; Liu, C. 
and Yu, X., 2015; Siva, A.C. et al., 2001; Steiner, E. et al., 2006). Despite this unique 
feature, ARTD4 is catalytically active and poly-ADP-ribosylates MVP as well as itself 
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(Barkauskaite, E. et al., 2015; Berger, W. et al., 2009; Butepage, M. et al., 2015; 
Kickhoefer, V.A. et al., 1999).  
ARTD5/PARP5a/Tankyrase-1 and ARTD6/PARP5b/Tankyrase-2 are two closely 
related ARTD family members sharing 83% sequence identity between each other 
and 89% sequence identity with the catalytic ARTD domain (Kaminker, P.G. et al., 
2001; Kuimov, A.N. et al., 2001; Smith, S. et al., 1998). They differ from other ARTD 
members because of their unique domain organization, that is composed of a 
SAM domain, which is required for the tankyrases oligomerization, and the 
characteristic catalytic ARTD domain (Barkauskaite, E. et al., 2015; Haikarainen, T. 
et al., 2014; Hottiger, M.O. et al., 2010; Schreiber, V. et al., 2006). Their N-terminal 
consists of a region comprising of 24 ankyrin repeats, which are segmented into 
five ARD (ARD I-V) and are used to interact with the target proteins (Haikarainen, 
T. et al., 2014; Karlberg, T. et al., 2013; Smith, S. et al., 1998; Seimiya, H. et al., 2004). 
ARTD5 has an additional region at the N-terminal that contains an HPS domain; 
this additional region most likely has a regulatory function, although it is not well 
studied and its main function is unknown so far (Haikarainen, T. et al., 2014; 
Kaminker, P.G. et al., 2001; Karlberg, T. et al., 2013). 
Tankyrase-1 localizes to multiple subcellular sites, as it has been found in the 
cytoplasm as well as in the nucleus (Karlberg, T. et al., 2013; Smith, S. and de Lange, 
T., 1999; Cook B.D. et al., 2002; Seimiya, H. and Smith, S., 2002). Although 
tankyrase-1 does not contain an NLS, it is present in the nucleus through its 
interaction with the telomeric repeat binding factor 1 (TRF1), which contains an NLS 
(Karlberg, T. et al., 2013; Smith, S. and de Lange, T., 1999; Hsiao, S.J. and Smith, S., 
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2008). The intracellular location of tankyrase-2 is less characterized but it has been 
reported to have a localization similar to that of tankyrase-1 (Haikarainen, T. et al., 
2014; Karlberg, T. et al., 2013; Sbodio, J.I. et al., 2002). Tankyrases have been 
implicated in a diverse range of functions including telomere maintenance, WNT 
signaling, mitosis and mediation of insulin stimulated glucose uptake 
(Barkauskaite, E. et al., 2015; Haikarainen, T. et al., 2014).  
ARTD5 has first been discovered as a factor that regulated telomere length by 
binding the negative regulator of telomere length TRF1 and was originally named 
tankyrase 1 due to its interaction with this factor (Smith, S. et al., 1998). ARTD5 
catalyzes auto-poly-ADP-ribosylation and poly-ADP-ribosylation of TRF1, and, a 
careful analysis of ARTD5 auto-ADP-ribosylation revealed that it synthesizes ADP-
ribose polymers with an average length of 20 ADP-ribose units, but polymers lack 
branching (Haikarainen, T. et al., 2014; Rippmann, J.F. et al., 2002; Smith, S. et al., 
1998).  
ARTD6 has also been reported to associate with and poly-ADP-ribosylate TRF1, 
indicating a potential redundant role of ARTD5 and ARTD6 in telomere regulation 
(Cook, B.D. et al., 2002; Haikarainen, T. et al., 2014; Kaminker, P.G. et al., 2001). 
ARTD6 also associates with ARTD5 and both enzymes share most of their protein 
partners including insulin-responsive aminopeptidase (IRAP), NuMA and 182 kDa 
tankyrase-binding protein (TAB182; Haikarainen, T. et al., 2014; Kaminker, P.G. et 
al., 2001; Karlberg, T. et al., 2013; Sbodio, J.I. and Chi, N.W., 2002; Sbodio, J.I. et al., 
2002; Seimiya, H. and Smith, S., 2002).  
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Overall, the recent findings about poly-ARTs and their relative targets establish 
poly-ADP-ribosylation as a protein modification involved in an impressive array of 
regulatory pathways. A better understanding of the role of these enzymes in both 
these physiological and pathophysiological processes will be of clinical relevance.  
1.3.3 The active mono-ARTDs  
As previously mentioned, the mono-ARTs of the ARTD family have amino acid 
substitutions in their catalytic centers that enables them to attach just mono ADP-
ribose moieties to the target proteins (Hottiger, M.O. et al, 2010; Kleine, H. et al, 
2008). This subfamily comprises of ARTD7-ARTD17, excluding ARTD9 and ARTD13, 
which are described as inactive or pseudo ARTDs. ARTD9 and ARTD13 lack both 
the catalytic glutamate as well as the histidine of the H-Y-E triad and are predicted 
to be catalytically inactive (Liu, C. and Yu, X., 2015; Otto, H. et al., 2005; Vyas, S. et 
al., 2014). 
The remaining mono-ARTDs do not contain the catalytic glutamate of the H-Y-E 
motif that is characteristic of polymer forming ARTDs, since it is required for 
elongation of the ADP-ribose chain (Otto, H. et al, 2005). For instance, the 
glutamate E988 in human ARTD1 (hARTD1) has been shown to be essential for the 
ARTD1 elongation reaction and, thus, for the formation of poly-ADP-ribose chains 
(Marsischky, G.T. et al., 1995; Rolli, V. et al., 1997). Despite this fundamental 
difference, mono-ARTDs also modify acidic residues and they are proposed to 
utilize the glutamate of the substrate protein and thus follow the substrate-
assisted catalysis mechanism (Kleine, H. et al., 2008).  
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However, several studies indicate that mono-ARTDs play critical roles in 
intracellular signaling, such as transcription, immunity, inflammation, and stress 
response and have been linked to many human diseases, including 
neurodegenerative and inflammatory diseases, and the onset and progression of 
cancers (Table 1.3; Fabrizio, G. et al., 2015a; Feijs, K.L. et al., 2013a). 
Table 1.3 Active mono-ARTDs. 
 
Modified from Fabrizio, G. et al., 2015a 
1.3.3.1 ARTD7 and ARTD8  
ARTD7 (PARP15/BAL3) was originally identified, together with ARTD8 
(PARP14/BAL2) as a gene closely related to ARTD9 (PARP9/BAL1; B-aggressive 
lymphoma 1, see Chapter 1.3.1.7; Aguiar, R.C. et al., 2000; Aguiar, R.C. et al., 2005; 
Butepage, M. et al., 2015)  
These three members of the ARTD family are characterized by the presence of N-
terminal macro domains, with two in ARTD9 and ARTD7, and three in ARTD8 
(Figure 1.4; Aguiar, R.C. et al., 2005). Thus, these are collectively known as macro 
domain containing-mono-ARTDs. Macro domains are protein domains known to 
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bind mono- and poly-ADP-ribose (Forst, A.H. et al., 2013; Han, S. and Tainer, J.A., 
2002; Kleine, H. and Luscher, B., 2009). Recently, macro domains 2 and 3 of ARTD8 
were reported to recognize and read mono-ADP-ribosylated ARTD10 and 
substrates of ARTD10 (Forst, A.H. et al., 2013). It has been demonstrated that these 
two ARTD8 macro domains bind to mono-ADP-ribosylated targets and this 
association is strictly dependent on the presence of mono-ADP-ribosylation, as 
they do not associate to poly-ADP-ribosylated proteins (Forst, A.H. et al., 2013). 
Thus, they have been indicated as mono-ADP-ribosylation reader modules.  
Both ARTD7 and ARTD8 demonstrate auto-mono-ADP-ribosylation activity 
(Aguiar, R.C. et al., 2005). 
Little is known about ARTD7, besides that it is localized to stress-granules along 
with ARTD8, it has been reported to have a transcriptionally repressive function 
through its N-terminal macro domains and its auto-ADP-ribosylation activity has 
been suggested to counteract the repressive effect of the macro domains (Aguiar, 
R.C. et al., 2005).  
Whereas ARTD7 remains poorly characterized, ARTD8 is better understood and 
has been implicated in STAT6 (Signal Transducer and Activator of Transcription 6)-
dependent transcriptional control and cytokine-regulated control of cellular 
metabolism (Cho, S.H. et al., 2011; Goenka, S. et al., 2007). Thus, it is also known as 
CoaSt6 (Collaborator of Stat6) and as an activator of interleukin 4 (IL-4)– and 
Stat6–dependent transcription. ARTD8 potentiated IL4-induced STAT6 
transactivation via its macro domains and catalytic activity (Goenka, S. and 
Boothby, M., 2006; Goenka, S. et al., 2007). ARTD8 also catalyses ADP-ribosylation 
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of p100, a protein that interacts with RNA polymerase II and functions as a bridging 
factor between Stat6 and the transcription machinery (Yang, J., et al., 2002). 
However, the functional consequences of this modification remain to be 
characterized in detail. 
Similarly, the role of ARTD8-mediated ADP-ribosylation of the HDAC2 and HDAC3 
histones deacetylases remains unclear. However, in the presence of IL-4, the ART 
activity of ARTD8 is activated, and HDAC2 and HDAC3 are ADP-ribosylated and 
released from their promoters, allowing the binding of Stat6 and the consequent 
transcription (Yang, J., et al., 2002). In line with this, a catalytically inactive mutant 
of ARTD8 did not enhance Stat6-mediated transcription, and ART inhibitors 
blocked IL-4–dependent transcription (Goenka, S. et al., 2007).  
Moreover, in response to IL-4, ARTD8 is also involved in proliferation and survival 
of B-lymphocytes, with a role in the regulation of the glycolytic activity of these 
cells (Cho, S.H. et al., 2009; Cho, S.H. et al., 2011). This is in line with the requirement 
for a major supply of cellular biomass to sustain continuous cell growth and 
proliferation of cancer cells. ARTD8 also interacts with and stabilizes the 
phosphoglucose isomerase/ autocrine motility factor (by inhibiting its 
ubiquitination), a cytosolic and secreted enzyme that is essential for glycolysis and 
gluconeogenesis and that is involved in tumor progression and metastasis 
(Yanagawa, T. et al., 2007). Recently, ARTD8 was also identified as a downstream 
effector of the Jun N-terminal kinase 2 (JNK2)-dependent pro-survival signal by 
binding to and inhibiting JNK1 pro-apoptotic activity, promoting the survival of 
myeloma cells (Barbarulo, A. et al., 2013). 
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Intriguingly, ARTD8 has been found to be localized not only in the nucleus, but 
also at the cell periphery, together with ARTD9, where it associates with actin fibres 
(Vyas, S. et al., 2013). Because human actin has been previously reported to be 
modified not only by the bacterial toxins, but also by a not yet identified 
endogenous enzyme (Fabrizio, G. et al., 2015a; Lodhi, I.J. et al., 2001), it could be 
hypothesized that the ART activity of ARTD8 can modify actin, affecting actin 
polymerization and cell proliferation. Finally, the ART activity of ARTD8 has been 
seen to be involved in the pathogenesis of asthma using a murine model of allergic 
airway disease, in line with the regulatory role of ARTD8 on IL-4– and STAT6–
dependent transcription and with the roles that IL-4 and STAT6 have in asthma 
(Mehrotra, P. et al., 2013). Thus, considering the widely studied roles of ARTD8 in 
cancer and its emerging role in allergic airway diseases, the targeting of ARTD8 
activity appears to be of particular therapeutic relevance for lymphoma, myeloma 
and asthma. 
1.3.3.2 ARTD10 
ARTD10, also known as PARP10, is the founding member of the mono-ARTDs and 
was initially discovered through in silico screening of ARTD family members (Ame, 
J.C. et al., 2004). It is a 150-kDa enzyme that comprises several domains of potential 
functional relevance. With the exception of the ART catalytic domain, ARTD10 
domain structure is unique from the other ARTDs. In addition to the C-terminal 
ART catalytic domain (amino acids 818-1025), the ARTD10 sequence is 
characterized by an RNA-recognition motif (RRM; amino acids 11-85), a glycine-
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rich domain (amino acids 281-399), a glutamic acid (Glu)-rich region (amino acids 
588-697) containing two ubiquitin interaction motifs (UIM; amino acids 650-667, 
673-690); and a leucine-rich nuclear export sequence (NES; amino acids 598-607; 
Figure 1.4). The RRM and the glycine-rich domain are both involved in the RNA 
binding (Yu, M. et al., 2005).  
ARTD10 is predominantly cytosolic under basal conditions, but it can shuttle 
between the cytoplasmic and the nuclear compartments (Kleine, H. et al., 2012). 
The nuclear export of ARTD10 is mediated through its NES, while a region that acts 
as a nuclear localization signal (NLS), that has been mapped in the middle of 
ARTD10, defines its nuclear import (Kleine, H. et al., 2008). 
Besides mono-ADP-ribosylation, ARTD10 undergoes auto-ADP-ribosylation as 
well as modifying each of the four core histones. It has also been reported to 
interact with the proto-oncoprotein c-Myc, a key transcriptional regulator of cell 
proliferation (Kleine, H. et al., 2008; Yu, M. et al., 2005). When overexpressed in 
various cell lines, ARTD10 acts as an inhibitor of the c-Myc- and H-ras-mediated 
cell transformation and this role is independent of its ADP-ribosylation activity; 
neither c-Myc nor its heterodimerization partner Max were ADP-ribosylated by 
ARTD10 (Yu, M. et al., 2005). However, the catalytic activity of ARTD10 is strictly 
required to inhibit cell proliferation, since its catalytically inactive mutant is not 
effective (Herzog, N. et al., 2013). Specifically, the catalytically active ARTD10 
inhibits cell proliferation, as revealed by measurements of living cells, and this is a 
consequence of apoptosis induction, as determined by Annexin V staining and by 
analysis of cleaved ARTD1 (Herzog, N. et al., 2013).  
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Although it remains unknown which protein(s) are mono-ADP-ribosylated by 
ARTD10 to mediate this growth inhibitory phenotype, a possible candidate is the 
glycogen synthase kinase 3 beta (GSK3β), which is known to regulate cell 
proliferation and whose kinase activity is inhibited once it is modified by ARTD10 
(Feijs, K.L. et al., 2013b; Wu, D. and Pan, W., 2010).  
The ARTD10 target GSK3β appears to have a role in neurodegenerative disorders, 
as its overexpression causes neuronal cell death (Seira, O. and Del Rio, J.A., 2014). 
GSK3β has been implicated in the fatal neurodegenerative disease amyotrophic 
lateral sclerosis (ALS), which is characterized by degeneration of motor neurons, 
resulting in progressive motor paralysis. Mutations in the gene coding for 
superoxide dismutase (SOD1) are associated with approximately 20% of familial 
ALS. Different studies have shown that GSK3β inhibition can prevent motor neuron 
cell death in an in vitro ALS model that is characterized by expression of the G93A 
mutant of human SOD1 (Ahn, S.W. et al., 2012). Thus, through mono-ADP-
ribosylation of GSK3β, ARTD10 can act as an inhibitor of cell proliferation and also 
as a regulator of neuronal cell death.  
Recently, ARTD10 has also been reported to have a role in the NF-κB) transcription 
factor signaling. The NF-κB family is involved in cell proliferation, innate and 
adaptive immune responses, and further crucial processes, like inflammation and 
tumorigenesis (DiDonato, J.A. et al., 2012). ARTD10 is a regulator of the NF-κB 
pathway by mono-ADP-ribosylating NEMO, reducing its poly-ubiquitination and 
activation of NF-κB (Verheugd, P. et al., 2013). However, unlike the regulation of 
c-Myc, the regulation of NF-κB is dependent on ARTD10 catalytic activity and on 
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the UIMs (Verheugd, P. et al., 2013). Moreover, in addition to its role in cell 
signaling pathways that regulate proliferation and apoptosis, ARTD10 expression 
can also be induced by LPS and IFNα, which indicates its further involvement in 
immunological processes (Eckei, L. et al., 2017).  
1.3.3.3 ARTD11, ARTD16 and ARTD17  
ARTD11, ARTD16 and ARTD17 are three mono-ARTDs that, with the exception of 
the typical mono-ART catalytic domain, remain to be characterized for the 
presence of other motifs and domains. ARTD11, also denoted as PARP11, and 
ARTD16, also referred to as PARP8, are minimally investigated members of the 
mono-ARTDs. The limited studies available for them indicate they have no known 
domains outside of their catalytic one, with the exception of the single tryptophan-
tryptophan-glutamate (WWE) domain of ARTD11, which it has been reported to 
bind ADP-ribose (He, F. et al., 2012). Also their functions have not been determined 
to date.  
ARTD17, also known as PARP6, is a mono-ARTD with possible involvement in 
cancer. It has been described as a negative regulator of cell-cycle progression in 
HeLa cells, as ARTD17 overexpression was reported to arrest cells in S-phase and 
this was dependent on the presence of the catalytic domain (Tuncel, H. et al., 2012). 
Moreover, a role for ARTD17 as tumor suppressor involved in colorectal cancer 
development has been proposed. The immunohistochemical analysis of human 
colorectal cancer specimens has shown that ARTD17 expression is inversely 
correlated with Ki-67, which is a well-known proliferation marker, and is associated 
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with a good prognosis. Thus, it has been hypothesized that ARTD17 expression 
levels might be used as a prognostic biomarker for improved survival of patients 
with colorectal cancer (Tuncel, H. et al., 2012). However, the catalytic activity of 
ARTD17 has not been evaluated and its potential activity in other cellular functions 
has not yet been fully determined. 
1.3.3.4 ARTD12 
ARTD12, also known as PARP12, is a member of the mono-ARTDs whose function 
is still incompletely characterized. ARTD12 belongs to a subgroup of ARTD family 
members characterized by the presence of typical ZF motifs in its N-terminal 
domain, which are known to bind to viral, and also cytoplasmic, RNAs (Guo, X. et 
al., 2004; Guo, X. et al., 2007; Hall, T.M., 2005; Liang, J. et al., 2008). Thus, it is also 
referred to as ZC3HDC1, zinc finger CCCH type domain containing 1. ARTD12 exists 
in two isoforms denoted as long (L) and short (S) ARTD12 (ARTD12L and ARTD12S, 
respectively; Atasheva, S. et al., 2012). ARTD12L is a protein composed of 711 amino 
acids containing all the five ZF domains and the ART domain, which is crucial for 
the catalytic activity. ARTD12S is a protein of only 485 amino acids that contains 
the same five ZF domains, but lacks the ART domain (Atasheva, S. et al., 2012). 
ARTD12 is a mono-ADP-ribosyl-transferase with automodification activity and it 
possesses at least two distinct subcellular locations and related functions. Unlike 
many other ARTD members, ARTD12 is largely excluded from the nucleus, and 
appears to localize into distinct cytoplasmic structures in a protein domain-
dependent manner (Welsby, I. et al., 2014).  
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Upon ectopic expression or exposure to oxidative stress, it is recruited to stress-
granules (SGs), where ARTD12 blocks mRNA translation through its association 
with the translational machinery. Both the N-terminal domain and the integrity of 
the catalytic domain are essential for this function (Leung, A.K. et al., 2011; Welsby, 
I. et al., 2014). Moreover, ARTD12 associates with both long and short isoforms of 
ARTD13 (short isoform is missing the catalytic domain), ARTD5 and ARTD7 within 
these stress granules (Leung, A.K. et al., 2011). Otherwise, under stimulation with 
lipopolysaccharide (LPS), ARTD12 localizes into structures unrelated to SGs. The 
association into these structures has been found to correlate with increased NF-
κB signaling, suggesting a role for ARTD12 in inflammation (Welsby, I. et al., 2014). 
ARTD12 has been recently identified as a putative anti-viral gene, belonging to a 
large family of interferon-stimulated genes (ISGs) whose expression is often 
induced during viral infections (De Veer, M.J. et al., 2001; Liu, S.Y. et al., 2012). After 
infection by the alphavirus Venezuelan equine encephalitis virus (VEEV), ARTD12L 
is up-regulated and exhibits inhibitory effects on replication (Atasheva, S. et al., 
2012). The same inhibitory effects on replication of VEEV have also been shown for 
other alphaviruses and RNA viruses (Atasheva, S. et al., 2012). Interferon 
stimulation up-regulates Artd12 gene expression to counteract infections through 
inhibition of both cellular translation and virus replication. These inhibitions and 
antiviral activities depend on its binding to polyribosomes, via its RNA-binding 
domain, and requires its catalytic activity (Atasheva, S. et al., 2014). This process 
has been suggested to be a cellular defense against invading viral pathogens, 
although this has not yet been mechanistically investigated (Schoggins, J.W. et al., 
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2011). More recently, expression of ARTD12 has also been found elevated in tissues 
from mice subjected to bacterial superantigen Staphylococcal enterotoxin B (SEB) 
mediated toxic shock, suggesting a potential role of this protein during immune 
activation (Ferreyra, G.A. et al., 2014). 
1.3.3.5 ARTD14 
ARTD14 is a 75-kDa nuclear mono-ARTD that is also known as PARP7 or TiPARP 
(2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible PARP). Its expression is 
induced by TCDD, which is a carcinogen and a potent activator of the ligand-
activated transcription factor aryl hydrocarbon receptor (AHR; Diani-Moore, S. et 
al., 2010; Ma, Q. et al., 2001). Once activated by ligand binding, AHR translocates 
into the nucleus, dimerizes with its binding partner AHR nuclear translocator 
(ARNT) and acts as a transcription factor (Ma, Q. et al., 2001).  
Upon TCCD treatment, a decreased gluconeogenesis is observed, which is at least 
in part due to repression of AHR-mediated transcription of phosphoenolpyruvate 
carboxykinase (PEPCK). ARTD14 over-expression reproduces the TCDD effects on 
glucose metabolism, and it has been suggested that ARTD14 mediates these TCDD 
effects (Diani-Moore, S. et al., 2010). TCDD-dependent transcriptional induction of 
ARTD14 leads to ADP-ribosylation of cytosolic and mitochondrial PEPCKs (Diani-
Moore, S. et al., 2013). However, as AHR suppression also enhances ADP-
ribosylation, it is clear that the complex modulatory effects on ADP-ribosylation 
by AHR are far from being defined at present (Diani-Moore, S. et al., 2013). Further 
research has shown that ARTD14 is itself regulating AHR signaling in a negative 
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feedback loop by acting as a transcriptional repressor (MacPherson, L. et al., 2013). 
However, it also acts with a different mechanism from that of AHR repressor 
(AHRR), as the silencing of ARTD14, but not that of AHRR, increases TCDD-induced 
AHR protein levels, whereas the silencing of both ARTD14 and AHRR enhances 
AHR transactivation (Macpherson, L. et al., 2014). 
Interestingly, over-expression of MACROD1, one of the member of the macro 
domain family (see Chapter 1.6.1), but not that of MACROD2, is able to reverse the 
repressive effect of ARTD14, as shown in a reporter gene assay, and interacts with 
AHR (Ahmed, S. et al., 2015). This evidence suggests that ARTD14-mediated mono-
ADP-ribosylation functions as an important PTM in the pathway controlling the 
response to environmental toxins and that MACROD1 might antagonize the 
repressive effect of ARTD14 by removing mono-ADP-ribosylation from ARTD14, 
AHR and other so far unidentified substrates (Butepage, M. et al., 2015). 
1.3.3.6 ARTD15 
ARTD15, previously known as PARP16, is the smallest member of the ARTD family. 
It has been the first ARTDs to be found to associate with the endoplasmic reticulum 
(ER; Di Paola, S. et al., 2012). It is a single-pass transmembrane protein with the N-
terminal region (amino acids 1-280) positioned towards the cytoplasm, and the 
very short C-terminal tail (amino acids 300-322) in the ER lumen. In line with this 
orientation towards the cytosolic compartment, ARTD15 interacts with and 
modifies the nuclear transport factor karyopherin-β1/importin-β1 (Kapβ1; Di Paola, 
S. et al., 2012). Kapβ1 is selectively mono-ADP-ribosylated by ARTD15 and this 
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modification has been hypothesized to control the nucleo-cytoplasmic shuttling 
of cellular proteins, as the pivotal role of Kapβ1 is to be a carrier protein regulating 
the transport of various cargo proteins through the nuclear pore complex (Di 
Paola, S. et al., 2012). However, it remains open what the consequence of mono-
ADP-ribosylation is for the function of Kapβ1.  
ARTD15 also demonstrates auto-mono-ADP-ribosylation that could be inhibited 
with some well-characterized ARTD inhibitors, such as MIBG (meta-
iodobenzylguanidine) and PJ34 (N-(6-oxo-5, 6-dihydrophenanthridin-2-yl)-N, 
Ndimethylacetamide HCl; Di Paola, S. et al., 2012; Karlberg, T. et al., 2012). 
Furthermore, mono-ADP-ribosylation has not been reported to occur at arginine, 
glutamate or cysteine residues and could not be reverted by ADP-ribosyl-
hydrolase 1 and 3 (ARH1, ARH3; Di Paola, S. et al., 2012). Moreover, ARTD15 is 
required for activation of two proteins involved in the ER stress response during 
the unfolded protein response (UPR): the double-stranded RNA-dependent 
protein kinase (PKR)-like ER kinase (PERK) and the inositol-requiring enzyme 1α 
(IRE1α; Jwa, M. and Chang, P., 2012). During ER stress, ARTD15 has been found to 
auto-ADP-ribosylate itself and ADP-ribosylate PERK and IRE1α, increasing their 
kinase activities and the endoribonuclease activity of IRE1α, which are necessary 
for a proper execution of the UPR (Jwa, M. and Chang, P., 2012). However, the role 
of ARTD15 in the UPR needs further investigations. Considering the ability of 
ARTD15 to modify Kapβ1, PERK and IRE1α, it is emerging as a novel attractive 
therapeutic target, since it has a role in the regulation of nucleo-cytoplasmic 
trafficking and in the UPR, cellular processes that are both involved in different 
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diseases, such as inflammation, neurodegeneration and cancer (Fabrizio, G. et al., 
2015a).  
A recent study has implicated ARTD15 activity in cystic fibrosis (CF). This study 
provided evidence that analogs of latonduine, through the modulation of ARTD15 
activity, restored one of the most common mutations of the CF transmembrane 
conductance regulator gene (CFTR; Carlile, G.W. et al., 2016). This CFTR mutation 
generates a protein that is misfolded and retained in the endoplasmic reticulum. 
To date, a promising therapeutic approach was represented by the use of 
latonduine, a marine sponge metabolite identified as a corrector of this mutation. 
A series of latonduine analogs have further been developed and they have been 
shown to function as correctors of CFTR mutation by the inhibition of ARTD15 
activity and the consequent blocking of IRE1α ribosylation (Carlile, G.W. et al., 
2016). The ribosylation of IRE1α has been reported to be essential for its activation 
during the UPR (Jwa, M. and Chang, P., 2012). Preventing this activation through 
ARTD15 inhibition and IRE1α activity modulation blocked the increased expression 
of chaperones which should have helped to process the misfolded CFTR in the ER 
before transport for proteasomal degradation, thus allowing partially misfolded 
mutated CFTR to escape the ER quality control and traffic to the plasma membrane 
(Carlile, G.W. et al., 2016). Indeed, when surface expression of mutated CFTR is 
restored, it retains some function, however, its stability in the plasma membrane 
and open probability are reduced compared with wild-type channels (Hwang, T.C. 
and Sheppard, D.N., 2009; Lukacs, G.L. et al., 1993). These findings, in addition to 
opening new areas of investigation about IRE1α role in CFTR rescue, also 
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strengthened the importance of ARTD15-mediated ADP-ribosylation and its 
emerging role as a therapeutic target for different diseases, including those with 
protein-trafficking defects. 
1.3.4 The inactive ARTDs: ARTD9 and ARTD13 
ARTD9 is a nucleo-cytoplasmic shuttling protein that has been identified as a risk-
related gene product in aggressive diffuse large B-cell lymphoma (DLBCL), the 
most common non-Hodgkin lymphoma (Aguiar, R.C. et al, 2000; Camicia, R. et al., 
2013; Juszczynski, P. et al., 2006; Shaffer, A.L. 3rd et al., 2012). ARTD9, as for the 
other members of the macro domain-containing mono-ARTDs family (ARTD7 and 
ARTD8), has two prototypical macro domains within the N-terminus, which can 
bind mono- and poly-ADP-ribose (Barkauskaite, E. et al., 2015; Feijs, K.L. et al., 
2013c; Karras, G.I. et al., 2005). It has been described to possess transcriptional 
repressive activity that was dependent on interaction through these macro 
domains but independent of its catalytic activity, since ARTD9 does not show any 
ART activity (Aguiar, R.C. et al., 2005; Feijs, K.L. et al., 2013c). 
Over-expression of ARTD9 promoted lymphocyte migration, indicating a tumor-
promoting role in high-risk DLBCL (Aguiar, R.C. et al., 2000), which has been 
suggested to be through modulation of interferon gamma (IFNγ) signaling-related 
gene expression (Juszczynski, P. et al., 2006). It is known that IFNγ is secreted by 
host-activated tumor-infiltrating T lymphocytes and it induces expression of 
ARTD9 and its interactor BBAP (B-lymphoma and BAL-associated protein) in 
DLBCL cell lines. ARTD9 induction, in turn, promotes the transcription of 
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interferon-controlled genes (Juszczynski, P. et al., 2006). Thus, by inhibiting the 
host immune response against the lymphoma, ARTD9 can function as a 
transcriptional activator of tumor genes in an inflammatory environment. 
Furthermore, ARTD9 has been identified as a novel co-repressor of transcription 
of interferon response factor 1 (IRF1), a tumor suppressor (Camicia, R. et al., 2013). 
ARTD9 directly interacts with STAT1β (signal transducer and activator of 
transcription 1 isoform β) to inhibit IRF1 expression, repressing the anti-proliferative 
and pro-apoptotic INFγ-STAT1-IRF1-p53 complex (Camicia, R. et al., 2013).  
ARTD9 has also been linked to the DNA damage response pathway (Yan, Q. et al., 
2013). In response to DNA strand breaks, ARTD9 and its partner BBAP are recruited 
to DNA damage sites and co-localized with ARTD1 and its product poly-ADP-
ribose (Yan, Q. et al., 2013). At the DNA damage sites, ARTD9 and BBAP mediate 
the specific recruitment of the adaptor protein RAP80 (receptor-associated protein 
80) and checkpoint mediators 53BP1 (p53 binding protein 1) and BRCA1 through 
BBAP-mediated ubiquitination, which limits early and delayed DNA damage and 
enhances cellular viability (Yan, Q. et al., 2013).  
ARTD13, also known as Zinc-finger Antiviral Protein (ZAP/ZC3HAV1) or PARP13, 
according to previous classification, is a type 1 interferon-inducible host factor that 
regulates viral RNA transcripts. It was initially identified as zinc finger antiviral 
protein in a screen for host factors that confer resistance to the retrovirus murine 
leukemia virus (MLV) infection (Bick, M.J. et al., 2003; Gao, G. et al., 2002; Muller, 
S. et al., 2007). However, ARTD13 antiviral activities have been later expanded to 
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other retroviruses (HIV, human immunodeficiency virus) as well as different viral 
families (Mao, R. et al., 2013; Muller, S. et al., 2007; Zhu, Y. et al., 2011).  
ARTD13 binds directly to specific viral mRNAs through its N-terminal zinc finger 
domains and it recruits cellular mRNA degradation factors to promote 
degradation of the target viral mRNA and the inability of the virus to replicate 
efficiently (Guo, X. et al., 2004; Guo, X. et al., 2007; Zhu, Y. and Gao, G. 2008; Zhu, 
Y. et al., 2011). These antiviral properties are not due to ADP-ribosylation since full-
length ARTD13 is not catalytically active, nor is its short isoform (Kleine, H. et al., 
2008; Leung, A.K. et al., 2011). 
In fact, in humans ARTD13 exists in two major isoforms resulting from alternative 
splicing: the full length ARTD13.1, and the truncated ARTD13.2 (Hayakawa, S. et al., 
2011; Vyas, S. et al., 2013). Both isoforms lack ARTD activity and are unable to ADP-
ribosylate target proteins: the catalytic domain of ARTD13.1 lacks amino acid 
residues required for ADP-ribosylation activity, whereas ARTD13.2 completely 
lacks the catalytic domain. Three additional isoforms have been predicted based 
on sequence analyses but their expression in humans has not been experimentally 
verified (Todorova, T. et al., 2015). The two isoforms have been recently reported 
to localize to cytoplasmic stress granules along with ARTD5, ARTD7 and ARTD12 
and, interestingly when over-expressed, both of them decrease miRNA-mediated 
silencing (Leung, A.K. et al., 2011). ARTD13 is unique among ARTDs, as it is the only 
catalytically inactive ARTD shown to be targeted for ADP-ribosylation by other 
ARTDs (Leung, A.K., et al., 2011; Vyas, S. et al., 2013; Vyas, S. et al, 2014). 
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In addition to the antiviral functions of ARTD13, it acts as a pro-apoptotic and a 
pro-inflammatory factor and is a component of the TNF (tumor necrosis factor)-
related apoptosis-inducing ligand (TRAIL) mediated immune response to cancer 
(Todorova, T. et al., 2015). For all these reasons, ARTD13 represents a promising 
therapeutic target for the treatment of multiple disease states, including viral 
infections, autoimmune diseases and cancer. 
1.4 Sirtuins with ADP-ribosylation activity: SIRT4 and SIRT6 
In addition to the previously described families of ART, some members of the 
sirtuin family have also been reported to carry out protein ADP-ribosylation. Silent 
information regulator SIR2-like proteins (sirtuins or SIRTs) are a highly conserved 
class of enzymes found in a variety of phylogenetically distributed species, 
including archea, eubacteria, yeast, mammals and even viruses (Blander, G. and 
Guarente, L., 2004; Carafa, V. et al., 2016; Chen, B. et al., 2015; Denu, J.M., 2005; 
Frye, R.A. et al., 2000; Grubisha, O. et al., 2005). All the members of the sirtuin 
family share a conserved core domain that comprises approximately 200-275 
amino acids, which consists of a NAD+ binding site and a catalytic domain 
(Brachmann, C.B. et al., 1995; Frye, R.A., 1999; Sanders, B.D. et al., 2010). Additional 
N-terminal and/or C-terminal sequences of variable length flank this core domain 
and these extensions have been identified as targets of PTMs, with a role in 
regulating sirtuins function (Zhao, K. et al., 2003; Flick, F. and Luscher, B., 2012; 
Sanders, B.D. et al., 2010). 
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The mammalian sirtuin family is composed of seven proteins, SIRT1-7 that, 
according to molecular phylogenetic analysis, can be divided into four classes: 
class I groups SIRT1, SIRT2 and SIRT3, class II SIRT4, class III SIRT5 and class IV 
SIRT6 and SIRT7 (Frye, R.A., 2000; Vassilopoulos, A. et al., 2011). Sirtuins from class 
II and class III seem to have evolved earlier than the other classes, which, in fact, 
are only present in eukaryotes. Thus, SIRT4 and SIRT5 may be the most ancient 
mammalian sirtuins (Costantini, S. et al, 2013). The seven mammalian sirtuins have 
different cellular localizations: SIRT1 and SIRT2 have been detected in the nucleus 
and cytosol, SIRT3, SIRT4 and SIRT5 in mitochondria, whereas SIRT6 and SIRT7 are 
predominantly nuclear (Figure 1.5; Gertz, M. and Steegborn, C., 2010; Haigis, M.C. 
and Sinclair, D.A., 2010; Michan, S. and Sinclair, D., 2007; Michishita, E. et al., 2005; 
North, B.J. et al., 2003). 
 
Taken from Karagiannis, T.C. and Ververis, K., 2012 
Figure 1.5 Mammalian sirtuin family. Schematic representation of mammalian sirtuins, based on 
their activity (deacetylases, DAC, or ADP-ribosyl-transferases, ART), their subclasses distribution 
and their subcellular localization. DAC or ART binding domains are depicted in dark blue, zinc 
binding domains in black.  
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The SIRT family regulates a broad range of cellular processes including 
development, metabolism, DNA repair, DNA recombination, cellular 
differentiation, transcriptional regulation, apoptosis and lifespan (Blander, G. and 
Guarente, L., 2004; Carafa, V. et al., 2016; Costantini, S. et al, 2013; Denu, J.M., 2005; 
Grubisha, O. et al., 2005; Kupis, W. et al., 2016). Most mammalian SIRTs are 
reported to exhibit in vivo and in vitro histone deacetylation activity: NAD+ is used 
to deacetylate lysine and to simultaneously transfer the acetyl group onto ADP-
ribose, generating O-acetyl (OA)-ADP-ribose and releasing nicotinamide (Smith, 
J.S. et al., 2000; Blander, G. and Guarente, L., 2004; Haigis, M.C. and Sinclair, D.A., 
2010; Kupis, W. et al., 2016; Sauve, A.A. and Schramm, V.L., 2004). Interestingly, 
SIRT1 has been shown to deacetylate ARTD1 and to be functionally connected with 
it due to the use of their common substrate NAD+. These enzymes participate in 
common pathways that are important for different cell fate and metabolic 
decisions, but with counterbalancing roles (Canto, C. et al., 2015). In addition to 
their role as deacetylases, some sirtuins are able to catalyze mono-ADP-
ribosylation reactions, suggesting that some members of the family may be able 
to perform more than one biochemical reaction (Ahuja, N. et al., 2007; Haigis, M.C. 
and Sinclair, D.A., 2010; Kupis, W. et al., 2016; Liszt, G. et al., 2005). 
SIRT4 is a mitochondrial sirtuin, which has been reported an activity of cysteine-
specific mono-ADP-ribosylation on glutamate dehydrogenase (GDH; Herrero-
Yraola, A. et al., 2001; Haigis, M.C. et al., 2006). GDH is involved in the conversion 
of glutamate to α-ketoglutarate, and the ADP-ribosylated form of GDH results in 
inhibition of this activity with the consequent reduction of α-ketoglutarate 
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production (Herrero-Yraola, A. et al., 2001). This SIRT4-mediated modification of 
GDH is involved in the regulation of insulin secretion in pancreatic β cells (Haigis, 
M.C. et al., 2006). In SIRT4-deficient pancreatic β cells, GDH activity increases, 
leading to stimulation of insulin secretion in response to glutamine. Therefore, 
SIRT4 has an inhibitory effect on amino-acid–stimulated insulin secretion (Haigis, 
M.C. et al., 2006). 
SIRT6 has been reported to have auto-mono-ART activity and to catalyze mono-
ADP-ribosylation of ARTD1 in human cells, promoting DNA double-strand break 
repair by homologous recombination in response to oxidative stress (Mao, Z. et 
al., 2011; Mao, Z. et al., 2012). SIRT6 has also been associated with aging and cancer: 
SIRT6 expression diminishes with cellular senescence and its overexpression in 
non-senescent cells strongly stimulates homologous recombination repair, in an 
ARTD1-dependent manner (Mao, Z. et al., 2012). Thus, SIRT6 might counteract age-
related genomic instability, and the higher incidence of cancer, with age. 
Moreover, SIRT6 overexpression has been reported to induce apoptosis in 
different cancer cell lines (Van Meter, M. et al., 2011a). Interestingly, the activity of 
SIRT6 as tumor suppressor has been associated with its mono-ART activity and 
not, like other sirtuin members (SIRT1, SIRT2, SIRT3 and SIRT7), to the deacetylase 
one (Bruzzone, S., et al., 2013; Donadini, A. et al., 2013; Van Meter, M. et al., 2011b).   
However, although mono-ART activity has been linked with SIRT4 and SIRT6, the 
relevance of the sirtuins as cellular ARTs is in doubt, as the efficiency of this reaction 
has been reported to be very low. Sirtuin-mediated ADP-ribosylation needs to be 
better understood, since it represents an important area of future discovery. A 
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better characterization of the mechanistic basis of the reaction, the substrate 
specificity of the ADP-ribosylation activity, and of the relevance of this activity in 
vivo is an ongoing subject of investigation.   
1.5 ADP-ribosyl-hydrolases 
Both mono- and poly-ADP-ribosylation are reversible reactions: specific hydrolase 
enzymes are able to cleave these covalent bonds, thereby releasing the target 
protein. Poly-ADP-ribose (PAR)-glycohydrolase (PARG) can specifically hydrolyze 
the ribose–ribose bonds in PAR chains, while the ADP-ribosyl-hydrolases (ARHs) 
cleave the mono-ADP-ribose–protein bond (Lin, W. et al., 1997; Mashimo, M. et 
al., 2014; Takada, T. et al., 1993; Verheugd, P. et al., 2016). ARHs are enzymes that 
reverse mono-ADP-ribosylation reactions by catalyzing the removal of ADP-ribose 
from modified proteins (Figure 1.6; Mashimo, M. et al., 2014; Moss, J. et al., 1992). 
Considering that ADP-ribosylation of proteins generally leads to loss of function, 
removal of ADP-ribose could be associated with the reactivation of the target 
protein. Thus, the molecular characterization of ARHs supports the idea that 
reversible ADP-ribosylation cycle, controlled by the balance between the 
transferase and hydrolase activity, could have a role in the regulation of eukaryotic 
cell functions.  
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Taken from Fabrizio, G. et al., 2015a 
Figure 1.6 Schematic representation of the reversible mono-ADP‐ribosylation reaction. 
Mono-ARTs transfer the ADP-ribose moiety from NAD+ to a specific amino acid of the 
target protein, releasing nicotinamide. This modification leads to inactivation of the target 
protein. Specific hydrolase enzymes are able to cleave the covalent bond between ADP-
ribose and the side chain of target protein, restoring normal protein functions. 
A well-documented example of the regulatory role of ADP-ribosylation cycle is 
that of the photosynthetic bacterium Rhodospirillum rubrum, where it regulates 
the function of the enzyme dinitrogenase reductase (Li, X.D. et al., 2009; Lowery, 
R.G. and Ludden, P.W., 1988; Nordlund, S. and Ludden, P.W., 2004; Nordlund, S. 
and Hogbom, M., 2013; Wang, H. et al., 2005). This enzyme is reversible mono-
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ADP-ribosylated by an ART known as DRAT (dinitrogenase reductase ADP-ribosyl-
transferase), which modifies arginine 101 of dinitrogenase reductase (Lowery, R.G., 
and Ludden, P.W., 1988; Ma, Y. and Ludden, P.W., 2001; Pope, M.R. et al., 1985; 
Wang, H. et al., 2005). However, the dinitrogenase reductase could be fully 
reactivated by an ARH known as DRAG (dinitrogenase reductase activating 
glycohydrolase), as reviewed by Nordlund and Hogbom in 2013 (Nordlund, S. and 
Hogbom, M., 2013). Thus, Rhodospirillum rubrum represents the first example of 
how a vital biochemical process like nitrogen fixation is tightly regulated through 
an ADP-ribosylation cycle. 
The best characterized ADP-ribosyl-hydrolase is ARH1, which specifically 
hydrolyzes ADP-ribose-arginine bonds, leading to the release of free mono-ADP-
ribose and regeneration of the guanidino group of arginine (Moss, J. et al., 1986; 
Takada, T. et al., 1993). ARH1 is a soluble 39-kDa protein that in mammalian cells 
shows prevalently cytosolic activities, although some are also located on the cell 
surface (Hassa, P.O. et al., 2006; Mashimo, M. et al., 2014). In addition to mammals, 
ARH1 has also been identified in bacterial and avian systems (Lowery, R.G. and 
Ludden, P.W., 1988; Moss, J. et al., 1985; Moss, J. et al., 1986, Moss, J. et al., 1992). 
ARH1 activity exists in a variety of animal species, with the highest specific activities 
found in rat and mouse brain, spleen and testis (Moss, J. et al., 1992). Despite their 
functional similarities, ARH1 protein from human, rat and mouse tissues have only 
limited region of similarity in their deduced amino acids sequences (Moss, J. et al., 
1992). In these regions, the conserved aspartate residues (Asp 60 and Asp 61) of 
rat ARH1 have been demonstrated to be critical for catalytic activity, but not for 
77 
 
ADP-ribose binding (Mashimo, M. et al., 2014; Konczalik, P. and Moss, J., 1999). 
These active site residues appear to be conserved from bacteria to human and to 
have a critical role for catalysis (Mashimo, M. et al., 2014; Konczalik, P. and Moss, 
J., 1999).  
It has also been shown that ARH1 activity can counteract the ADP-ribosylation of 
Gαs that is catalyzed by cholera toxin, and that cellular knock down of ARH1 shows 
increased sensitivity to the deleterious effects of this toxin. However, during 
diseases, the extremely efficient ART activity of cholera toxin cannot be reversed 
by ARH1 (Mashimo, M. et al., 2014; Kato, J. et al., 2011).  
Besides ARH1, additional unidentified proteins exhibiting ADP-ribosyl lyase 
activities have been reported, which are thought to function on glutamate, lysine 
or cysteine residues, releasing a deoxy form of ADP-ribose (Oka, J. et al., 1984; 
Okayama, H. et al., 1978; Tanuma, S. and Endo, H., 1990). Enzymatic activities 
responsible for the hydrolysis of ADP-ribosyl-cysteine have been identified in 
human and bovine erythrocytes and in mitochondria from bovine liver (Jorcke, D. 
et al., 1998; Saxty, B.A. and van Heyningen, S., 1995; Tanuma, S. and Endo, H., 1990).  
In silico screening revealed two Arh-like genes, Arh2 and Arh3, which are 
homologous to the human Arh1 gene (Glowacki, G. et al., 2002). Despite their 
structural similarities, ARH family members have different functions. However, the 
discovery of ARH2 and ARH3 suggested that the hydrolase family is larger than 
originally thought. ARH2 is the closest relative of ARH1, with which it shares 45% 
sequence identity, but does not exhibit any detectable activity on ADP-ribose-
arginine, -cysteine, -diphtamide or –asparagine bonds (Koch-Nolte, F. et al., 2008; 
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Mashimo, M. et al., 2014; Oka, S. et al., 2006). Thus, it is possible that ARH2 is 
inactive, or is a candidate for glutamate- or aspartate-specific ARH.   
ARH3 is an enzyme localized in the nucleus and in mitochondria with unexpected 
activity, since it is capable of hydrolyzing poly-ADP-ribose and O-acetyl-ADP-
ribose, but not mono-ADP-ribose (Mashimo, M. et al., 2014; Oka, S. et al., 2006). 
The critical aspartate residues of ARH3 (Asp77 and Asp78) are located in a region 
similar to that required for hydrolase activity in ARH1, but distinct from that of 
PARG (Mashimo, M. et al., 2014; Oka, S. et al., 2006). Also, the analysis of 
tridimensional structure indicates the presence of an α-helical protein fold with 
pseudo two-fold symmetry, confirming the difference from the mixed α-helix/β-
sheets secondary structure prediction of PARG (Koch-Nolte, F. et al., 2008; 
Mashimo, M. et al., 2014; Mueller-Dieckmann, C. et al., 2006). 
All these data are consistent with the conclusion that ARH3 might be a functional 
PARG, but structurally unrelated to the real PARG (Mashimo, M. et al., 2014; Oka, 
S. et al., 2006). 
The characterization of ADP-ribosyl-hydrolase activities strongly support the 
significance of the mono-ADP-ribosylation reaction and the existence of an ADP-
ribosylation cycle, even though the functional interplay of the constituents of such 
a cycle remains to be demonstrated. Further investigations are necessary, also 
considering the recent findings about macro domain containing protein that have 
been reported to be able to remove mono-ADP-ribose from substrate proteins 
and, thus, reverse mono-ADP-ribosylation reactions (see Chapter 1.6 below). 
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1.6 ADP-ribose binding modules 
Different receptor and adaptor proteins have been described for their special 
ability to recognize specific signals such as small second messenger molecules and 
PTMs, thereby participating in various cellular signaling pathways. The molecular 
recognition is usually carried out by globular protein modules that recognize their 
ligand substrate with high specificity and act by changing the cellular localization, 
the local concentration or the specific activity of their target (Till, S. and Ladurner, 
A.G., 2009).  
Considering the recent scientific advances in the PTMs field and the increasing 
awareness on ADP-ribosylation reactions, it has been of considerable interest to 
identify and characterize protein binding motifs and/or modules able to bind 
mono- and poly-ADP-ribose. Recent evidences indicate there are four principal 
ADP-ribose binding domains and motifs: 
i) the Nudix domain,  
ii) the poly-ADP-ribose binding peptide motif, 
iii) the poly-ADP-ribose binding zinc-finger (PBZ) domain, 
iv) the macro domain. 
The Nudix domain is a domain containing the consensus sequence 
GX5EX7REUXEEXGU, where X is any amino acid and U is a hydrophobic amino acid, 
typically isoleucine, leucine, or valine. This domain has been found in phosphatases 
(Bessman, M. J. et al., 1996; Gabelli, S.B. et al., 2001). The poly-ADP-ribose binding 
peptide motif consists of hydrophobic and positively charged amino acids with the 
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consensus sequence [HKR]-X-[AIQVY]-[KR]-[AILV]-[FILPV], and lies within histones 
(H3, H4, H2A and H2B), XRCC1 (X-ray cross complementing group 1 protein), p53 
and RNPs (ribonucleoproteins; Gagne, J.P. et al., 2008; Pleschke, J.M. et al., 2000). 
The PBZ domain is characterized by the following consensus sequence 
[K/R]XXCX[F/Y]GXXCXBBXXXXHXXX[F/Y]XH, where B is a basic amino acid residue 
and X any amino acid. The PBZ domain has been found in DNA repair and 
checkpoint proteins, for example one and two PBZ domains are present in 
checkpoint with forkhead and ring finger domains (E3 ubiquitin protein ligase; 
CHFR) and aprataxin and PNKP (polynucleotide kinase/phosphatase) like factor 
(APLF) proteins, respectively (Ahel, I. et al., 2008; Eustermann, S. et al., 2010; Kanno, 
S. et al., 2007). The macro domain represents protein modules that have been 
found in protein across different species (Karras, G.I. et al., 2005). Macro domains 
regulate different cellular functions that will be discussed in the next paragraph. 
Collectively, the identification of specific ADP-ribose-binding sites in several 
proteins that participate in cellular signal network suggests ADP-ribosylation could 
be involved in protein-protein and protein/DNA interactions, protein localization 
or protein degradation.     
1.6.1 Macro domains 
Macro domains are a family of evolutionarily conserved proteins that can interact 
with ADP-ribose or other NAD derivatives (Forst, A.H. et al., 2013; Neuvonen, M. 
and Ahola, T., 2009). Members of the macro domain family have been conserved 
throughout evolution, with homologues identified in viruses (coronaviruses, 
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alphaviruses), archea (Archaeoglobus fulgidus), bacteria (Escherichia coli), 
invertebratres (Drosophila melanogaster), anphibians (Xenopus laevis), plants 
(Arabidopsis thaliana, Oryza sativa) and mammals (humans, mice; 
Anantharaman, V. et al., 2002; Han, W. et al., 2011; Till, S., and Ladurner, A.G., 2009). 
In humans, so far, ten human genes encoding 11 members of the macro domain 
family have been identified, since macroH2A includes the two isoforms 
macroH2A1.1 and macroH2A1.2 (Table 1.4; Han, W. et al., 2011).  
Table 1.4 Human macro domain family proteins.  
 
Modified from Han, W. et al., 2011 
Although the first macro domain was discovered more than 20 years ago, only in 
the recent years it has been demonstrated that macro domains can bind ADP-
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ribose, definitively establishing the connection between macro domains and ADP-
ribosylation reactions and opened up new interesting research areas (Karras, G.I. 
et al., 2005). Macro domains are not identical: their structural differences 
predetermine macro domain containing protein to act solely as a reader of mono-
ADP-ribose or poly-ADP-ribose, or to act as a reader and eraser of the 
modification as well. A globular macro domain comprises six stranded mixed β-
sheets and five α-helices, which form a cleft for the ligand. The binding occurs via 
stacking interaction with the adenine ring, strengthened through the interactions 
with the pyrophosphate of ADP-ribose and with specificity provided by hydrogen 
bonding with the distal ribose (Karras, G.I. et al., 2005; Han, W. et al., 2011; Till, S. 
and Ladurner, A.G. 2009).  
Different macro domains are capable of interacting with monomeric, polymeric, 
or both forms of ADP-ribose and other NAD derivatives. For example, the macro 
domain of the histone variant macroH2A1.1 and the chromatin remodeller ALC1 
are binding module for poly-ADP-ribose (Feijs, K.L. et al., 2013c; Gottschalk, A.J. 
et al., 2009; Timinszky, G. et al., 2009). Other macro domains interact with mono-
ADP-ribosylated proteins, such as the macro domain of the Af1521 protein from 
Archaeoglobus fulgidus, which represents the first evidence of a macro domain 
containing protein able to recognize mono-ADP-ribosylated targets (Dani, N. et 
al., 2009). Recently, other members of the human macro domain containing 
proteins, such as ARTD8, macroD1, macroD2 and C6orf130 (O-acetyl-ADP-ribose 
deacetylase, also name TARG1), have been associated to mono-ADP-ribosylation 
and demonstrated to reverse this reaction (Feijs, K.L. et al., 2013c; Forst, A.H. et al., 
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2013; Jankevicius, G. et al., 2013; Rosenthal, F. et al., 2013; Sharifi, R. et al., 2013). 
Additionally, some macro domains are O-acetyl-ADP-ribose (OAADPr) binding 
modules able to efficiently catalyze the hydrolysis of OAADPr, which is a 
metabolite from the sirtuin-mediated NAD+-dependent deacetylation reactions 
(Chen, D. et al., 2011; Tong, L. and Denu, J.M., 2010). Thus, all of these macro 
domain-containing proteins are mono-ADP-ribosyl-hydrolases that can reverse 
mono-ADP-ribosylation, removing mono-ADP-ribose from modified proteins. 
These findings define macro domain-containing proteins as the functional 
antagonists of intracellular mono-ARTs and definitively establishes mono-ADP-
ribosylation as a fully reversible PTM (Rosenthal, F. et al., 2013).  
Macro domains are involved in different biological processes, since it has been 
demonstrated they can function in DNA repair, chromatin remodelling, 
developmental mechanisms depending on poly-ADP-ribose production or acting 
in concert with sirtuins as potential in vivo regulators of cellular OAADPr produced 
by NAD+-dependent deacetylation reactions catalysed by these enzymes 
(Changolkar, L.N. and Pehrson, J.R., 2006; Changolkar, L.N. et al., 2007; Chen, D. et 
al., 2011; Timinszky, G. et al., 2009). 
1.6.2 Macro domains as affinity tools 
The demonstration that macro domains have ADP-ribose binding properties 
opens new possibilities for studying ADP-ribosylation reactions. In fact, during the 
past years, one of the major difficulties in the analysis of this PTM was the lack of 
biochemical tools able to easily recognize ADP-ribosylated proteins. The 
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characterization of the Af1521 macro domain from Archaeoglobus fulgidus and 
the demonstration that it can bind not only ADP-ribose, but also ADP-ribosylated 
proteins, confirmed that macro domains represent protein–protein interaction 
domains (Karras, G.I. et al., 2005). This finding prompted researchers to evaluate 
the possibility to use the macro domain module as an affinity tool to isolate ADP-
ribosylated proteins (Dani, N. et al., 2009). Particularly, Dani and colleagues 
showed that Af1521 can be used as a selective bait for high-affinity purification of 
mono-ADP-ribosylated proteins. Moreover, when used in combination with mass 
spectrometry, it is a powerful tool for the identification of mono-ADP-ribosylated 
target, since it allows identification of a series of previously known ADP-ribosylated 
protein in addition to a large number of new substrates that need to be individually 
validated (Dani, N. et al., 2009). Therefore, the use of macro domains as an affinity 
tool represents an important step toward the discovery of new ART targets for 
which it is of extreme importance understanding the physiological role and the 
pharmacological potential associated with this protein modification. 
1.7 Mono-ADP-ribosylation substrates 
Several proteins have been identified as targets of mono-ADP-ribosylation 
reactions and their modification has numerous and diverse effects on protein 
functions and cellular pathways, including DNA damage, RNA metabolism, 
chromatin organization, transcription, protein trafficking, signal transduction, 
stress responses and cell cycle regulation (Di Girolamo, M. et al., 2005; Feijs, K.L. 
et al., 2013a; Gibson, B.A. and Kraus, W.L., 2012; Scarpa, E.S. et al., 2013). For most 
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of these ADP-ribosylated substrates the modified amino acids have been 
identified, while the specific enzymes that are responsible for these modifications 
are still not known. An example of an orphan ART substrate is that of the G-protein 
β subunit, whose functional, enzymatic mono-ADP-ribosylation has been found 
both in isolated plasma membranes from different cell lines (including Swiss 3T3, 
CHO and HL60 cells), and in intact cells (Lupi, R. et al., 2000). Specifically, mono-
ADP-ribosylation of the β subunit occurs on arginine 129 (Arg129), a critical amino 
acid residue located in the β common-effector-binding surface (Chen, Y. et al., 
1997; Weng, G. et al., 1996; Yan, K. and Gautam, N., 1997; Yan, K. et al., 1996). The 
reaction is catalyzed by an unknown plasma membrane-associated mono-ART, 
with an intracellular catalytic site. Interestingly, the modified β subunit can be de-
ADP-ribosylated by a cytosolic ARH, which regenerates a native βγ dimer by 
releasing the bound ADP-ribose (Lupi, R. et al., 2000). Mono-ADP-ribosylation of 
this Arg129 residue prevents β subunit-dependent modulation of effectors such as 
type 1 adenylyl cyclase (AC), phosphoinositide 3-kinase (PI3K) and phospholipase 
C (PLC; Lupi, R. et al., 2000; Lupi, R. et al., 2002). Thus, the ADP ribosylation/de-
ribosylation cycle seems to correspond to a functional activation/inactivation cycle 
of the βγ dimer, modulating its function.      
Of note, it is of particular interest that the mono-ADP-ribosylation of the β subunit 
has been shown to be regulated by hormonal control: it can be increased upon 
activation of specific G-protein coupled receptors (GPCRs) such as thrombin, 
serotonin and cholecystokinin receptors (Lupi, R. et al., 2002). Our group has 
reported that β subunit mono-ADP-ribosylation is differentially modulated by 
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GPCRs and, particularly, that hormone stimulation of the thrombin receptor 
induces β subunit mono-ADP-ribosylation, thus affecting G-protein signaling (Di 
Girolamo, M. et al., 2005). Conversely, hormone stimulation of the gonadotropin-
releasing hormone receptor (GnRHR) inhibits β subunit mono-ADP-ribosylation 
and simultaneously activates the ADP-ribosylation factor 6 (ARF6; Dani, N. et al., 
2011). This activation of ARF6, in turn, acts as a competitive inhibitor for the β 
subunit modification, becoming the preferred substrate of the endogenous mono-
ART (Dani, N. et al., 2011).  
The demonstration that the β subunit is physiologically modified by mono-ADP-
ribosylation is of extreme interest both because of the central role that the βγ 
dimer plays in signal transduction pathways downstream of GPCRs, and because 
this was the first in vivo demonstration of a PTM for the G-protein β subunit.  
An intracellular ADP ribosylation/de-ribosylation cycle has also been described for 
the mitochondrial protein GDH. Cysteine-specific ADP-ribosylation of GDH causes 
substantial inhibition of its enzymatic activity in intact Hep-G2 cells (Herrero-
Yraola, A. et al., 2001). Further studies have identified SIRT4 as the enzyme 
responsible for the mono-ADP-ribosylation of GDH. Specifically, SIRT4 ADP-
ribosylates GDH and reduces its activity by 50% in β cells during calorie-sufficient 
conditions, opposing the effects of calorie restriction (Haigis, M.C. et al., 2006). 
During calorie restriction there is an increase in GDH activity accompanied by a 
downregulation of SIRT4, a finding that contrasts with the expectation of the 
increase in sirtuins activity. The downregulation of SIRT4 could depend on the 
reduction in the NAD/NADH ratio observed during calorie restriction (Haigis, M.C. 
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et al., 2006). The lower NAD/NADH ratio may downregulate SIRT4 activity and 
reduce the ADP-ribosylation of GDH that, thus, shows increased activity. Due to 
the central position of GDH in metabolism, where it lies as the crossroads of several 
important pathways, a tight control of its catalytic activity is essential.  
Another yet-to-be identified cellular ART modifies the elongation factor 2 (EF-2): 
its ADP-ribosylated form has been detected in a wide variety of eukaryotic cell 
types and it has been proposed to serve as a mechanism for regulating cellular 
protein synthesis (Fendrick, J.L. et al., 1992).  
Also the cytoskeletal proteins desmin, actin and tubulin have been described as 
target of intracellular mono-ADP-ribosylation. Desmin is a muscle-specific 
intermediate filament protein and it has been described as a substrate for an 
endogenous arginine specific mono-ART that, however, has not yet been 
molecularly characterized (Huang, H.Y. et al., 1993). ADP-ribosylated desmin 
cannot assemble into intermediate filaments in vitro and, when incubated with 
ARH, the self-assembly properties of the protein are restored (Zhou, H. et al., 1996).   
Actin is another intracellular target of mono-ADP-ribosylation: it can be mono-
ADP-ribosylated by arginine-specific ART in homogenates of various cells and 
tissue. Mono-ADP-ribosylation of non-muscle actin inhibits its ability to 
polymerize in chicken heterophils, affecting some of the actin-mediated functions 
such as the release of azurophilic granules (Terashima, M. et al., 1996). Moreover, 
it has been reported that in HL-60 cells mono-ADP-ribosylation of actin is involved 
in the modification of the cytoskeleton and can lead to apoptosis (Lodhi, I.J. et al., 
2001).  
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Also tubulin can be a target of mono-ADP-ribosylation as it has been initially 
demonstrated by an in vitro analysis (Raffaelli, N. et al., 1992). Because ribosylation 
of tubulin blocks its self-assembly properties, it has been proposed that the ADP-
ribosylation sites could be essential for tubulin assembly (Terashima, M. et al., 
1999). More recently, Dani and colleagues confirmed the fact that tubulin is a 
target of mono-ADP-ribosylation demonstrating it was one of the proteins 
identified by mass spectrometry after a GST (glutathione S-transferase)-mAf1521 
pull-down assay (Dani, N. et al., 2009).  
Additionally, the transcriptional corepressor C-terminal binding protein, brefeldin 
A (BFA)-induced ADP-ribosylated substrate (CtBP1/BARS) is another target that 
can be modified by mono-ADP-ribosylation (Di Girolamo, M. et al., 1995; Feng, Y. 
et al., 2003). CtBP1/BARS functions as both a transcriptional corepressor and as a 
modulator of Golgi structure and upon BFA stimulation, it results in mono-ADP-
ribosylation catalyzed by an unknown intracellular mono-ART (De Matteis, M.A. et 
al., 1994; Di Girolamo, M. et al., 1995). The ADP-ribosylation of CtBP1/BARS causes 
its inactivation. Specifically, it loses its catalytic activity and its ability to promote 
the fission of Golgi tubules (Weigert, R. et al., 1999). Specific inhibitors of BFA-
induced ADP-ribosylation are able to prevent the toxic effect of BFA on the Golgi 
complex, supporting the functional role of this reaction (Weigert, R. et al., 1997).  
Moreover, the ARF6 has been identified as a new target of mono-ADP-
ribosylation, that specifically occurs on arginine 110 (Arg110; Dani, N. et al., 2011). 
ARF6 is involved in the regulation of plasma-membrane related processes, and in 
the reorganization of the cortical actin cytoskeleton (D'Souza-Schorey, C. and 
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Chavrier, P., 2006; Donaldson, J.G., 2003; Honda, A. et al., 1999). Moreover, it is 
emerging as a key component of tumor invasion and metastasis, and its mono-
ADP-ribosylation seems to contribute to the regulation of these ARF6-mediated 
functions (Dani, N. et al., 2013). Thus, ARF6 can be regarded as a promising target 
for therapeutic intervention in cancer. The molecular chaperone GRP78/BiP has 
also been reported to undergo intracellular mono-ADP-ribosylation. Its mono-
ADP-ribosylation and the specific role of this modification will be detailed 
discussed in the next paragraphs.  
1.8 GRP78/BiP 
The 78 kDa glucose-regulated protein GRP78, also known as BiP (immunoglobulin 
heavy chain-binding protein), is a molecular chaperone initially described in 1977 
(Shiu, R.P. et al.,1977). It is also referred to as HSPA5, Heat Shock Protein family A 
(HSP70) member 5, since it is a member of the 70 kDa Heat Shock Family of Stress 
Proteins (HSP70; Daugaard, M. et al., 2007; Murphy, M.E., 2013). Although it shares 
about 60% amino acid sequence homology with HSP70, including the ATP-
binding site required for its role as a chaperone in protein folding, there are two 
distinct aspects that differ between GRP78/BiP and HSP70 (Daugaard, M. et al., 
2007; Murphy, M.E., 2013). Firstly, GRP78/BiP has a signal peptide sequence that 
targets it to the ER, whereas HSP70 does not contain this sequence and is cytosolic, 
and translocating to the nucleus upon stress (Daugaard, M. et al., 2007; Murphy, 
M.E. 2013). Secondly, GRP78/BiP is not affected by heat shock conditions that, 
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instead, greatly elevated the expression of HSP70 and other members of the heat 
shock protein family (Murphy, M.E., 2013; Wooden, S.K. and Lee, A.S., 1992).   
GRP78/BiP, which primarily resides in the lumen of the ER, has a central role in ER-
mediated cellular processes (Lee, A.S., 2001). It functions as a facilitator of proper 
protein folding, preventing intermediates from aggregating and targeting 
misfolded proteins for proteaosomal degradation (Flynn, G.C. et al., 1991; Ellgaard, 
L. and Helenius, A., 2003; Romisch, K., 2005). In addition, it has a role in binding of 
calcium for storage at high concentrations in the ER lumen and it serves as an ER 
stress signaling regulator, controlling the activation of transmembrane ER stress 
sensors (Ni, M. and Lee, A.S., 2007). 
Specific mono-ADP-ribosylation of GRP78/BiP was demonstrated in 1994 (Ledford, 
B.E. and Leno, G.H., 1994). The mono-ADP-ribosylation of GRP78/BiP was detected 
in response to nutritional stress, a condition that depletes the ER of proteins, 
resulting in a reduction of translation activity. Laitusis and co-workers have 
hypothesized that this ADP-ribosylation is related to the rate of protein synthesis 
and processing (Laitusis, A.L. et al., 1999). According to this model, in cells with 
high rate of protein synthesis GRP78/BiP is in its active state, complexed with 
protein-folding intermediates and not available for the ADP-ribosylation. A 
physiological, or induced, decrease of protein synthesis results in the accumulation 
of the active, free form of the chaperone that is mono-ADP-ribosylated and, thus, 
inactivated. Hence, the modification of GRP78/BiP by mono-ADP-ribosylation 
could be a system to balance the amount of the active, functional chaperone with 
both protein processing and synthesis.    
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Although GRP78/BiP mono-ADP-ribosylation has been known for long time, the 
enzyme responsible for this modification has not yet identified. It was previously 
postulated that an arginine-specific enzyme of the ARTC family would be needed 
to modify GRP78/BiP and it has been recently reviewed by Fabrizio et al. in 2015 
(Di Girolamo, M. et al., 2005, Fabrizio, G. et al., 2015b). Moreover, it has been 
demonstrated that mono-ADP-ribosylation of GRP78/BiP occurs on two arginine 
residues (R470, R492) in the substrate binding domain of the chaperone and 
analysis of the mutated protein is in line with the concept that this PTM can 
interfere with substrate binding (Chambers, J.E. et al., 2012). 
1.8.1 GRP78/BiP and Unfolded Protein Response (UPR) 
The ER represents one of the major signal-transducing organelle, providing a 
highly selective quality control system to ensure correct protein folding and 
assembly, and recognizing unfolded proteins that can be repaired or targeted for 
proteasomal degradation. A number of biochemical, physical and pathological 
stimuli, such as ER calcium depletion, glucose deprivation, oxidative stress and 
DNA damage can disrupt ER homeostasis and lead to accumulation of unfolded 
or misfolded proteins in the ER, causing the so called “ER stress”. Eukaryotic cells 
have evolved a coordinated cellular response to adapt to adverse conditions in 
order to maintain homeostasis and survive. One such coping mechanism is the 
activation of the UPR (Gardner, B.M. et al., 2013; Grootjans, J. et al., 2016; Kaufman, 
R.J., 1999; Strzyz, P., 2016; Welihinda, A.A. et al., 1999). 
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Activation of the UPR has three main consequences, ultimately resulting in 
enhancement of ER protein folding capacity through expansion of the ER and 
increased expression of chaperones and foldases, an initial transient inhibition of 
protein synthesis to temporarily stop production of new proteins, and induction 
and activation of the ER-associated degradation (ERAD) system that retro-
translocates terminally misfolded proteins from the ER for proteasome-dependent 
degradation (Olzmann, J.A. et al., 2013;  Ni, M. and Lee, A.S. 2007; Qi, L. et al., 
2017). If the ER stress conditions are not resolved and still continuing persisting, an 
ER stress-induced cell death arises. Generally, ER stress-associated cell death 
occurs through caspase activation, although caspase-independent necrosis and 
autophagy have also been observed (Hitomi, J. et al., 2004; Nakagawa, T. et al., 
2000; Ullman, E. et al., 2008). The UPR in mammalian cells is regulated by three ER 
transmembrane proteins: activating transcription factor 6 (ATF6), inositol-
requiring 1 alpha (IRE1α), and double-stranded RNA-dependent protein kinase 
(PKR)-like ER kinase (PERK; Brewer, J.W., 2014; Hetz, C., 2012; Mori, K., 2000). Each 
sensor is composed of an ER luminal domain sensitive to accumulation of 
misfolded proteins, an ER transmembrane domain that can target proteins for 
localization to the ER membrane, and a cytosolic functional domain (Figure 1.7; 
Schroder, M. and Kaufman, R.J., 2005).  
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Modified from Schroder, M. and Kaufman, R.J., 2005 
Figure 1.7 Architecture of the ER stress sensors. Schematic representation of the principal 
domains of the ER stress sensors IRE1α, PERK and ATF6. The orange bars represent regions 
sufficient for signal transduction or oligomerization. The blue bars represent regions 
binding to GRP78/BiP. A black box represents the signal peptide and the hatched box 
depicts the region of limited homology between IRE1 and PERK. The following domains are 
indicated. bZIP: basic leucine zipper; GLS1 and GLS2: Golgi localization sequences 1 and 2; 
TAD: transcriptional activation domain; TM: transmembrane domain.  
GRP78/BiP is a key regulator of UPR. In addition to GRP78/BiP that actively binds 
nascent polypeptide chains, there is some GRP78/BiP that interacts with the 
luminal domain of ATF6, IRE1α and PERK, keeping them inactive (Bertolotti, A. et 
al., 2000; Chen, X. et al., 2002; Shen, J. et al., 2002). Importantly, the peptide-
binding site of GRP78/BiP that associates with the receptors is the same that binds 
to hydrophobic patches of misfolded or unfolded ER peptides (Rutkowski, D.T. and 
Kaufman, R.J., 2004). 
During ER stress, the GRP78/BiP that binds the UPR-signaling proteins is recruited 
to the misfolded nascent proteins that are accumulating in the ER and, thereby, it 
releases its binding of ATF6, IRE1α and PERK. Once released, these three protein 
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sensors become functional, initiating the UPR (Figure 1.8; Brewer, J.W., 2014; Hetz, 
C., 2012; Merksamer, P.I. and Papa, F.R., 2010; Ron, D. and Walter, P., 2007). The 
first pathway to be activated, within minutes, is PERK, followed by ATF6 and, lastly, 
by IRE1α (Novoa, I. et al., 2003). 
 
 Modified from Zhang, K. and Kaufman, R.J., 2008 
Figure 1.8 The mammalian UPR pathways. During ER stress GRP78/BiP preferentially binds 
to unfolded or misfolded proteins, thus driving the equilibrium of GRP78/BiP binding 
away from IRE1α, PERK and ATF6. These three proteins are the initiators of the three main 
signaling cascades of the UPR.  
Despite disparate signaling mechanisms, each signaling pathway activates 
transcription factors that mediate the induction of a variety of UPR response 
genes. These UPR signaling pathways are examined in the next paragraphs. 
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1.8.1.1 PERK  
PERK is the first pathway to be activated, within minutes from UPR starting (Brewer, 
J.W. et al., 2014; Novoa, I. et al., 2003). PERK is a type I ER-resident transmembrane 
protein that, under normal conditions, is bound to GRP78/BiP. Following ER stress, 
GRP78/BiP dissociates, thereby allowing PERK to autophosphorylate and dimerize, 
also inducing transphosphorylation (Bertolotti, A. et al., 2000; Brewer, J.W. et al., 
2014; Cui, W. et al., 2011; Liu, C.Y. et al., 2000). Once activated, PERK phosphorylates 
the α subunit of eukaryotic translation initiation factor (elF2α) on serine 51 (Brewer, 
J.W. et al., 2014; Cui, W. et al., 2011; Harding, H.P. et al., 1999; Shi, Y. et al., 1998; 
Wek, R.C. et al., 2006). This interferes with global mRNA binding of ribosomal 60s 
and 40s subunits and results in global translational attenuation and reduction of 
protein synthesis, thus reducing ER workload (Brostrom, C.O. and Brostrom, M.A., 
1998; Harding, H.P. et al., 1999; Hinnebusch, A.G., 1994; Liu, Z. et al., 2015; Wek, 
R.C. et al., 2006)  
Although in general phosphorylation of elF2α attenuates mRNA translation, 
translation of certain mRNAs with short open reading frames in the 5’-UTR is 
enhanced by phosphorylation of eIF2α (Harding, H.P. et al., 2000; Liu, Z. et al., 
2015; Wek, R.C. et al., 2006). ATF4 is an example of such mRNA and its expression 
results in upregulation of UPR target genes encoding proteins involved in amino 
acid biosynthesis, antioxidative stress response, and ER stress-induced apoptosis 
(Harding, H.P. et al., 2003; Liu, Z. et al., 2015). 
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Activation of PERK by ER stress is reversible: activated PERK can be rapidly 
dephosphorylated upon restoration of ER homeostasis. Also elF2α 
phosphorylation is a controlled mechanism: the C/EBP (CCAAT-enhancer-binding 
protein) homologous protein (CHOP), which is a pro-apoptotic transcription factor, 
is activated by ATF4; CHOP upregulates the growth arrest and DNA damage 
inducible gene 34 (GADD34) which dephosphorylates eIF2α, thus acting as a 
negative feedback loop and relieving the cell of the translational repression during 
prolonged ER stress (Chambers, J.E. et al., 2015; Liu, Z. et al., 2015; Marciniak, S.J. 
et al., 2004; Novoa, I. et al., 2001).   
1.8.1.2 ATF6 
After PERK activation and reduction of protein synthesis, ATF6 cleavage occurs 
next most rapidly. The relative delay is caused by the need for nuclear translocation 
of ATF6 and the induction of transcription and protein synthesis. ATF6 is 
comprised of two transmembrane basic leucine zipper (bZIP) transcription factors, 
ATF6α and ATF6β, which under normal conditions are held in the ER in a complex 
with GRP78/BiP (Yoshida, H. et al., 2000). When ER stress occurs and GRP78/BiP 
dissociates from ATF6, it translocates to the Golgi apparatus where the full length 
90 kDa ATF6 is proteolytically processed by two Golgi resident enzymes: site-1 
protease (S1P) and site-2 protease (S2P; Shen, J. and Prywes, R. 2004; Hetz, C. et 
al., 2012; Ye, J. et al., 2000). This releases a 50 kDa cytosolic bZIP transcription 
factor, which translocates into the nucleus and binds to several different promoter 
elements of ER stress response genes (Haze, K. et al., 1999; Hetz, C. et al., 2012; 
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Kokame, K. et al., 2001; Wang, Y. et al., 2000; Yoshida, H. et al., 1998). Among these 
target genes are XBP1, CHOP, as well as ER chaperones such as GRP78/BiP, which 
allow the ER to cope with the increased protein folding demand following UPR/ER 
stress (Haze, K. et al., 1999; Hetz, C. et al., 2012; Yoshida, H. et al., 2000).  
1.8.1.3 IRE1α 
IRE1α is a type 1 transmembrane serine/threonine receptor protein kinase that can 
also function as an endonuclease (Chen, Y. and Brandizzi, F., 2013; Tirasophon, W. 
et al., 1998; Tirasophon, W. et al., 2000). In response to ER stress and to subsequent 
release from GRP78/BiP, IRE1α homodimerizes and becomes autophosphorylated, 
leading to activation of its kinase and endoribonuclease functions (Chen, Y. and 
Brandizzi, F., 2013; Shamu, C.E. and Walter, P., 1996; Welihinda, A.A. and Kaufman, 
R.J., 1996). The endoribonuclease activity is responsible for promoting increased 
splicing of X-box binding protein 1 (XBP1) mRNA, a process by which a 26-
nucleotide sequence of XBP1 mRNA is excised leading to a shift in its reading frame 
to create spliced XBP1 (XBP1s; Jiang, D. et al., 2015; Lee, K. et al., 2002). Unlike the 
unspliced XBP1 protein, which is rapidly degraded, XBP1s encodes a bZIP 
transcription factor with a potent transactivation domain (Jiang, D. et al., 2015; Lee, 
A.H. et al., 2003; Poothong, J. et al., 2017). XBP1s translocates to the nucleus where 
it leads to expression of a number of UPR target genes including genes involved 
in folding, secretion, degradation and ER translocation of proteins (Jiang, D. et al., 
2015; Lee, A.H. et al., 2003; Yoshida, H. et al., 2001; Poothong, J. et al., 2017). 
Compared to activation of PERK and ATF6, there is a delay in the IRE1α pathway 
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due to the fact that the substrate XBP1 mRNA is expressed at low levels in non-
stressed cells, but is upregulated by ATF6 in the presence of ER stress (Lee, K. et 
al., 2002; Oslowski, C.M. and Urano, F., 2011).  
1.8.2 Additional GRP78/BiP localizations  
GRP78/BiP is generally regarded as an ER resident chaperone protein. However, 
recent evidence suggests that GRP78/BiP can be actively translocated to other 
cellular locations and be secreted, thus assuming additional functions that control 
cellular signaling, proliferation, invasion, apoptosis, inflammation and immunity, 
with implications in cancer progression and therapeutic resistance (Figure 1.9; Lee, 
A.S., 2014).  
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Figure 1.9 Different GRP78/BiP localizations and functions. In addition to its main ER localization, 
GRP78/BiP can be actively translocated to other cellular locations, assuming additional 
functions. N = nucleus; ER = Endoplasmic reticulum; PM = plasma membrane.   
A cytosolic novel isoform named GRP78va, deriving from ER stress-induced 
alternative pre-mRNA splicing, has been found at high levels in leukaemic cell lines 
and in leukaemia patient samples, specifically enhancing PERK signaling to 
promote cell survival under conditions of ER stress (Ni, M. et al., 2009; Ni, M. et al., 
2011). However, it is still uncertain which client proteins the cytosolic GRP78/BiP 
100 
 
interacts with. Moreover, a cytosolic distribution of GRP78/BiP in astroglia cells has 
been shown to protect these cells against neurotoxicity (Qian, Y. et al., 2000; Qian, 
Y. et al., 2005). A nuclear form of GRP78/BiP has also been observed, specifically 
after its ectopic over-expression or its induction by ER stress, and it has been 
proposed it might have a role in the DNA cross-linking and in protecting the DNA 
damage-induced apoptosis (Ni, M. et al., 2011). 
ER stress also promotes GRP78/BiP relocalization to the mitochondria, which are 
physically and functionally interconnected with the ER. Immunoelectron 
microscopy experiments confirmed the GRP78/BiP localization to the 
mitochondrial membrane compartment and demonstrate that this event occurs 
during UPR activation (Sun, F.C. et al, 2006). Mitochondria-associated GRP78/BiP 
has been shown to bind to the proto-oncogene serine/threonine-protein kinase 
RAF1, contributing to the maintenance of mitochondrial permeability and 
protecting against ER-stress-induced apoptosis (Shu, C.W. and Huang, C.M., 
2008).  
ER stress, or ectopic expression of GRP78, has also been associated with an 
additional atypical form of GRP78/BiP, that has been shown to preferentially 
localize on the cell surface of stressed endothelial cells and cancer cells (but not in 
either non-stressed or non-cancer cells), where it can act as a receptor that 
regulates different cellular activities (Zhang, Y. et al., 2010). First evidence of cell 
surface GRP78/BiP was reported in 1998, and was induced by thapsigargin 
treatment of human rabdomyosarcoma cells (Delpino, A. et al., 1998). Further 
studies indicated that there are numerous cancer cell lines whose global profile of 
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the cell surface proteome revealed the presence of GRP78/BiP and that, among 
other chaperone proteins, it is present in relatively high abundance (Shin, B.K. et 
al., 2003).  
The understanding of how an ER resident protein such as GRP78/BiP can localize 
to the cell surface is an interesting aspect to be elucidated. It has been shown that 
the murine tumor cell DnaJ-like protein-1 (MTJ-1), as well as being a 
transmembrane protein, also acts as a co-chaperone to GRP78/BiP within the ER 
(Chevalier, M. et al., 2000). Silencing the MTJ-1 gene expression by small interfering 
RNA (siRNA) abolishes cell surface localization of GRP78/BiP, thus suggesting that 
MTJ-1 is essential for transport to the cell surface (Misra, U.K. et al., 2005). Another 
specific protein that in the prostate cancer cell line PC-3 has been reported to be 
able to transport GRP78/BiP to the cell surface is the tumor suppressor prostate 
apoptosis response 4 (PAR-4, also known as PAWR; Burikhanov, R., et al., 2009). 
However, it has been proposed that, since GRP78/BiP is expressed to such high 
levels in tumors, it may oversaturate the ER protein retrieval mechanism, resulting 
in co-trafficking to the cell surface with its client proteins (Li, J. and Lee, A.S., 2006; 
Luo, B. and Lee, A.S., 2013). 
Cell surface GRP78/BiP acts as a multifunctional receptor impacting both cell 
proliferation and viability. A well-documented example of this function is 
represented by cell surface GRP78/BiP in prostate cancer cells, which acts as a 
high-affinity receptor for the activated form of the plasma proteinase inhibitor 
alpha-2-macroglobulin (α2M*; Misra, U.K. et al., 2002). The binding of α2M* to cell 
surface GRP78/BiP can promote cellular proliferation by triggering the extracellular 
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signal-regulated kinase (ERK) and the serine/threonine-protein kinases (AKT) 
activation, increasing DNA and protein synthesis (Misra, U.K. and Pizzo, S.V., 2012).  
Another pro-proliferative mechanism associated with GRP78/BiP is the interaction 
of cell surface GRP78/BiP with Cripto-1 (also known as teratocarcinoma-derived 
growth factor 1), a GPI-anchored oncoprotein that is developmentally regulated 
(Shani, G. et al., 2008). Cell surface GRP78/BiP is a necessary mediator of Cripto 
proliferative signaling in human cancer and disruption of cell surface GRP78/BiP 
and Cripto complex has been associated with blocking of different Cripto 
activation pathways (Kelber, J.A. et al., 2009).   
1.8.3 GRP78/BiP and cancer 
GRP78/BiP expression levels are highly induced in a variety of cancer cells and 
solid tumors, including breast, lung, prostate and ovarian cancers, melanoma and 
glioma cells (Bini, L. et al., 1997; Chatterjee, S. et al., 1994; Fernandez, P.M. et al., 
2000; Koomagi, R. et al., 1999; Xing, X. et al., 2006). These findings correlate with 
the high proliferative rates of cancer cells and the observation that the knockdown 
of GRP78/BiP by siRNA inhibits tumor cell invasion in vitro as well as tumor growth 
and metastasis aggressiveness in xenograft models, suggesting an important role 
of GRP78/BiP in cancer progression (Fu, Y. and Lee, A.S., 2006; Gutierrez, T. and 
Simmen, T., 2014; Tan, J.S. et al., 2016; Urra, H. et al., 2016; Zhang, J. et al., 2006). 
The first evidence that GRP78/BiP is required for tumor growth came from the 
observation that fibrosarcoma cells with GRP78/BiP knockdown were unable to 
form tumors or they quickly regressed in vivo (Jamora, C. et al., 1996). Increasing 
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evidence has suggested an important cytoprotective role for GRP78/BiP in cancer 
as well as conferring drug resistance. In head and neck cancer (HNC) cell lines, 
GRP78/BiP is highly expressed and its knockdown by siRNA significantly reduced 
cell growth and colony formation, inhibiting migration and invasive ability (Chiu, 
C.C. et al., 2008). Over-expression of GRP78/BiP in gastric cancer correlates with 
tumor size, depth of invasion, lymphatic and venous invasion, lymph node 
metastasis and stage of disease (Zheng, H.C. et al., 2008). Moreover, its over-
expression is inversely correlated with patient survival and its knockdown in gastric 
cancer xenograft mouse model inhibits tumor growth and metastasis (Zhang, J., 
et al., 2006). In hepatocellular carcinoma high GRP78/BiP expression correlates 
with increasing histological grade (Shuda, M. et al., 2003). Also in prostate tumors 
GRP78/BiP expression is markedly higher than that in benign prostate tissue, and 
the degree of GRP78/BiP expression correlates with increased risk of recurrence 
and reduced survival (Daneshmand, S. et al., 2007). In patients with diffuse large 
B-cell lymphoma, over-expression of GRP78/BiP is associated with worse overall 
survival (Mozos, A. et al., 2011). 
However, while the majority of evidence indicates GRP78/BiP as a prognostic 
marker for poor outcomes in solid tumors, a few exceptions do exist. There is no 
evidence of a correlation between GRP78/BiP and pathological stage in lung 
cancer: patients with positive GRP78/BiP expression tend toward better prognosis 
(Uramoto, H. et al., 2005). Also in neuroblastoma, GRP78/BiP expression is higher 
in more differentiated tumors and correlates with better survival for patients with 
both well and poorly differentiated tumors (Hsu, W.M. et al., 2005). Finally, in 
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primary resected oesophageal adenocarcinoma, GRP78/BiP appears to be more 
elevated in the early stages of tumor as compared to the more advanced ones or 
to the normal oesophageal squamous epithelium. Moreover, survival analysis 
suggests a trend to better survival from oesophageal cancer in patients with higher 
levels of GRP78/BiP (Langer, R. et al., 2008). 
1.8.3.1 GRP78/BiP as a novel therapeutic target 
GRP78/BiP over-expression has been widely reported in many human cancers and 
associated with aggressive properties. Interfering with its activity in those tumors 
can reverse the malignant phenotypes, suggesting that GRP78/BiP might become 
a really attractive target for new drug development. Recently, specific GRP78/BiP 
inhibitors acting at multiple levels have been identified but the most interesting 
challenge is represented by the cell surface expression of GRP78/BiP, since it is 
primarily found in malignant but not normal cells and, thus, offers the opportunity 
for cancer-specific therapy and drug delivery with minimal harmful effects on 
normal cells. 
Agents that inhibit the synthesis, the stability or the activity of GRP78/BiP already 
exist and they are able to simultaneously suppress its function, but the main 
problem is to minimize their toxicity to normal organs. A study on heterozygous 
knockout mouse models revealed that a 50% decrease in GRP78/BiP expression 
has no effect on normal organs but significantly impedes tumor growth (Dong, D. 
et al., 2011). Thus, these agents that selectively block the induction of GRP78/BiP 
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should only affect tumors that require a high level of the chaperone, saving normal 
organs. 
An alternative strategy is represented by the gene therapy directed against the 
GRP78/BiP promoter. Because GRP78/BiP promoter is highly active in aggressive 
solid tumors, it could be used to direct expression of suicide genes, 
immunosuppressors and tumor suppressors. An example of GRP78/BiP promoter-
driven suicide gene therapy activated by photodynamic therapy has been 
reported and it has been shown to cause regression of sizable human breast 
cancer tumor in mouse xenograft models in combination with ganciclovir (Dong, 
D. et al., 2004). 
Alternatively, a selective destruction of GRP78/BiP at the protein level might be 
possible using the bacterial toxin Subtilase cytotoxin (SubAB). It consists of a 
binding pentamer of B units and an active A subunit; this A subunit (SubA) is a 
subtilase-like serine protease that, when transported to the ER, selectively attacks 
GRP78/BiP. SubA cleaves GRP78/BiP at a single site (Leucine 416 and Leucine 417) 
in an exposed loop connecting the ATPase and the substrate-binding domain of 
the molecule, thereby inactivating it (Montecucco, C. and Molinari, M., 2006; 
Paton, A.W. et al., 2006). The selective cleavage of GRP78/BiP by SubA releases 
PERK, IRE1α and ATF6 leading to overwhelming activation of the UPR and 
subsequent apoptosis (Matsuura, G. et al., 2009; Wolfson, J.J. et al., 2008).  
Another way to effectively inactivate GRP78/BiP in cancer cells is to target its ATP-
binding domain, since the ATPase catalytic activity of GRP78/BiP is necessary for 
its anti-apoptotic function (Reddy, R.K. et al., 2003). Recently, a number of novel 
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naturally occurring compounds have been demonstrated to down-regulate 
GRP78/BiP, including (-)-epigallocatechin gallate (EGCG), honokiol and aspirin 
(also known as salicylate; Ermakova, S.P. et al., 2006; Deng, W.G. et al., 2001). These 
compounds are able to directly bind to the ATP binding domain of the chaperone 
and, thus, inhibit its ATPase activity, sensitizing cancer cells to chemotoxic agents 
(Martin, S. et al., 2013).  
Furthermore, GRP78/BiP inhibition of protein refolding activity could be achieved 
through the use of an unconjugated peptide derived from the co-chaperone BAG1 
(BCL2 associated athanogene 1), that binds to the substrate binding domain of 
GRP78/BiP and inhibit its functionality (Maddalo, D. et al., 2012). Prostate cancer 
cells that stably express this peptide showed reduced growth and apoptosis in 
xenograft models in a manner dependent on binding to GRP78/BiP (Maddalo, D. 
et al., 2012).  
Moreover, GRP78/BiP can be also inactivated by acetylation. It has been shown 
that GRP78/BiP is acetylated after histone deacetylase (HDAC) inhibition and, once 
acetylated, it dissociates from the three UPR stress sensors, causing UPR activation 
(Kahali, S. et al., 2010). Vorinostat is a drug already approved by FDA for the use 
in some types of cancer and, since it is an HDAC inhibitor, it could be used to 
interfere with GRP78/BiP activity (Kahali, S. et al., 2010; Manal, M. et al., 2016). In 
addition, several synthetic peptides containing GRP78/BiP-binding motifs fused to 
cell-death inducing peptides or cytotoxic drugs have been shown to induce 
apoptosis in many cancer cells in vitro, including human prostate and breast 
cancer cells, human melanoma, chemotherapy-resistant B lineage acute 
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lymphoblastic leukemia cells and multidrug resistant gastric cells (Miao, Y.R. et al., 
2013). 
Recently, a high affinity GRP78/BiP-specific mouse monoclonal IgG 
(immunoglobulin G) antibody (MAb159) was identified as a promoter of 
endocytosis and degradation of cell surface GRP78/BiP, thereby activating 
apoptosis (Liu, R. et al., M, 2013). Ab159 induces cancer cell death and suppresses 
the growth of colon and lung xenografts, the metastatic growth of human breast 
and melanoma xenografts and the growth of prostate cancer and leukemia in 
genetically engineered mouse models (Liu, R. et al., M, 2013). Another mouse 
monoclonal IgG antibody targeting the carboxyl-terminal domain of GRP78/BiP, 
C107, has been tested for its ability to induce apoptosis in melanoma cells in vitro 
and slow their growth as xenografts in mice (de Ridder, G.G., 2012). Also a human 
monoclonal IgM antibody (PATSM6) isolated from a patient with gastric cancer 
has been reported to simultaneously bind multiple GRP78/BiP molecules on the 
surface of tumor cells, inducing apoptosis in human multiple myeloma cells and 
suppressing human melanoma growth both in vitro and in xenografts (Hensel, F. 
et al., 2013; Rasche, L. et al., 2013; Rauschert, N., et al. 2008). It has also been 
reported that autoantibodies against GRP78/BiP from ovarian cancer patients 
promote apoptosis and decrease the invasiveness of ovarian cancer cells (Cohen, 
M. and Petignat, P., 2011). Moreover, autoantibodies against GRP78/BiP from 
prostate cancer patients are able to block cell surface GRP78/BiP signaling, 
potentially reducing the risk of cancer-related thrombotic events (Al-Hashimi, A.A. 
et al., 2010). 
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Overall, the existence of specific inhibitors and targeting agents directed against 
GRP78/BiP appears to hold great therapeutic promise. Their clinical efficacy, as well 
as a better understanding of the mechanisms of the stress-induced relocalization 
of GRP78/BiP from the ER to the cell surface and the other organelles, a broad 
identification of its interactive partners, and a deep characterization of the role of 
GRP78/BiP as a cancer prognostic marker, will greatly advance the knowledge of 
GRP78/BiP in cancer biology.  
1.9 Conclusions  
ADP-ribosylation is a reversible PTM catalyze by different classes of enzymes: 
ARTCs, ARTDs and some member of the sirtuin family. These include both mono- 
and poly-ADP-ribosylation, that, moreover, can be reversed by enzymes, such as 
ARHs, PARGs and macro domain containing proteins, which cleave the covalent 
bond to release the target protein. All these reactions have been established as 
important resources in the regulation of the biological activity of several proteins. 
Additionally, the role of this modification has been linked to different human 
diseases, such as inflammation, diabetes, neurodegeneration, and cancer, thus 
revealing the need for the development of specific ART inhibitors. Though the 
modification was discovered over 50 years ago, it has been only in the recent years 
that knowledge about ADP-ribosylation has been greatly improved.  
Thanks to several proteomics techniques it has been possible to identify the ADP-
ribosylation sites of previously known substrates. Moreover, novel ADP-
ribosylated targets with central roles in signal transduction and intracellular 
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trafficking have been identified, as well as the discovery of a large number of new 
enzymes that can catalyze this PTM.  
As a further confirmation of this being a challenging and exciting time in the field 
of ADP-ribosylation, a database of ADP-ribosylated proteins named “ADPriboDB” 
(http://ADPriboDB.leunglab.org) has been created very recently, as published on 
July 2016 by Vivelo and colleagues (Vivelo, C.A. et al., 2016). It is the first publicly 
available database containing information about ADP-ribosylated proteins 
collected from 1975 to 2015, with the aim of facilitating researchers finding and 
using this cumulative information about ADP-ribosylation reactions. 
However, further improved understanding of how these enzymes are regulated 
and how the reaction they catalyze impacts upon different cellular functions are 
required. A better awareness of the basic biology of ADP-ribosylation in human 
physiology and pathology would have obvious clinical relevance for the treatment 
of various diseases. Considering the importance of ADP-ribosylation, the general 
aim of this study was to investigate the cellular role of GRP78/BiP mono-ADP-
ribosylation. Specifically, the enzyme involved in the modification of the chaperone 
was identified, and the cellular localization of this enzyme was characterized. Then, 
the cellular role of this long-known GRP78/BiP mono-ADP-ribosylation in 
processes such as UPR and cancer was explored. Moreover, some aspects of the 
interaction between the mono-ART ARTD10 and its target GAPDH (glyceraldehyde 
3 phosphate dehydrogenase) were investigated.  
 
110 
 
Chapter 2 
2.1 Materials 
2.1.1 Chemicals 
All chemicals used for the work presented here were of high quality and are listed 
in Table 2.1 along with their suppliers. 
Table 2.1 List of chemicals used in this study. 
Name Supplier 
β-Mercaptoethanol Fluka 
Acetic acid Carlo Erba 
Acrylamide stock solution: 40% (w/v) acrylamide/bis-acrylamide 
(37.5:1) 
Sigma-Aldrich 
Agarose Sigma-Aldrich 
Amersham ECL Western Blotting Detection Reagent GE Healthcare Life Sciences 
Amersham Hyperfilm ECL GE Healthcare Life Sciences 
Amersham Low Molecular Weight Calibration Kit for SDS 
Electrophoresis 
GE Healthcare Life Sciences 
Ammonium chloride (NH4Cl) Sigma-Aldrich 
Ammonium persulfate (APS) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Annexin-V (FITC conjugated) BD Biosciences 
Bacto Agar BD Biosciences 
BigDye Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 
Bio-Rad Protein Assay Bio-Rad 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
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Calcium chloride (CaCl2) Carlo Erba 
Chloroform Carlo Erba 
cOmplete Mini EDTA-free Protease Inhibitor Cocktail Tablets Roche Life Science 
Coomassie Brilliant Blue G Sigma-Aldrich 
Cycloheximide (Chx) Sigma-Aldrich 
DEPC-treated water Ambion 
Dimethyl pimelimidate (DMP) Pierce 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Disodium phosphate (Na2HPO4) Sigma-Aldrich 
DL-Dithiothreitol (DTT) Sigma-Aldrich 
DNA ladder 100bp Nippon genetics 
DRAQ5  Cell Signaling 
Dulbecco’s modified Eagle’s medium (DMEM) Gibco/Lonza 
Ethanol Carlo Erba 
Ethanolamine (C2H7NO) Sigma-Aldrich 
Ethidium bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Ethylene glycol-bis(2-aminoethylether) N,N,N′,N′-tetraacetic acid 
(EGTA) 
Sigma-Aldrich 
FastGene Gel/PCR Extraction Kits Nippon genetics 
Fetal bovine serum (FBS) Gibco/Lonza 
Formaldehyde Sigma-Aldrich 
GenElute Plasmid Miniprep Kit Sigma-Aldrich 
Glutathione-sepharose resin GE Healthcare Life Sciences 
Glycerol Merk 
Glycine Sigma-Aldrich 
Hanks' Balanced Salt Solution without calcium and magnesium 
(HBSS=) 
Gibco 
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Hepes Sigma-Aldrich 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Hoechst Stain solution Sigma-Aldrich 
Hydrogen chloride (HCl) Carlo Erba 
Isopropanol Carlo Erba 
Isopropyl-β-D-thiogalactoside (IPTG) Sigma-Aldrich 
jetPEI Polyplus 
jetPRIME Polyplus 
KAPA Taq PCR Kit Kapa Biosystems 
Kodak BioMax XAR Film Sigma-Aldrich 
Lysozyme  Sigma-Aldrich 
L-Glutamine Gibco 
L-Glutathione reduced (GSH) Sigma-Aldrich 
Magnesium chloride (MgCl2) Sigma-Aldrich 
MagPurix Cultured Cell DNA Extraction Kit Zinexts 
Methanol Carlo Erba 
Minimal Essential Medium (MEM) Gibco/Lonza 
Minimal Essential Medium Non-Essential Amino Acids (MEM 
NEAA) 
Life Technologies 
Monosodium phosphate (NaH2PO4) Sigma-Aldrich 
MOPS Sigma-Aldrich 
Mowiol 4-88 Calbiochem 
Nitrocellulose membrane Perkin Elmer 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Nuclease free water Ambion 
NucleoSEQ Macherey-Nagel 
Paraformaldehyde 
Electron Microscopy 
Sciences 
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Penicillin-streptomycin (P/S) Life Technologies 
Phosphate-buffered saline (PBS) Gibco 
Ponceau Red Sigma-Aldrich 
Potassium acetate (CH3CO2K) Sigma-Aldrich 
Potassium chloride (KCl) Merk 
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich 
Power SYBR Green PCR Master Mix Applied Biosystems 
Propidium iodide BD Biosciences 
Protein-A sepharose resin (CL-4B)  GE Healthcare Life Sciences 
Puromycin Sigma-Aldrich 
Qiagen Plasmid Maxi Kit Qiagen 
QuikChange Site-Directed Mutagenesis Kit Stratagene 
Ribonuclease inhibitor Takara 
Roswell Park Memorial Institute 1640 Medium (RPMI) Gibco/Lonza 
Rubidium chloride (RbCl) Sigma-Aldrich 
Running buffer 10X Bio-Rad Laboratories 
Saponin Sigma-Aldrich 
Silver nitrate (AgNO3) Sigma-Aldrich 
Skim milk powder Fluka 
Sodium azide (NaN3) Sigma-Aldrich 
Sodium carbonate (Na2C2O3) Sigma-Aldrich 
Sodium chloride (NaCl) Carlo Erba 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Sodium hydroxide (NaOH) Carlo Erba 
Sodium tetraborate (Na2B4O7) Sigma-Aldrich  
Sodium thiosulfate (Na2S2O3) Sigma-Aldrich 
Thapsigargin Sigma-Aldrich 
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Transfer buffer 10X Bio-Rad Laboratories 
Triethanolamine (C6H15NO3) Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane (Tris) Sigma-Aldrich 
Triton X-100 Bio-Rad Laboratories 
TRIzol reagent Invitrogen 
Trypsin-EDTA (0.5%), no phenol red Gibco 
Tryptone Peptone BD Biosciences 
Trypan Blue Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
Yeast Extract BD Biosciences 
3MM filter paper Whatman 
 
2.1.2 Oligonucleotides 
All oligonucleotides used in the studies presented in this thesis, and their 
application, are listed in Table 2.2.   
Table 2.2 List of oligonucleotides used in this study. 
Name 5’-3’ Sequence Application 
 
ARTC1fwE240G 
TCCCTGGAGAGGAAGGGGTGCTGATCCCC Site-directed 
mutagenesis 
ARTC1revE240G 
GGGGATCAGCACCCCTTCCTCTCCAGGGA Site-directed 
mutagenesis 
ARTC1fwE238/240G TCCCTGGAGGGGAAGGGGTGCTGATCCCC 
Site-directed 
mutagenesis 
ARTC1revE238/240G 
GGGGATCAGCACCCCTTCCCCTCCAGGGA Site-directed 
mutagenesis 
ARTC1 qRT For GGCCTCATGGAAGCACTTCA (qRT)-PCR 
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ARTC1 qRT Rev GAGAAGAGGTCTCGTCGTGTGA (qRT)-PCR 
ATF4 qRT For TTGAGGATAGTCAGGAGCGT (qRT)-PCR 
ATF4 qRT Rev TGGAACACACAGCTACAGCA (qRT)-PCR 
CHOP qRT For ACCAAGGGAGAACCAGGAAACG (qRT)-PCR 
CHOP qRT Rev TCACCATTCGGTCAATCAGAGC (qRT)-PCR 
GAPDH qRT For CAACTTTGGTATCGTGGAAGGAC (qRT)-PCR 
GAPDHqRT Rev ACAGTCTTCTGGGTGGCAGTG (qRT)-PCR 
GRP78 For TAGCATCTGAGCTGGCTCCT PCR 
GRP78 Rev GTGTCAGGCGATTCTGGTCA PCR 
GRP78/BiP qRT For ACGTGGAATGACCCGTCTGT (qRT)-PCR 
GRP78/BiP qRT Rev AACCACCTTGAACGGCAAGA (qRT)-PCR 
XBP1 qRT For TTACGAGAGAAAACTCATGGC (qRT)-PCR 
XBP1 qRT Rev GGGTCCAAGTTGTCCAGAATGC (qRT)-PCR 
siGENOME Human 
HSPA5 siRNA 
SMARTpool 
CCACCAAGAUGCUGACAUU 
GAAAGGAUGGUUAAUGAUG 
CGACUCGAAUUCCAAAGAU 
CAGAUGAAGCUGUAGCGUA 
Gene silencing 
siRNA1ARTC1 AUGCAUGAGACACGGGACA dTdT Gene silencing 
siRNA2ARTC1 ACACGGAGUUCCAGGCCAA dTdT Gene silencing 
siRNA3ARTC1 GCCCUGGCCUCCUUUGAUG dTdT Gene silencing 
siRNA4ARTC1 GCGAGUACAUCAAAGACAA dTdT Gene silencing 
All oligonucleotide sequences were purchased from Sigma-Aldrich; siGENOME 
Human HSPA5 siRNA reagent was from Dharmacon.  
2.1.3 Antibodies 
All the primary antibodies used in this study were raised against the following 
proteins: actin, ART1, ATF6, calnexin, calreticulin, flag, GAPDH, giantin, GRP78/BiP, 
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GST, lamp-1, protein disulfide isomerase (PDI), tubulin and WGA. The secondary 
antibodies used were anti-mouse and anti-rabbit. Their specific supplier, animal 
host, dilution and application (WB: Western Blotting; IF: immunofluorescence) are 
listed in Table 2.3. 
Table 2.3 List of antibodies used in this study. 
Name Supplier Animal host Dilution Application 
Anti-Actin Sigma-Aldrich Mouse 1:2000 WB 
Anti-ART1 Sigma-Aldrich Rabbit 1:500 WB 
Anti-ART1 AbCam Rabbit 1:70  IF 
Anti-ATF6 Imgenex Mouse 1:100 IF 
Anti-Calnexin BD Biosciences Mouse 1:50  IF 
Anti-Calreticulin AbCam Mouse 1:100  IF 
Anti-Flag Sigma-Aldrich Mouse 1:5000  WB 
Anti-Flag Sigma-Aldrich Rabbit 1:500  IF 
Anti-GAPDH Santa Cruz Mouse 
1:1000 
1:50 
WB 
IF 
Anti-Giantin 
Giuseppe Di Tullio 
(FMNS) 
Mouse 1:100 IF 
Anti-GRP78/BiP BD Biosciences Mouse 1:1000 WB 
Anti-GRP78/BiP Santa Cruz Rabbit 1:100  IF 
Anti-GST 
Giuseppe Di Tullio 
(FMNS) 
Rabbit 
1:1000  
1:10000  
WB 
IF 
Anti-HA Cell Signalling Rabbit 
1:600 
1:1000 
IF 
WB 
Anti-Lamp1 Sigma-Aldrich Mouse 1:100 IF 
Anti-Mouse Calbiochem Goat 1:10000 WB 
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Anti-Mouse  
(Alexa Fluor 488) 
Thermo Fisher 
Scientific 
Goat 1:400 IF 
Anti-Mouse 
(Alexa Fluor 546) 
Thermo Fisher 
Scientific 
Goat 1:400 IF 
Anti-PDI Stressgen Mouse 1:100 IF 
Anti-Rabbit Calbiochem Goat 1:10000 WB 
Anti-Rabbit 
(Alexa Fluor 488) 
Thermo Fisher 
Scientific 
Goat 1:400 IF 
Anti-Rabbit 
(Alexa Fluor 546) 
Thermo Fisher 
Scientific 
Goat 1:400 IF 
Anti-Tubulin Sigma-Aldrich Mouse 1:2000 WB 
Anti-WGA 
Thermo Fisher 
Scientific 
/ 1:200 IF 
 
2.1.4 Solutions and buffers 
All solutions and buffer used were freshly prepared and are listed in Table 2.4. 
Table 2.4 List of solutions and buffers used in this study. 
Name Contents 
 
Annexin-V binding buffer 10 mM Hepes/NaOH (pH 7.4), 10 mM NaCl, 2.5 mM CaCl2 
Binding buffer 
50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1.5 mM MgCl2, 10% FBS; 
0.5 mM DTT (before use) 
Blocking buffer A 3% milk (w/v) in 1X PBS  
Blocking buffer B 10% FBS (v/v) in 1X PBS  
Cell lysis buffer 
20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mg EGTA, 1% 
Triton X-100; 1 mM DTT (before use), 1 protease inhibitor cocktail 
tablet per 10 mL of lysis buffer (before use) 
Destaining solution 30% (v/v) methanol, 10% (v/v) acetic acid, 40% (v/v) H2O 
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Developing solution 0.04% (v/v) formaldehyde in 2% (w/v) Na2C2O3 
Fixing solution 50% (v/v) methanol, 5% (v/v) acetic acid, 45% (v/v) H2O 
GST-eluition buffer 
20 mM Tris-HCl (pH 8), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 10 
mM GSH 
GST-lysis buffer 20 mM Tris-HCl (pH 8), 150 mM NaCl, 1 mM EDTA, 1 mM DTT  
GST-washing buffer 1X PBS, 1 mM DTT 
IF Blocking solution 0.05% saponin, 0.5% BSA, 50 mM NH4Cl in PBS  
LB agar LB medium plus 1.5% (w/v) agar: autoclaved 15 min at 121°C 
LB medium 
1% Tryptone Peptone, 0.5% Yeast extract, 1% NaCl, autoclaved 
15 min at 121 °C 
Mowiol 4-88 solution 20 mg Moviol, 80 mL 1X PBS, 40 mL glycerol, pH 6-7 
Paraformaldehyde 4% Paraformaldehyde 8%, PBS 10X, H2O 
1X PBS 
1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 
7.4 
Ponceau Red staining 
solution  
0.1% (w/v) Ponceau Red in 5% (v/v) acetic acid 
RF1 buffer 
100 mM RbCl, 50 mM MnCl2, 30 mM CH3CO2K, 10 mM CaCl2, 
15% (v/v) glycerol, pH 5.8 
RF2 buffer 
RbCl 10 mM, MOPS 10 mM, CaCl2 75 mM, glycerol 15% (v/v), pH 
6.8 
RIPA buffer 
100 mM Tris-HCl (pH 7.5), 1% Igepal, 0.5% deoxycholate, 0.1% 
SDS; 1 protease inhibitor cocktail tablet per 10 mL of RIPA buffer 
(before use) 
Sample buffer 4X 
250 mM Tris-HCl (pH 6.8), 40% (v/v) glycerol, 0.02% (w/v) 
Bromophenol blue, 8% (w/v) SDS; 20% (v/v) β-Mercaptoethanol 
(before use) 
Sensitizing solution 0.02% Na2S2O3 (w/v) in H2O 
Silver Nitrate solution 0.1% (w/v) AgNO3 in water 
Staining solution 
50% (v/v) methanol, 40% (v/v) H2O, 10% (v/v) acetic acid, 0.1% 
(w/v) Coomassie Brilliant Blue G 
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T-PBS 0.05% (v/v) Tween-20 in 1X PBS  
1X TAE  40 mM Tris (pH 7.6), 20 mM acetic acid, 1 mM EDTA 
Trypan Blue solution 0.4% (w/v) Trypan Blue in PBS 
WB Blocking solution 1% (w/v) BSA or 5% (w/v) milk in T-PBS  
 
2.1.5 Software 
The following software were used in this study: 
• Excel (Microsoft), version 2016 for Windows; 
• FinchTV (Geospiza Inc.), version 1.4.0; 
• GraphPad PRISM (GraphPad software Inc.), version 4.0 for Windows; 
• ImageJ (NIH), version 1.43; 
• LSM510 (Carl Zeiss Inc.), version 3.2 SP3;  
• Primer Express (Applied Biosystems Inc.), version 3.0; 
• 7500 Fast System (Applied Biosystems Inc.). 
2.2 Methods 
2.2.1 Cell culture and treatments 
2.2.1.1 Growth conditions and propagation of cell lines 
The cell lines used and their respective culture media are listed in Table 2.5. 
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Table 2.5 List of cell lines used in this study. 
Cell line Culture medium  
 
A2780 RPMI 1640 + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
CAOV-3 DMEM + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
CHO DMEM + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
HeLa 
MEM + 10% FBS + 5 mM NEAA + 2 mM L-Glutamine + 100 U/mL 
P/S  
IGROV-1 RPMI 1640 + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
OVCA-432 RPMI 1640 + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
OVCAR-3 RPMI 1640 + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
OVCAR-5 RPMI 1640 + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
SKOV-3 RPMI 1640 + 10% FBS + 2 mM L-Glutamine + 100 U/mL P/S 
 
Chinese Hamster Ovary (CHO) cells and Human cervical cancer (HeLa) cells were 
from American Type Culture Collection (ATTC, USA). Human ovarian carcinoma 
cell lines A2780, CAOV-3, IGROV-1, OVCA-432, OVCAR-3, OVCAR-5 and SKOV-3 
were obtained from the Mario Negri Institute for Pharmacological Research, kindly 
provided by Dr. Eugenio Erba.  
The cells were cultured in 10 cm2 petri dishes under controlled atmosphere in the 
presence of 5% CO2 at 37°C. All cell culture work was performed under sterile 
conditions. Cells were subcultured 2-3 times per week at a dilution of 1:3 - 1:10, 
depending on the cell line. For subculture, cells were washed once with HBSS= and 
detached from the petri dish by adding 0.05% Trypsin-EDTA for 5 minutes. After 
addition of fresh medium to block the protease action, cells were collected into a 
plastic tube and centrifuged for 5 min at 1200 rpm (revolutions per minute). The 
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supernatant was aspirated, the cell pellet was resuspended in fresh medium and 
placed in a new petri dish. All cell lines were routinely tested for Mycoplasma 
contamination by fluorescence microscopy using Hoechst staining. 
2.2.1.2 Cell freezing and recovery 
Cells from one 10 cm2 petri dish were grown to ~80/90% confluency as described 
above. After the centrifugation, the cell pellet was resuspended into 1 mL of 
freezing solution. An appropriate freezing solution was used for each cell line, 
following the recommendations for cryopreservation available on the cell line data 
sheets. The freezing solutions used for each cell lines are listed in Table 2.6. 
Table 2.6 List of cell line freezing solutions used in this study. 
Cell line Freezing solution 
 
A2780 Culture medium + 50% FBS + 10% DMSO 
CAOV-3 Culture medium + 5% DMSO 
CHO FBS + 10% DMSO 
HeLa FBS + 10% DMSO 
IGROV-1 Culture medium + 10% DMSO 
OVCA-432 Culture medium + 10% DMSO 
OVCAR-3 Culture medium + 50% FBS + 10% DMSO 
OVCAR-5 Culture medium + 10% DMSO 
SKOV-3 Culture medium + 10% DMSO 
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The cells were afterwards transferred into a cryotube and placed directly on ice. 
After about 24 hours at -80°C, the tubes were transferred in the liquid nitrogen 
cell storage (-196°C).  
For recovery of the cells after freezing, the frozen cells were directly thawed into 
a 10 cm2 petri dish with fresh complete medium and 1 mL of FBS. The cells were 
allowed to attach for one day and then their medium was replaced with fresh 
complete medium. 
2.2.1.3 Cell stress treatments 
To evaluate the possible role of hARTC1 in ER stress, the cells were treated with 
different types of know stressors, which are listed below. For cell stress treatments, 
cells were seeded in 6-well plates, cultured until ~80/90% confluency and treated 
with DTT, thapsigargin or subjected to heat shock or hypoxia. DTT is a water-
soluble reducing reagent that blocks disulfide-bond formation, thereby quickly 
leading to ER stress. For DTT treatment, the medium of cells grown for 24 hours 
was replaced with new medium containing 2 mM DTT. After incubation for 20 
minutes, 60 minutes or 120 minutes, cells were collected and analyzed as described 
below. Thapsigargin is a specific inhibitor of the sarcoplasmic/endoplasmic 
reticulum calcium-ATPase. Treatment with thapsigargin results in a decrease of ER 
calcium levels that, in turn, causes the loss of the activity of the calcium-dependent 
ER chaperones and leads to the accumulation of unfolded proteins, consequently 
activating ER stress. Thapsigargin is sparingly soluble in aqueous buffer, but it is 
soluble in organic reagent such as DMSO. For thapsigargin treatment, the medium 
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of cells grown for 24 hours was replaced with new medium containing 0.3 μM or 
1 μM thapsigargin. After incubation for 20 minutes, 60 minutes, 120 minutes, 18 
hours or 24 hours, cells were collected and analyzed as described below. For 
thapsigargin experiments, cells treated with DMSO without thapsigargin were also 
analyzed, in order to validate thapsigargin specific effect. DMSO did not affect 
GRP78/BiP protein expression or GRP78/BiP ADP-ribosylation. For heat shock 
treatment, the medium of cells grown for 24 hours was replaced with new medium 
and the plate was placed in an incubator with temperature set to 42°C. After 24 
hours, the plate was removed from the incubator and cells were collected and 
analyzed as described below. For hypoxia treatment, the medium of cells grown 
for 24 hours was replaced with new medium that was preincubated at least for 
one hour in hypoxic conditions. After addition of this new medium, the plate was 
placed in an incubator set to 0.1% of O2, 37°C and 5% of CO2. After 24 hours, the 
plate was removed from the incubator and cells were collected and analyzed as 
described below. Cell stress treatments were analyzed by (qRT)-PCR, Western 
Blotting, macro-domain far-Western Blotting or immunofluorescence (see 
Chapters 2.2.3; 2.2.4, 2.2.6; 2.2.7).   
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2.2.1.4 Cell transfection 
2.2.1.4.1 Cell transfection with DNA (plasmids) 
To over-express a protein of interest DNA transfection was performed using jetPEI 
reagent. All the cDNAs used were produced in the laboratory of my supervisor, 
Dr. Maria Di Girolamo. 
Cells were seeded in petri dishes 24 hours prior to transfection. The number of 
cells seeded varied among the cell lines and was calculated such that the cells 
would be ~50-70% confluent on the day of the transfection. The transfection mix 
was prepared according to the manufacturer’s protocol using a DNA:jetPEI ratio 
of 1:2 (w/v) in 150 mM NaCl, with a 15-30 minutes incubation at room temperature 
prior to addition to the culture. The amount of DNA transfected and the relative 
volume of jetPEI and NaCl depended on the surface of cell growth are listed in 
Table 2.7. 
Table 2.7 DNA transfection protocol according to the cell culture vessel per well. 
Culture vessel 
Amount of DNA 
(μg) 
Volume of jetPEI 
reagent  
(μL) 
Volume of NaCl 
solution for both 
DNA and jet PEI 
(μL) 
Total volume of 
complexes 
added per well  
(μL) 
 
24-well 1 2 50 100 
12-well 2 4 50 100 
6-well 3 6 100 200 
10 cm2 petri dish 10-20 20-40 250 500 
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Specifically, DNA was diluted in 150 mM NaCl to the final volume recommended 
for each specific culture vessel. The DNA solution was vortexed gently and spun 
down briefly. In a separate tube, jetPEI was diluted in 150 mM NaCl to the final 
volume recommended for each specific culture vessel, vortexed gently and spun 
down briefly. The jetPEI solution was added to the DNA solution all at once. The 
obtained DNA/jetPEI mixture was vortexed immediately, spun down briefly and 
kept for 15 to 30 minutes at room temperature. In the meantime, cell medium was 
aspirated and replaced with an appropriate volume of serum free medium. Finally, 
the DNA/jetPEI mixture was added drop-wise to the cells and homogenized by 
gently swirling the plate. The petri dish was then returned to the cell culture 
incubator and cells were analyzed as required. 
2.2.1.4.2 Cell transfection with siRNAs 
To down-regulate a protein of interest siRNA transfection using jetPRIME reagent 
was performed, following the guidelines mentioned in the instruction manual. 
Cells were seeded in petri dishes 24 hours prior to transfection. The number of 
cells seeded varied among the cell lines and was calculated such that the cells 
would be ~50-60% confluent one day after the transfection.  
To silence hARTC1 cells were transfected with a pool of different siRNAs at 30 nM 
each (details are given in Chapter 4); to silence GRP78/BiP cells were transfected 
with 100 nM of siGENOME Human HSPA5 siRNA reagent.  
Oligonucleotides used for gene silencing were resuspended in DEPC-treated 
water using an appropriate volume to have a 20 μM stock concentration. Once 
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resuspended, aliquots of 20 µL were prepared and stored at -20°C, avoiding 
multiple freeze-thaw cycles. 
The volume of jetPRIME and jetPRIME Buffer needed for complex formation 
depended on the surface of cell growth and are outlined in Table 2.8. 
Table 2.8 siRNA transfection protocol according to the cell culture vessel per well. 
Culture vessel 
Volume of jetPRIME reagent 
(μL) 
Volume of jetPRIME Buffer 
(μL) 
 
24-well 2 50 
12-well 3 100 
6-well 4 200 
 
Specifically, siRNA oligonucleotides were diluted into an appropriate volume of 
jetPRIME Buffer, depending on the specific culture vessel used. After having mixed 
the solution by pipetting up and down, jetPRIME reagent was added. The obtained 
mixture was then vortexed, spun down briefly and incubated for 10 to 15 minutes 
at room temperature. In the meantime, cell medium was replaced with an 
appropriate volume of serum free medium. Finally, the transfection mix was added 
drop-wise to the cells. The petri dishes, gently rocked back and forth, was then 
returned to the cell culture incubator and analyzed as required.  
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2.2.2 Cell biology 
2.2.2.1 Cell proliferation assay 
To determine the effect of hARTC1 on cell proliferation, cells either over-expressing 
or silenced for hARTC1 were analyzed by direct counting of the cells. Cells were 
seeded in 12-well plates and counted every 24 hours for 3 days. At the designated 
time points, the incubation medium was aspirated and cells were detached adding 
500 µL of 0.05% Trypsin-EDTA for 5 minutes. After addition of 500 µL of fresh 
medium, cells were collected into a plastic tube and 10 µL of cell suspension were 
loaded into a Neubauer chamber. Cell number was determined by twice counting 
4 fields with 16 squares each.  
The total number of cells/mL was calculated as follow:  
 
2.2.2.2 Cell viability assay 
To determine the effect of hARTC1 on cell viability, cells either over-expressing or 
silenced for hARTC1 were analyzed by Trypan Blue exclusion test. Cells were 
seeded in 12-well plates. 24 hours later, the incubation medium was aspirated and 
cells were detached adding 500 µL of 0.05% Trypsin-EDTA for 5 minutes. After 
addition of 500 µL of fresh medium, cells were collected into a plastic tube. One 
part of the cell suspension and one part of Trypan Blue solution were put into a 
new small plastic tube, mixed by pipetting up and down and incubated for five 
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minutes at room temperature. Afterwards, 10 µL of the composite were loaded 
into a Neubauer chamber and dead and live cells were determined by twice 
counting 4 fields with 16 squares each. The numbers of living and dead cells were 
used to calculate the viability, as well as the total number of cells.  
The percent viability was calculated as follow:  
 
The number of total cells was calculated as described in Chapter 2.2.2.1. 
2.2.2.3 Annexin-V/Propidium Iodide dual staining for apoptosis 
Analysis of cells undergoing apoptosis was evaluated by binding of FITC-
conjugated Annexin-V and uptake of propidium iodide by flow cytometry (FCM) 
on a BD Facs CANTO flow cytometer.  
Cells were seeded in 6-well plates and analyzed every 24 hours for 3 days. At the 
designated time points, the incubation medium was aspirated and cells were 
washed twice with HBSS=. Cells were detached adding 2 mL of 5 mM EDTA until 
they were just released from the plate surface. After addition of an equal volume 
of HBSS= to deactivate EDTA, cells were harvested into a plastic tube and 
centrifuged at 1100 rpm for 5 minutes at 4°C. The supernatant was removed and 
cells were resuspended in 1 mL of HBSS=. The cellular suspension was transferred 
into round bottom polystyrene tubes and subsequently centrifuged at 1100 rpm 
for 5 minutes at 4°C. HBSS= was removed and cell pellet was resuspended in 200 
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µL of Annexin-V binding buffer containing 5 µL of FITC-conjugated Annexin-V. 
The sample was vortexed and incubated for 10 minutes at room temperature in 
the dark. After this time, a volume of 2 mL of Annexin-V binding buffer was added 
and the sample was centrifuged at 1100 rpm for 5 minutes at 4°C. The supernatant 
was removed and the pellet was resuspended in 200 µL of Annexin-V binding 
buffer containing 10 µL of Propidium Iodide (20 µg/mL). After being vortexed, cells 
were immediately analyzed by flow cytometry. 
2.2.3 Biochemistry 
The expression of a protein of interest was analyzed by Western Blotting, 
measuring the protein levels through antibody binding to the specific proteins of 
interest. Before the immunological detection, sample proteins were extracted from 
their source using an optimized lysis buffer, separated within a gel through 
electrophoresis and transferred to a membrane via a “blotting” procedure. After 
proteins immobilization on the membrane, the proteins of interest were identified 
using antibodies conjugated for visualization via chemiluminescent mechanism. 
2.2.3.1 Preparation of total lysates 
Cells were seeded in 6-well plates or in 10 cm2 petri dishes and treated as required. 
At the designated time points, the incubation medium was aspirated and cells 
were washed 3 times briefly with 3-5 mL of cold 1X PBS. In the meantime, cell lysis 
buffer was prepared as indicated in the Chapter 2.1.4. After aspirating 1X PBS, cell 
lysis buffer was added to the cells and cells were scraped and transferred into a 
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1.5 mL Eppendorf tube. During the harvesting of cells, they were always kept on 
ice. The Eppendorf tube was placed on a rotating wheel for 20 minutes and then 
sonicated 3 times for 3-4 seconds, with 5 seconds rest in between, using an 
ultrasonic bath with a 60% amplitude output. Whole cell lysate was centrifuged at 
11400 rpm for 10 minutes in a centrifuge chilled to 4°C. The resulting pellet was 
discarded and the supernatant was aspirated, transferred into a fresh Eppendorf 
tube and stored at -80°C until use.   
2.2.3.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
2.2.3.2.1 Assembly of polyacrylamide gels 
Two 16 x 18 cm glass plates were used for assembling a regular gel. The glass plates 
were assembled to form a chamber using two 1.5 mm plastic spacers aligned along 
their lateral edges. The plates were then fixed using two clamps and mounted on 
a plastic base, which sealed the bottom.  
The resolving gel was poured first and was prepared by mixing distilled H2O, 40% 
(w/v) acrylamide/bis-acrylamide solution, 1.5 M Tris-HCl pH 8.8, 10% (w/v) SDS, in 
order to have the selected concentration of acrylamide, 375 mM of Tris-HCl, 0.1% 
(w/v) SDS. Then, 0.1% (w/v) APS and 0.1% (v/v) TEMED were added. The solution 
was pipetted and poured in the gap between the plates, leaving ~5 cm for the 
stacking gel. Soon after pouring, the gel was covered on the top with distilled 
water to avoid the solution making contact with oxygen, which inhibits the 
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polymerization. To allow it to gel, it was left standing for 45-60 minutes at room 
temperature. 
After the setting of the resolving gel, the distilled water was removed and the 
stacking gel was poured next. The stacking gel was prepared by mixing distilled 
H2O, 40% (w/v) acrylamide/bis-acrylamide solution, 0.5 M Tris-HCl pH 6.8, 10% 
(w/v) SDS, in order to have 4% (w/v) of acrylamide, 125 mM Tris-HCl, 0.1% (w/v) 
SDS. Then, 0.1% (w/v) APS and 0.1% (v/v) TEMED were added. The solution was 
pipetted and poured onto the resolving gel. A Teflon 15-well comb was 
immediately placed between the glasses, into the stacking gel. Normally, this gel 
was allowed to polymerize for 60 minutes at room temperature. 
2.2.3.2.2 Sample preparation and running 
The concentration of protein in the samples was determined using Bio-Rad Protein 
Assay. 2 µL of the sample were diluted in 780 μL of sterile water and put into a 
disposable plastic cuvette. 200 μL of Bradford reagent were added to the sample 
and mixed well. The absorbance of the sample was measured at 595 nm. The 
protein concentration of the sample was determined using a calibration curve 
previously constructed by plotting the absorbance at 595 nm of samples 
containing known BSA concentrations.  
After quantification, samples were prepared for gel electrophoresis using ~60-100 
µg of total proteins. An adequate volume of each sample was mixed with 4X 
sample buffer, adding distilled water to make the total volume to 120-150 µL. After 
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mixing well, samples were heated at 100°C for 10 minutes in a Multi-Block Heater 
(Lab-Line, IL, USA), cooled at room temperature and briefly centrifuged.  
Before loading, once the gel was polymerized, the comb was removed from gel 
without disturbing the wells and the wells were washed twice with 1X running 
buffer, that was prepared from 10X stock by dilution with distilled water. 
The heated samples were loaded into the wells and one or two wells were loaded 
with 20 µL of molecular weight standards which served to follow the running of 
the samples and for the cutting of the membrane at the given protein molecular 
weights. Aliquots of highly purified protein standards were prepared reconstituting 
the lyophilized mixture with 200 µL of 1X sample buffer. After a brief centrifugation, 
aliquots of 20 µL were prepared and stored at -20°C or immediately use. 
The gel was then transferred into the electrophoresis apparatus (Hoefer Scientific 
Instruments) and the gel chamber was filled with 1X running buffer. A covering lid 
was placed properly on the gel chamber by connecting corresponding electrodes 
(black to black and red to red), while the other ends of electrodes were connected 
to a voltage supply unit. The electrophoresis was carried out under a constant 
current of 8 mA for overnight runs.   
2.2.3.2.3 Silver Staining and gel drying 
After electrophoresis, the gel was incubated with fixing solution for 15 minutes at 
room temperature with gentle shaking. Then it was rapidly washed three times 
with water and finally placed in water for 1 hour on a shaking platform. The gel was 
then incubated in sensitizing solution for 1-2 minutes, rapidly washed twice with 
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water and incubated for 30 minutes at 4°C with chilled silver nitrate solution. After 
that, the gel was incubated with developing solution. The development was 
stopped by adding 5% acetic acid solution and washed twice with water before 
adding 1% acetic acid solution. Finally, the gel was dried with a gel dryer (Hoefer 
Scientific Instruments) at 80°C for 4 hours.   
2.2.3.2.4 Coomassie Brilliant Blue staining 
The running gel was carefully transferred to a staining box and rinsed with 
deionized water. Enough staining solution to cover the gel was poured into the 
staining box and kept in rocking position for 2 hours to stain the gel. After 
discarding the used staining solution, the gel was incubated with destaining 
solution for 1-2 hours under constant shaking, to remove excess stain. The gel was 
then extensively washed with water to reduce unbound dye background and dried 
as described above. 
2.2.3.3 Western blotting 
2.2.3.3.1 Protein transfer onto nitrocellulose 
One piece of nitrocellulose membrane, and two pieces of 3MM filter paper, were 
cut to the size of a gel. Just before SDS-PAGE running was finishing, the Western 
Blotting “sandwich” was assembled. Firstly, 2-3 sponges were soaked in 1X transfer 
buffer, facing the positive pole of the transfer chamber. One piece of filter paper 
was laid on the three sponges and nitrocellulose was laid above the filter paper.  
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Once the gel had finished running, it was removed from the running rig and glass 
plates. It was rinsed with 1X transfer buffer and carefully transferred onto the 
nitrocellulose. After that, another piece of 3MM filter paper was placed on the gel. 
The excessive transfer buffer and air bubbles in between the gel, the membrane 
and the filter paper were removed by gently rolling and pressing with a pipette. 
Another 3 sponges were placed on top and the negative pole of the transfer 
chamber was used to close off the sandwich. 
This blot sandwich was slotted into the blotting apparatus (Hoefer Scientific 
Instruments) that was subsequently filled with 1X transfer buffer. Transfer was 
carried out at a constant current of 400 mA for 5 hours.  
2.2.3.3.2 Ponceau Red staining 
To check protein transfer, the sandwich was disassembled and the nitrocellulose 
filter was stained with Ponceau Red, a reversible red-coloured protein dye.  
Briefly, the membrane was incubated with Ponceau Red solution for 5 minutes at 
room temperature under constant agitation. At the end of this incubation time, 
the membrane was rinsed twice with 5% acetic acid and once with water, to 
remove the excess of unbound dye. After the destaining, the transferred proteins 
were visualized as red bands on the nitrocellulose membrane. 
2.2.3.3.3 Immunostaining 
Membrane-immobilized proteins were probed with specific antibodies to identify 
and quantitate the protein of interest. To perform the probing, the nitrocellulose 
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membrane was cut into strips with a razor blade. The strips were incubated in 
blocking solution for 60 minutes at room temperature, to block non-specific 
binding of the antibodies.  
Following the blocking step, the strip was washed 3 times for 5 minutes with T-
PBS. Then, it was incubated with a primary antibody directed against the protein 
of interest, diluted at the appropriate concentration in blocking solution. 
Incubation with primary antibody was performed for 1 hour at room temperature 
or overnight at 4°C. 
The primary antibody was then discarded and the strip was washed 3 times with 
T-PBS, for 5 minutes each. After washing, the strip was incubated for 1 hour at 
room temperature with an appropriate HRP (horseradish peroxidase)-conjugated 
secondary antibody diluted in blocking solution.  
Finally, the strip was washed 3 times for 5 minutes with T-PBS and then incubated 
with ECL (enhanced chemiluminescence) reagent in the dark, according to the 
manufacturer instructions. The excess substrate was removed from the strip by 
holding it upright and touching a piece of blotting paper with the bottom edge of 
the strip. The drained piece of membrane was placed into an autoradiography 
cassette, using a plastic wrap to cover it. After gently smoothing out any air 
pockets, the autoradiography film was placed on the top of the strip. Typically, 
exposure time ranged from few seconds to several minutes, and usually repeated 
exposures were done, varying the time, as needed, for optimal detection. To finally 
visualize the protein band, the film was developed using an auto-processor in a 
darkroom. Densitometric evaluation was carried out with ImageJ software. 
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2.2.4 Molecular biology 
Different molecular biology experiments were performed, each with a specific aim. 
Site-directed mutagenesis was used to create a catalytically inactive mutant of the 
protein of interest. Small- and large-scale DNA preparations were used to obtain 
the DNA of interest, that would be used for protein expression analysis through 
DNA transfection. RNA extraction, reverse transcription and quantitative real-time 
Polymerase Chain Reaction (qRT)-PCR were performed for the measurements of 
gene transcription. DNA extraction, PCR and DNA sequencing were performed to 
search for the presence of mutation(s) in a specific sequence of interest. 
2.2.4.1 Site-directed mutagenesis 
Point mutations were generated using QuikChange Site-Directed Mutagenesis Kit 
following the protocol supplied by the manufacturer. Single mutagenesis of 
glutamate 240 to glycine (E240G) or double mutagenesis of both glutamate 238 
and glutamate 240 to glycine (E238G/E240G) were performed on the plasmid 
pME.CD8ART1.  
The mutagenic primers were designed to contain the specific mutation in the 
middle, with 10 to 15 bases of the correct sequences flanking on either side. Primers 
were normally between 25 and 45 bases in length, terminated in one or more 
cytosine or guanine bases, had a GC content of more than 40% and a melting 
temperature (Tm) of 78°C or higher. The primers used are listed in Table 2.1.2. 
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The PCR reaction was set up in a final volume of 50 μL and contained the following 
components:  
5 μL of 10X reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl pH 
8.8, 20 mM MgSO4, 1% Triton X-100, 1 mg/mL nuclease-free BSA); 
50 ng of plasmid DNA;  
125 ng of forward primer (1.5 μL); 
125 ng of reverse primer (1.5 μL); 
1 μL of supplied dNTP mix; 
2.5 U/μL of PfuTurbo DNA polymerase (1 μL); 
sterile double distilled water to make the volume to 50 µL. 
PCR was carried out using a programmable thermal cycler, with the following 
cycling conditions: 1 cycle of 95°C for 1 minute; 18 cycles of 95°C for 30 seconds, 
55°C for 1 minute and 68°C for 12 minutes; 1 cycle of 68°C for 7 minutes; 4°C for 
infinity. 
Following the amplification reaction, the PCR product was digested by adding 10 
U/µL of Dpn I restriction enzyme, which digested the parental, non-mutated, 
methylated plasmid. The reaction was incubated for 1 hour at 37°C. 16 µL of the 
Dpn I-treated DNA were used to transform 80 µL of DH5α competent cells.  
2.2.4.2 Preparation of competent cells 
Escherichia coli DH5α bacterial strain was used to produce competent cells by 
rubidium chloride method (Kushner, 1978). Bacteria were streaked and incubated 
overnight on a LB plate. Next day, one single colony was inoculated into 10 mL of 
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LB and grown overnight at 37°C with shaking at 225 rpm. 1 mL of the overnight 
saturated culture was inoculated into 9 mL of fresh LB and grown until the optical 
density (OD) at 600 nm was 0.3. The bacteria were sub-cultured 1:20 into 100 mL 
pre-warmed LB and grown until the OD at 600 nm reached 0.48. The cells were 
chilled on ice and centrifuged at 3000 rpm at 4°C for 5 minutes. The obtained 
supernatant was removed and the pellet gently resuspended in 40 mL of chilled 
RF1 buffer. The suspension was left on ice for 2 hours, centrifuged as before and 
gently resuspended in 4 mL of chilled RF2 buffer. Aliquots of 200 µL were prepared 
in sterile 1.5 mL Eppendorf tubes and stored at -80°C. 
2.2.4.3 Transformation of bacteria by heat-shock 
Competent DH5α bacteria were thawed on ice and 80 µL added to 15 µL of 
plasmid, equaling approximately 15 ng of DNA. After gently mixing, the mixture 
was left on ice for 30 minutes, heat shocked for 120 seconds at 42°C and then 
returned to ice for 2 minutes. 600 µL LB were added and the mixture was inverted 
gently before incubating at 37°C for 90 minutes under a constant shaking of 200 
rpm. The culture was then plated on LB agar containing 100 µg/mL of ampicilin 
and incubated overnight at 37°C. The next day, an isolated bacterial colony was 
picked from the plate and used to inoculate 5 mL of LB containing the appropriate 
antibiotic. The culture was incubated overnight at 37°C and used for preparation 
of bacterial glycerol stocks. 
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2.2.4.4 Preparation of glycerol stocks of bacteria 
800 µL of overnight bacterial culture grown in LB medium supplemented with 100 
µg/mL of ampicilin were gently mixed with 200 µL of sterile glycerol (20% v/v). 
After approximately 5 minutes at room temperature, cells were transferred to -
80°C for long-term storage. 
2.2.4.5 Small-scale preparation of plasmid DNA (miniprep) 
Plasmid DNA for small-scale preparation was purified using the GenElute Plasmid 
Miniprep Kit according to the manufacturer‘s instructions. All the solutions 
used were supplied with the kit. A single colony from a plate obtained after 
transformation of bacteria was inoculated in 2 mL of LB medium containing 100 
µg/mL of Ampicilin and shaken overnight at 200 rpm and 37°C. The day after, the 
overnight culture was transferred into a 2 mL Eppendorf tube and pelleted by 
centrifugation at 13000 rpm for 5 minutes. The supernatant was removed and the 
cell pellet was resuspended in 200 µL of Resuspension Solution, vortexing or 
pipetting up and down to thoroughly resuspend the cells until homogeneous. Cell 
lysis was achieved by addition of 200 µL Lysis Solution. The content was 
immediately mixed by gentle inversion until the mixture became clear and viscous 
and it was allowed to stand at room temperature for 3-5 minutes. Cell debris 
precipitation was obtained by adding 350 µL of Neutralisation/Binding Solution 
and gently inverting the tube 4–6. The precipitate was collected by centrifugation 
at 13000 rpm for 10 minutes.  A spin column inserted into a collection tube was 
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prepared for use by addition of 500 µL of Column Preparation Solution and 
centrifuged for 1 minute at 13000 rpm. The flow-through liquid was discarded.  
The supernatant obtained after addition of Neutralisation/Binding Solution and 
centrifugation of the mixture was transferred to the spin column and centrifuged 
at 13000 rpm for 1 minute. The flow through liquid was discarded and 750 µL of 
Wash Solution were added to the spin column. After centrifugation at 13000 rpm 
for 1 minute, the flow through liquid was discarded and the column was 
centrifuged again at 13000 rpm for 1 minute without any additional Wash Solution 
to remove the excess of ethanol from the spin column.  
The spin column was then transferred into a new fresh collection tube and 50 µL 
of sterile water were added. This was allowed to stand for 1 minute prior to elution 
of the DNA by centrifugation at 13000 rpm for 1 minute. The resultant eluent 
containing the DNA was ready for immediate use or storage at –20°C. The 
concentration and purity of the sample were measured by spectrophotometric 
analysis. Specifically, 2 μL of DNA were diluted in 198 μL of sterile water (1:100 
dilution), put into a 96-well UV compatible plate and analyzed using a 
spectrophotometer. The DNA concentration and purity were assessed by UV 
spectroscopy. 
The concentration of DNA was calculated from the absorbance at 260 nm using 
the formula based on the Beer-Lambert law (that predicts a linear change in 
absorbance with concentration): 
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Purity was calculated measuring the A260/A280 ratio. A ratio of ~1.8 is generally 
accepted as “pure” for DNA. The sequence of all the constructs purified were 
confirmed by automated DNA sequencing performed at the BMR Genomic service 
(Padua, Italy). 
2.2.4.6 Large-scale preparation of plasmid DNA (maxiprep) 
Large-scale DNA plasmid preparation was performed using the Qiagen Plasmid 
Maxi Kit, following the manufacturer‘s purification protocol. All the solutions 
used were supplied with the kit. A small amount of bacteria transformed with the 
plasmid of interest were scraped from the glycerol stock, inoculated in 2 mL of LB 
medium containing 2 µL of 100 µL/mL ampicilin and grown overnight at 37°C 
under continuous shaking at 200 rpm for 6-8 hours.  
This preculture was used to inoculate 250 mL of LB containing 100 µL/mL ampicillin. 
After an overnight incubation, the bacteria were collected by centrifugation at 
6000 rpm in JA14 rotor for 10 minutes at 4°C. The supernatant was removed and 
the cell pellet was resuspended in 10 mL of Buffer P1, vortexing or pipetting up 
and down until no cell clumps remained. 10 mL of Buffer P2 were added to the 
content, mixed thoroughly by vigorously inverting the sealed tube 4–6 times and 
incubated at room temperature for 5 minutes. After addition of 10 mL of chilled 
Buffer P3, the content was mixed immediately and thoroughly by vigorously 
inverting 4–6 times and incubated on ice for 20 minutes. The sample was 
centrifuged at 8000 rpm for 60 minutes at 4°C and the supernatant, containing 
plasmid DNA, was recovered and centrifuged again at 8000 rpm for 15 minutes at 
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4°C. In the meanwhile, a column was equilibrated by applying 10 mL of Buffer QBT 
and the column was allowed to empty by gravity flow. The recovered supernatant 
was applied to the equilibrated column and allowed to enter the resin by gravity 
flow. After complete passage of the sample through the column, it was washed 
twice by adding 30 mL of Buffer QC.  
When all the Buffer QC has completely passed through the column, DNA was 
eluted by adding 15 mL of Buffer QF. The eluate was collected into a 50 mL falcon 
tube.  
DNA precipitation was obtained by adding 10.5 mL of room-temperature 
isopropanol to the eluted DNA. Sample was immediately mixed by inverting the 
tube 4–6 times and centrifuged at 8000 rpm for 60 minutes at 4°C. The 
supernatant was carefully decanted and the DNA pellet was washed with 15 ml of 
room-temperature 70% ethanol. After centrifugation at 18000 rpm for 15 minutes, 
the supernatant was carefully decanted without disturbing the pellet. The pellet 
was allowed to air-dry and then redissolved in a suitable volume (300-400 μL) of 
sterile water. The concentration and purity of the sample were measured by 
spectrophotometric analysis, as described in Chapter 2.2.4.5. The sample was then 
aliquoted into sterile 1.5 mL Eppendorf tubes and stored at -20°C. 
2.2.4.7 Total RNA extraction 
Cells were seeded in 6-well plates and treated as required. At the designated time 
points, cell medium was removed and cells were washed twice with 1 mL of ice 
cold HBSS=. 1 mL of TRIzol reagent was added per well and, after pipetting several 
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times, cells were collected into a sterile 1.5 mL Eppendorf tube RNase- and DNase-
free. The sample was stored at -20°C until RNA extraction.  
To obtain RNA, the sample was thawed and 200 μL of chloroform were added per 
1 mL of TRIzol reagent used for the initial homogenization. The sample was mixed 
by vigorous shaking by hand for 15 seconds and incubated for 3 minutes at room 
temperature. Following centrifugation of 11400 rpm for 15 minutes at 4°C, the 
mixture separated into a lower red phenol-chloroform phase, an interphase, and 
a colorless upper aqueous phase, that exclusively contained RNA. This upper 
aqueous phase was carefully transferred into a new fresh Eppendorf tube without 
disturbing the underlying interphase. The volume of the aqueous phase should be 
about 50-60% of the volume of TRIzol reagent used.  
The subsequent precipitation of the RNA from the aqueous phase was obtained 
by adding 1 mL of isopropanol per 1 mL of TRIzol reagent used for the initial 
homogenization. The sample was incubated for 10 minutes at room temperature 
and centrifuged at 11400 rpm for 10 minutes at 4°C. The precipitated RNA formed 
a gel-like pellet at the tube bottom of the tube.  
After completely removing the supernatant, the RNA pellet was washed with 1 mL 
of 75% ethanol per 1 mL of TRIzol reagent used for the initial homogenization. The 
sample was mixed by vigorous shaking by hand for 15 seconds and centrifuged at 
9000 rpm for 5 minutes at 4°C. The leftover ethanol was removed as much as 
possible, without touching the pellet, and the RNA pellet was allowed to air dry. 
10-15 μL of DEPC-treated water were added to the pellet and mixed gently by 
pipetting. RNA concentration and purity were measured by spectrophotometric 
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analysis. Specifically, 2 μL of RNA were diluted in 198 μL of DEPC-treated water 
(1:100 dilution), put into a 96-well UV-compatible plate and analyzed using a 
spectrophotometer.  
The concentration of RNA was calculated from the absorbance at 260 nm using 
the formula based on the Beer-Lambert law (that predict a linear change in 
absorbance with concentration): 
 
Purity was calculated measuring the A260/A280 ratio. A ratio of ~2 is generally 
accepted as “pure” for RNA. The obtained RNA was stored at -20°C or used directly 
for cDNA synthesis.  
2.2.4.8 Reverse transcription 
Total RNA preparations were retro-transcribed using the High-Capacity cDNA 
Reverse Transcription Kit, following the manufacturer's instruction. All the 
components used were supplied with the kit. All steps were carried out on ice, 
unless otherwise specified. cDNA was generated using 2 µg of total RNA in a total 
reaction volume of 20 µL.   
Firstly, RNA sample was prepared putting 2 µg of total RNA in DEPC-treated water 
for a reaction volume of 10 µL. Sample was left on ice until addiction of the RT 
Master Mix. 
RT Master Mix (10 µL) was prepared as follows: 
- 2 μL of 10X RT Buffer; 
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- 0.8 μL of 25 x dNTP Mix (100 mM);  
- 2 μL of 10 x RT Random Primers;  
- 1 μL of MultiScribe Reverse Transcriptase; 
- 0.5 μL of RNase Inhibitor (not included in the kit); 
- 3.7 µL of DEPC-treated water.  
10 µL of RT Master Mix were added to 10 µL of RNA sample, pipetting up and 
down two times to mix. The tube was sealed, briefly centrifuged to spin down the 
contents and to eliminate any air bubbles and placed into the thermal cycler.  
The reverse transcription was performed using the following conditions: 25°C for 
10 minutes; 37°C for 120 minutes; 85°C for 5 minutes; 4°C for infinity. After setting 
the reaction volume to 20 µL, sample was loaded into the thermal cycler and the 
reverse transcription run was started. The resulting cDNA was used immediately 
for (qRT)-PCR, or the cDNA was stored at -20°C until use.  
2.2.4.9 Quantitative real-time Polymerase Chain Reaction (qRT)-PCR 
cDNA obtained from retro transcription reactions were used to measure 
expression levels of different genes. The cDNA samples were diluted to 20 ng/µL 
adding 80 µL of DEPC-treated water to the 20 µL of retro transcription reactions. 
Gene-specific primers were designed by using Primer Express 3.0 software and are 
listed in Table 2.1.2. Primers were resuspended using an appropriate volume of 
DEPC-treated water to have a 100 µM stock concentration. Once resuspended, 
aliquots were prepared and stored at -20°C, avoiding multiple freeze-thaw cycles. 
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The amplifications were done with the SYBR Green PCR Master Mix. For each 
reaction, the following mixture was used:  
- 5 µL of Power SYBR Green PCR Master Mix; 
- 1.2 µL of primers at the concentration of 150 nM;  
- 0.8 μL of DEPC-treated water; 
- 3 µL of cDNA (60 ng).  
PCR assays were performed in 96-well optical reaction plates using the ABI 7500HT 
machine (Applied Biosystem). Instrument settings were as follow: 95°C for 10 
minutes, followed by 40 cycles at 95°C for 15 seconds and then 1 minute at 60°C.  
The experiments were carried out in triplicate for each data point. Baseline values 
of amplification plots were set automatically and threshold values were kept 
constant to obtain normalized cycle times and linear regression data.  
The relative quantification in gene expression was determined using the ΔΔCt 
method, obtaining the fold changes in gene expression normalized to an internal 
control gene, and relative to one calibrator. The housekeeping gene GAPDH was 
used as internal control to normalize all data, while the choice of the calibrator 
varied among the different experiments and it is specified in the text where 
relevant. 
2.2.4.10 Automated genomic DNA extraction 
Samples of frozen cells were directly thawed and centrifuged at 10000 rpm for 5 
minutes. The supernatant was removed and the cell pellet was washed once with 
1 mL of 1X PBS. Samples were vortexed and, after resuspending the cell pellet using 
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1 mL of 1X PBS, they were centrifuged a second time for 5 minutes at 6000 rpm. 
400 μL of provided Buffer BL2 and 20 μL of provided proteinase K solution were 
added to each sample, that were subsequently mixed by vortexing. Afterwards, 
samples were incubated at 56°C in a thermomixer set at 800 rpm overnight, until 
they were completely lysed. Lysis time varies depending on the type and quantity 
of samples, without influencing the preparation; considering each sample derived 
from one 10 cm2 petri dish, an overnight lysis was used. Subsequently, DNA 
extraction was performed using the automated extractor MagPurix (Zinexts). 
2.2.4.11 DNA quantification 
DNA concentration and purity were estimated using 
a NanoDrop Spectrophotometer (Thermo Scientific). For quantification, 1 μL of 
sterile double distilled water was applied to the pedestal to calibrate the 
instrument. Then, each DNA sample was mixed, 1 μL was applied to the pedestal 
and reading was measured. After quantification of all samples, their concentration 
was adjusted as appropriate for subsequent analysis. Specifically, samples were 
diluted in sterile double distilled water to a final concentration of 50 ng/μL. 
2.2.4.12 Standard PCR  
Samples were subjected to standard PCR amplification using the KAPA Taq PCR 
Kit. After having properly thawed and mixed all the reagents needed, a PCR mix 
containing the appropriate volume of all reaction components was prepared. The 
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forward and reverse primers that were used for the PCR were designed using 
Primer-BLAST and are listed in Table 2.1.2.  
The PCR reaction was set up in a final volume of 25 μL and contained the following 
components:  
- 2.5 μL of 10X provided reaction buffer; 
- 1 μL of genomic DNA;  
- 1 μL of primer mix (forward plus reverse); 
- 0.5 μL of supplied dNTP mix; 
- 0.1 μL of KAPA Taq DNA Polymerase; 
- sterile bidistilled water to make the volume to 25 µL (19.9 µL). 
PCR amplification was performed in a programmable thermal cycler, using the 
following cycling conditions: 1 cycle of 95°C for 5 minutes; 40 cycles of 95°C for 30 
seconds, 67°C for 30 seconds and 72°C for 30 seconds; 1 cycle of 72°C for 7 
minutes; 4°C for infinity. 
2.2.4.13 Agarose gel electrophoresis 
The amplification products were analyzed by electrophoresis. 5 μL of the PCR 
product, mixed with 3 μL of Bromophenol blue, were loaded on a 2% agarose gel 
in 1X TAE buffer. 0.5 µL/mL ethidium bromide were added to the gel to make 
visualization of the DNA via UV light possible. The gel was run for 15 minutes at 
200 mV in 1X TAE buffer. A DNA ladder of 100 bp was used to determine the size 
of the amplified products.  
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2.2.4.14 Purification of PCR products 
The Fastgene Gel/PCR Extraction Kit was used for the purification of the PCR 
products. All buffers were provided with the kit. One volume of sample (20μL) was 
mixed with five volumes of Binding Buffer GP1 by vortexing. A FastGene GP 
Column was placed into a collection tube and the sample mixture from previous 
step was applied into the column. After centrifugation at 13000 rpm for 30 
seconds, the flow-through was discarded and the column was placed back into 
the collection tube. 600 μL of Wash Buffer GP2 were added to the column and it 
was centrifuged at 13000 rpm for 30 seconds. The flow-through was discarded and 
the column was placed back into the collection tube. An additional centrifugation 
of 2 minutes at 13000 rpm was performed to dry the column matrix. The FastGene 
GP Column was transferred into a new microcentrifuge tube and 20 µL of Elution 
Buffer GP3 were added to the centre of the column matrix. This was allowed to 
stand for 2 minutes until Elution Buffer was absorbed by the matrix. Elution of 
purified DNA was obtained with another centrifugation at 13000 rpm for 2 
minutes. 
2.2.4.15 DNA sequencing and analysis 
Sequencing was carried out using the BigDye Terminator v.3.1 Cycle Sequencing 
kit, following the standard protocol.  
For each reaction, this specific mixture was prepared: 
- 0.1 μL of provided Big Dye Solution;  
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- 0.1 μL of provided Big Dye Buffer; 
- 0.6 μL of primer reverse; 
- 2 μL of PCR product; 
- sterile double distilled water to make the volume to 20 µL (17.2 µL). 
The sequencing reactions were run for 2 hours, using the following cycling 
conditions: 96°C for 1 minute; 25 cycles at 96°C for 10 seconds, 50°C for 5 seconds 
and 60°C for 4 minutes; 4°C for infinity.  
Each reaction was purified with NucleoSeq and the final sequencing was obtained 
using the automatic sequencer ABI PRISM 3130 XL Genetic Analizer (Applied 
Biosystems). Sequence results were then visualized using the FinchTV software 
version 1.4.0 and compared to the actual NCBI (National Center for Biotechnology 
Information) reference sequences of the gene of interest human Grp78/BiP. 
2.2.5 Co-immunoprecipitation experiments  
Co-immunoprecipitation experiments were performed to validate the specific 
protein-protein interaction between ARTD10 and GAPDH. To perform co-
immunoprecipitation, an antibody against a target protein (HA-ARTD10) was 
coupled to Sepharose beads through protein A, then the complexes containing 
the target protein were immunoprecipitated with the antibody-coupled beads by 
centrifugation. Protein components in the complexes were then separated by 
SDS-PAGE and visualized by Western Blotting using antibodies specific to the 
different components (anti-HA and anti-GAPDH). 
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For the experiment, semi-confluent transiently transfected cells were incubated 
with RIPA buffer (500 µL/10 cm2 petri dish). The cells were scraped off the plate 
and broken by shearing (14 times) through a 25-gauge syringe needle. During the 
harvesting of the cells they were always kept on ice. The obtained lysates were 
then collected and centrifuged at 13000 rpm for 15 minutes at 4°C. The protein 
concentration of the supernatants was measured using Bio-Rad Protein assay kit, 
following the procedure described in Chapter 2.2.3.2.2. After quantification, 
samples were incubated with 2 μg of anti-HA antibody for each 500 μg of lysate. 
Incubation was overnight at 4°C under constant shaking (200 rpm). The day after, 
the samples were incubated with 40 μL of a 50% slurry of protein-A Sepharose 
resin for 1 hour at 4°C, with constant rotation (200 rpm). The resin was washed 
three times with RIPA buffer, and then boiled in loading buffer. The samples were 
then analyzed Western Blotting using antibodies raised against GAPDH or the HA 
tag.  
2.2.6 Immunofluorescence microscopy 
Immunofluorescence experiments were performed to analyze the localization of 
the proteins of interest using markers for different cellular compartments, and to 
quantify the amount of the specific protein in these different cellular 
compartments. For immunofluorescence, cultured cell lines were fixed onto glass 
slides and then probed using two different antibodies. The first one bound to the 
target protein, but was not fluorescently labeled itself (primary antibody). The 
second one (secondary antibody) specifically recognized the primary antibody 
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and carried a fluorescent dye. The fluorescent dyes used were Alexa Fluor dyes: 
Alexa Fluor 488 was used for green-fluorescence, while Alexa Fluor 546 was used 
for red-fluorescence. Depending on the host species of the primary antibody, 
Alexa 488- or Alexa 546-conjugated goat anti-rabbit or anti-mouse antibodies 
were used. For DNA staining, the cell permeable far-red fluorescent DNA dye 
DRAQ5 (1,5-bis{[2-(di-methylamino)ethyl]amino}-4, 8-dihydroxyanthracene-9,10-
dione) was used.  
2.2.6.1 Cell fixation and immunolabeling 
Cells were seeded onto 24-well glass slides and left for 24 hours to attach. Cells 
were then transfected for the indicated time or left untreated and immediately 
fixed. For fixation, the medium was completely removed carefully from the wells 
and cells, after being washed 5 times with 1X PBS, were incubated with 300 μL of 
4% paraformaldehyde for 10 minutes at room temperature. After washing 5 times 
with 1X PBS, cells were permeabilized with 300 μL of IF blocking solution for 20 
minutes at room temperature. IF blocking solution was then removed, cells washed 
5 times with 1X PBS and stained with the primary antibodies solution. Appropriate 
primary antibodies (Table 2.1.3) were prepared by diluting in IF blocking solution. 
8 μL spots of antibodies solution were incubated with each glass slide. After a 1 
hour incubation at room temperature in the dark, cells were washed 5 times with 
1X PBS and stained with the secondary antibodies solution. 8 μL spots of 
secondary antibodies diluting in IF blocking solution (Table 2.1.4) were incubated 
with each slide for 1 hour at room temperature in the dark. Glass slides were then 
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rinsed 5 times with 1X PBS and mounted using Mowiol 4-88 solution. They were 
left to dry overnight and stored at 4°C until analysis by confocal microscopy. 
2.2.6.2 Immunofluorescence analysis with confocal microscopy 
Immunofluorescence samples were observed using a laser scanning confocal 
microscopy (Zeiss LSCM 510) equipped with 40X and 63X oil emersion objectives. 
Optical confocal sections were taken at 1 Airy unit with a resolution of 512x512 or 
1024x1024 pixels and exported as TIFF files.  
2.2.6.3 Co-localization analysis 
Co-localization was analyzed using LSM510-3.2 software. To assess the co-
localization the background immunofluorescence was removed by adjusting the 
threshold levels and the histo and co-localization functions of the above software 
were used. The software provided two co-localization coefficients that range from 
0 (no co-localization) to 1 (complete co-localization). The co-localization 
coefficients indicated the amount of pixels of the channel A that co-localized with 
pixels from channel B and vice versa. Finally, the co-localization extent was 
expressed as a percentage of co-localizing immunofluorescent pixels relative to 
the total immunofluorescence per channel.  
2.2.7 GST-Af1521 macro domain affinity tool 
The Af1521 macro domain from Archaeoglobus fulgidus was used as an affinity 
probe for recognizing ADP-ribosylated targets, taking advantage of the previous 
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demonstration of its high affinity for ADP-ribose and its ability to bind not only 
ADP-ribose, but also ADP-ribosylated proteins (Karras, G.I. et al., 2005). Dani and 
colleagues demonstrated it could be used in pull-down experiments in 
combination with mass spectrometry, allowing identification of mono-ADP-
ribosylated target (Dani, N. et al., 2009). In addition to pull-down experiments, the 
macro domain Af1521 was used for the setting up of biochemical and 
immunofluorescence techniques, revealing as a useful tool for the identification of 
ADP-ribosylated proteins.  
2.2.7.1 GST-Af1521 macro domain purification 
pGEX4T1 vector containing GST-Af1521 macro domain (wild-type) and GST-Af1521 
(G42E) macro domain (mutant) were produced in our laboratory by Annalisa Stilla, 
by sub-cloning His-Af1521 macro domain (wild-type) and His-Af1521 (G42E) macro 
domain (mutant) kindly provided by Dr. Ladurner A. (EMBL Genome Biology Unit, 
Heidelberg, Germany).  
For purification, a small amount of DH5α Escherichia coli strain harbouring the 
GST-Af1521 macro domain (wild-type) or the GST-Af1521 (G42E) macro domain 
(mutant) were scraped from the glycerol stock (see Chapter 2.2.4.4) and inoculated 
in 100 mL of LB containing 100 µg/mL of Ampicilin. The culture was grown 
overnight at 37°C under continuous shaking (200 rpm). This culture was diluted 
1:20 in 500 mL of the same medium and grown under the same conditions, 
constantly monitoring the OD at 600 nm. As soon as the OD approximately 
reached 0.6, the fusion protein was induced for about 3 hours and 30 minutes at 
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37°C with 0.5 mM IPTG. The total bacterial culture was harvested by centrifugation 
at 600 rpm for 15 minutes at 4°C. The resulting bacterial pellet was re-suspended 
(40 mL/L of culture) in GST-lysis buffer in the presence of protease inhibitors and 
0.5 mg/mL lysozyme. The suspension was incubated for 30 minutes on ice under 
continuous shaking and then stored at -80°C overnight. In parallel, 1 mL of the 
induced and non-induced cultures was taken to confirm the protein expression. 
Samples were collected by centrifugation and lysed with sample buffer. 25 µL of 
the lysates were fractionated on polyacrilamide gel that was subsequently stained 
with Coomassie brilliant blue, as described in Chapter 2.2.3.2.4.  
The following day, the bacterial suspension was thawed at room temperature and 
1% Triton X-100 and 1 mM fresh DTT were added. The suspension was incubated 
for 20 minutes on ice under continuous shaking and then lysed by sonication on 
ice (5-7 pulse of 10 seconds each). The lysate was then centrifuged at 15000 rpm 
for 15 minutes at 4°C. The supernatant was recovered and added to 1 mL of 
glutathione-sepharose resin previously equilibrated in lysis buffer. The suspension 
was incubated for 2-3 hours at 4°C under gentle agitation and then pelleted at 
200 rpm for 8 minutes at 4°C to sediment the matrix. After discarding the 
supernatant, the resin was packed into a 10 mL column and washed 5-10 times 
with GST-washing buffer. Protein elution was started by adding 300 µL of GST-
elution buffer, followed by 6 elution with 1 mL of GST-elution buffer. The purified 
protein was then dialyzed (1:200 v/v) against 1X PBS. The resulting protein 
concentration was measured using Bio-Rad Protein assay kit, following the 
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procedure described in Chapter 2.2.3.2.2. The protein was then aliquoted and 
stored at -80°C.  
2.2.7.2 GST-Af1521 macro domain cross-linking 
For cross-linking, the resin was washed twice with a 10-fold volume of 0.2 M 
Sodium tetraborate pH 8.6, the supernatant was removed and the resin was 
incubated with a 10-fold volume of 0.2 M Sodium tetraborate pH 8.6. It was 
centrifuged and subsequently incubated with a 2-fold volume of triethanolamine 
added with 20 mM DMP for 1 hour at room temperature. After this step, the 
supernatant was discarded and washed once with a 10-fold volume of 0.2 M 
ethanolamine pH 8.2. Then, the cross-linking reaction was quenched by incubating 
the resin with 0.2 M ethanolamine pH 8.2 for 1 hour at room temperature. The 
resin was washed 3 times with 10-fold volume of 1X PBS and once with a 10-fold 
volume of 0.1 M glycine pH 2.5. These washes were repeated 3 times. Finally, the 
resin was washed 3 times with 1X PBS and stored in 1X PBS plus 0.02% NaN3 at 
4°C. For every step, a small amount of resin (7 µL) was taken to check the cross-
linking procedure by SDS-PAGE analysis.  
2.2.7.3 GST-Af1521 macro domain pull-down assay 
2-10 mg of total lysates for each sample, solubilized with 700 μL of RIPA buffer, 
were incubated with a glutathione-sepharose resin for 2 h at 4 °C, for the 
preclearing step. The supernatant underwent a two-step pull-down; the first with 
50 μg of macro domain mutant (G42E) covalently cross-linked to a resin, which 
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cannot recognize ADP-ribosylated proteins. In this way, all the proteins that non-
specifically recognize the cross-linked Af1521 macro domain were eliminated. After 
an overnight incubation at 4°C, the supernatant of the first pull-down was 
incubated overnight at 4°C with 50 μg of macro domain wild-type. The beads were 
collected with centrifugation at 200 rpm for 5 minutes and washed 3 times with 1 
mL of RIPA buffer. Proteins that remained bound to the resin were eluted at 100°C 
for 5 min with sample buffer and subjected to SDS-PAGE. The eluted proteins 
analyzed by gels underwent Coomassie brilliant blue staining or silver staining, 
and the bands of interest were analyzed by MALDITOF-MS (matrix-assisted laser 
desorption/ionization time-of-flight-mass spectrometry) or by LC-MS/MS (liquid 
chromatography tandem-mass spectrometry). 
2.2.7.4 GST-Af1521 macro domain far-Western Blotting 
For far-Western Blotting, cell lysates were prepared as described in Chapter 2.2.3.1. 
Samples were separated by SDS-PAGE using an 8% polyacrylamide gel and 
subsequently blotted onto nitrocellulose filter, as described previously. After 
protein transfer onto nitrocellulose, the membrane was initially incubated with 
blocking buffer A for 1 hour at room temperature, followed by an overnight 
incubation at 4°C with blocking buffer B. The day after, the solution was discarded 
and the filter was incubated with binding buffer containing 50 ng/mL of purified 
GST-macro domain (wild-type or mutant) for 1 hour at room temperature. The 
binding buffer was discarded and the filter was washed 3 times with T-PBS, 5 
minutes each. The membrane was then incubated with a polyclonal anti-GST 
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antibody for 3 hours at room temperature. Following 3 washes of 5 minutes each 
with T-PBS, the filter was incubated with an HRP-conjugated anti-rabbit antibody 
for 90 minutes at room temperature. Finally, the membrane was washed 3 times 
with T-PBS for 5 minutes each and incubated with ECL reagent in the dark for ECL-
based detection with autoradiography films, following the same procedure 
described in Chapter 2.2.3.3.3. 
2.2.7.5 GST-Af1521 macro domain immunofluorescence 
Cells were seeded onto 24-well glass slides and left for 24 hours to attach. Cells 
were then transfected for the indicated time or left untreated and immediately 
fixed and permeabilized. The procedures used for fixation and permeabilization 
were the same of that described in Chapter 2.2.5.1. After that, cells were incubated 
with 60 ng/μL of purified GST-macro domain (wild-type or mutant) diluting in IF 
blocking solution for 1 hour at room temperature, in the dark. Cells were then 
washed and incubated with a primary anti-GST antibody and then with a specific 
secondary antibody, following the protocol described previously for 
immunofluorescence cells labeling. The primary and secondary antibodies used 
with the appropriate dilutions are listed in Table 2.1.3  
After mounting the glass slides with Mowiol 4-88 solution, they were left to dry 
overnight and stored at 4°C until analysis by confocal microscopy. 
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2.2.8 Statistical analysis 
For analysis of mRNA copy number and protein levels, all quantitative data were 
expressed as mean±standard deviation (SD) of three or more separate 
experiments (unless otherwise specified).  
All statistical analyses were performed using the GraphPad PRISM software version 
4.0. 
For cell stress treatments and cell transfection experiments, Unpaired Student’s t-
tests were performed on the means and the p values were calculated. A p-value 
less than 0.05 or 0.01 was considered to be statistically significant, as specified in 
each figure. For ovarian cancer cell lines screening, the D'Agostino and Pearson 
omnibus normality test was used to check the uniform distribution of the values. 
For co-localization analysis, values were expressed as mean±standard error of the 
mean (SEM) of three or more separate experiments (unless otherwise specified). 
They were analyzed by one-way analysis of variance (ANOVA) and a p-value less 
than 0.0001 was considered to be statistically significant.  
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Chapter 3 
Mono-ADP-ribosylation of GRP78/BiP by hARTC1 expressed within the 
endoplasmic reticulum 
3.1 Introduction 
ARTCs comprise a small group of proteins that are either GPI-anchored enzymes 
localized at the external side of the plasma membrane, or are secreted into the 
extracellular compartment (Glowacki, G. et al., 2002; Koch-Nolte, F. et al., 2008). 
Rat, mouse and human ARTCs have been well studied and characterized. Rat (r) 
and mouse (m) have six functional enzymes (ART1, ART2.1 and ART2.2, ART3, ART4 
and ART5), with the Artc2 gene that is duplicated. Human (h) ARTC family is 
composed of only four proteins (hARTC1, hARTC3, hARTC4 and hARTC5), since 
Artc2 is a pseudogene containing three premature in-frame stop codons that 
preclude its expression. Two of these four hARTCs, hARTC1 and hARTC5, are active 
enzymes, whereas hARTC3 and hARTC4 are inactive proteins that lack any 
enzymatic activity due to the presence of mutations in their active site motif. 
Among these active hARTCs, hARTC5 lacks the GPI-anchor signal sequence and is 
secreted, thus hARTC1 represents the only active, non-secreted member of the 
family.  
Several reports suggest that hARTC1 is localized to the plasma membrane, as it 
has been demonstrated to be involved in the modification of arginine residues of 
soluble or plasma-membrane-associated protein targets such as integrin α7, HNP-
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1 and of other cell surface molecules (LFA-1, CD45, CD43 and CD44; Paone, G. et 
al., 2002; Seman, M. et al., 2003; Zolkiewska, A. and Moss, J., 1993; for a detailed 
description of substrates target of mono-ADP-ribosylation hARTC1-mediated see 
Introduction, Chapter 1.2.1.1). However, there is also a report indicating that 
hARTC1 can also have an intracellular localization, anchored to the membrane of 
the sarcoplasmic reticulum of rabbit skeletal muscle (Soman, G. et al., 1984). 
The first aim of my study was to precisely define the cellular localization of hARTC1 
in mammalian cells. To this end, I performed immunofluorescence experiments to 
analyze the localization of both over-expressed and endogenous protein, using 
markers for different cellular compartments. Moreover, once the specific cellular 
localization of hARTC1 was identified, additional substrate proteins that could be 
ADP-ribosylated were sought. Indeed, there is a large number of proteins, both 
extracellular and intracellular, that have been demonstrated to undergo mono-
ADP-ribosylation. However, the enzyme(s) responsible for their modification still 
remains to be identified. Interestingly, most of these targets have been reported 
to have a role in cell signaling and metabolism and the enzymatic activities 
involved in their modifications have been shown to be both cytosolic and 
membrane associated. Thus, it could be possible that hARTC1 is involved in some 
of these previously reported mono-ADP-ribosylation reactions.  
To identify one or more novel possible targets of hARTC1 several different 
approaches were used, including immunofluorescence and biochemical 
experiments, which took advantage of a previously described tool that is able to 
recognize ADP-ribosylated targets. Within this study, this tool was employed for 
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the development of novel techniques that, in addition to allowing identification of 
new targets of hARTC1-mediated mono-ADP-ribosylation, represent a relevant 
technological advance for the study of ADP-ribosylation reactions.    
3.2 Results 
3.2.1. hARTC1 is an ER-resident protein 
3.2.1.1 Study of over-expressed hARTC1 cellular localization in HeLa cells 
Previous reports have indicated that hARTC1 is involved in the modification of 
plasma membrane-associated proteins, suggesting it is localized to the cell 
membrane as is the case with its closest functional homologue ARTC2, which has 
been well described to be GPI-anchored to the cell membrane of T cells. To obtain 
information about the cellular localization of hARTC1, I analyzed cells by 
immunofluorescence. For these experiments, I used HeLa cells transfected with 
hARTC1. Furthermore, considering the established information about ARTC2 
localization, I also used cells transfected with the hamster cARTC2.1, employed as 
a marker for a plasma membrane localized ARTCs. Indeed, cARTC2.1 was 
previously cloned in my laboratory and characterized as a typical GPI-anchored, 
plasma membrane-associated, arginine-specific ART enzyme (Stilla, A. et al., 2011). 
Both hARTC1 and ARTC2.1 expression constructs were previously produced in our 
laboratory, using the eukaryotic expression vector pME.CD8LF with the Flag-tag 
at the N-terminus.  
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Specifically, HeLa cells were transiently transfected with Flag-tagged hARTC1 wild-
type (hARTC1 wt) or with Flag-tagged cARTC2.1 wild-type (cARTC2.1 wt). After 24 
hours of transfection cells were fixed with 4% PFA and stained with antibodies. 
Both hARTC1 wt- and cARTC2.1 wt-transfected cells were stained with anti-Flag 
antibody to visualize the over-expressed proteins. Wheat germ agglutinin (WGA) 
was used for plasma membrane staining. WGA is a 36 kDa protein that selectively 
recognizes sialic acid and N-acetylglucosaminyl sugar residues, which are 
predominant components of the plasma membrane. Thus, it is one of the most 
widely used markers for membrane labeling.  
 
Modified from Fabrizio, G. et al., 2015b 
Figure 3.1 hARTC1 wt and cARTC2.1 wt co-localization with WGA, a plasma membrane 
marker. Representative immunofluorescence images of HeLa cells transiently transfected 
with Flag-hARTC1 wt or Flag-cARTC2.1 wt, stained with anti-Flag (red) and anti-WGA 
(green) antibodies, as indicated. The WGA intracellular localization is due to cell 
permeabilization. The scale bar represents 10 μm. The data shown are representative of 
at least three independent experiments.  
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Of note, the analysis of cells by confocal microscopy revealed that hARTC1 wt had 
a prevalent intracellular localization, with only a minimal co-localization with WGA 
(Figure 3.1, hARTC1 wt). On the contrary, a substantial amount of the cARTC2.1 wt 
co-localized with the plasma membrane, as expected (Figure 3.1, cARTC2.1 wt). 
To further evaluate the cellular localization of hARTC1, multiple 
immunofluorescence experiments were performed, analyzing the co-localization 
of the over-expressed hARTC1 wt and cARTC2.1 wt with various organelle markers. 
For each experiment, HeLa cells were transiently transfected for 24 hours with 
hARTC1 wt or with cARTC2.1 wt, fixed with 4% PFA and permeabilized. Cells were 
then stained using an anti-Flag antibody to visualize the over-expressed proteins, 
whereas organelles were labeled with appropriate fluorescent markers.  
Firstly, a possible co-localization with the ER was investigated. The ER was labeled 
using two alternative markers: calnexin and calreticulin (Figure 3.2). These proteins 
are well known to be ER resident, but while calnexin is an abundant 90 kDa 
chaperone localized to the membrane of the ER, calreticulin is a 48 kDa protein 
located in the lumen of the reticulum. Both calnexin and calreticulin are widely 
used as ER markers (Williams, D.B., 2006; https://www.ncbi.nlm.nih.gov/gene/811). 
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.2 hARTC1 wt and cARTC2.1 wt co-localization with ER markers. 
Representative immunofluorescence images of HeLa cells transiently transfected with 
Flag-hARTC1 wt or Flag-cARTC2.1 wt, stained with an anti-Flag antibody (red) and 
antibodies raised against calnexin or calreticulin (green), as indicated. The scale bar 
represents 10 μm. The data shown are representative of at least three independent 
experiments.  
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The analysis of cells by confocal microscopy revealed that hARTC1 wt was mainly 
located at the ER, as it substantially co-localized with both the ER markers calnexin 
and calreticulin (Figure 3.2, hARTC1 wt). This was not the case for cARTC2.1 wt for 
which, instead, little co-localization with the ER was detectable (Figure 3.2, 
cARTC2.1 wt).  
To complete the analysis of the cellular localization of the enzymes, the expression 
of hARTC1 wt and cARTC2.1 wt was compared with the additional organelle 
markers giantin and lamp1. Giantin is one of the most commonly used Golgi 
markers, as it is a resident Golgi protein, specifically located to the cis/medial-Golgi 
apparatus (Linstedt, A.D. and Hauri, H.P., 1993). Lamp1 is a protein primarily 
localized at lysosomal membranes and, thus, typically used as a lysosomal marker 
(https://www.ncbi.nlm.nih.gov/gene/3916).  
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.3 hARTC1 wt and cARTC2.1 wt co-localization with Golgi and lysosomal 
markers. Representative immunofluorescence images of HeLa cells transiently 
transfected with Flag-hARTC1 wt or Flag-cARTC2.1 wt, stained with an anti-Flag 
antibody (red) and antibodies raised against giantin and lamp1 (green), as indicated. 
The scale bar represents 10 μm. The data shown are representative of at least three 
independent experiments.  
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The analysis of cells by confocal microscopy revealed that neither hARTC1 wt nor 
cARTC2.1 wt were localized in the Golgi apparatus or on lysosomes, since no co-
localization was detectable with the correspondent organelle markers (Figure 3.3).   
Since the confocal microscopy analysis revealed an unexpected hARTC1 wt 
intracellular localization, which seemed to mostly co-localize with the ER markers, 
and was different from cARTC2.1 wt, a more detailed analysis was performed, 
evaluating, for each experiment, the amount of co-localization between the Flag-
tagged enzymes and the different cellular markers (Figure 3.4). For co-localization 
assessment, I used the LSM510-3.2 software, as specified in Chapter 2.2.6.3 of the 
Materials and Methods. Co-localization was expressed as a percentage of co-
localizing immunofluorescence over the total immunofluorescence per channel 
(Figure 3.4).  
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.4 Quantification of co-localization of hARTC1 wt and cARTC2.1 wt with 
specific organelle markers. Co-localization of ARTCs with specific organelle 
markers is shown in the upper panel, while that of organelle markers with 
ARTCs is shown in the lower panel. The column graphs show the percentage 
of overlapping red (Flag-tagged ARTCs) and green (organelle markers) pixels. 
The data were obtained from three independent experiments, with at least 50 
cells per experiment (mean±SEM). * indicates significantly different from the 
co-localization coefficient 0, which correspond to immunofluorescence of non-
transfected cells of the same sample (p < 0.0001). 
Co-localization analysis indicated that main location of hARTC1 wt was at the ER, 
with a 42±1.7% co-localization with the ER protein marker calnexin and 36±1.2% 
with the other ER protein marker calreticulin (Figure 3.4, white bars). Additionally, 
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hARTC1 wt was partly localized to the plasma membranes, with about 21±0.5% co-
localization with WGA, and only to a lower extent could it be found in the Golgi 
apparatus (9±0.5% co-localization with giantin) or on lysosomes (7±0.4% co-
localization with lamp1; Figure 3.4, white bars). In contrast, only 10% of cARTC2.1 
wt co-localized with the ER proteins calnexin and calreticulin (8±0.4% and 9±0.6%, 
respectively), whereas most of cARTC2.1 wt co-localized with the plasma 
membrane (53±0.8% co-localization with WGA), as expected (Figure 3.4, black 
bars). Only a minimal co-localization was seen with the Golgi marker giantin 
(3±0.3%) or with the lysosomal marker lamp1 (5±0.2%; Figure 3.4, black bars). 
Thus, quantification analysis confirmed that hARTC1 wt was prevalently localized 
to the ER, as it co-localized with two different ER markers (calnexin and 
calreticulin), whereas there was very little co-localization with other intracellular 
compartments (Fabrizio, G. et al., 2015b). 
Immunofluorescence experiments (Figure 3.2), and the corresponding quantitative 
analysis (Figure 3.4), reveal an ER cellular localization for hARTC1. However, it was 
possible that the detected fluorescence within the ER compartment was due to 
newly synthesized proteins that transiently passed through the ER. To exclude this 
possibility, additional immunofluorescence experiments were performed, 
exposing cells transfected with the ARTCs to cycloheximide (chx), a well-known 
treatment used for protein synthesis inhibition. To address this point, HeLa cells 
were transiently transfected for 24 hours with hARTC1 wt, cARTC2.1 wt, and also 
with a Flag-tagged cARTC2.1 double mutant E207G/E209G (cARTC2.1 dm) and 
with Flag-tagged hARTC4 (hARTC4). HeLa cells expressing these constructs were 
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incubated for 3 hours in the absence (Figure 3.5, control) or in the presence of chx 
(Figure 3.5, chx), and then analyzed by immunofluorescence microscopy. To 
visualize the over-expressed proteins, the cells were stained with an anti-Flag 
antibody. At the same time, the ER compartment was stained with an antibody 
against protein disulfide isomerase (PDI), which is one of the most abundant ER-
associated endogenous proteins. The co-localization of the different ARTC 
enzymes with PDI was quantified using the Zeiss LSM510-3.2 software, as 
described in the Materials and Methods. 
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.5 hARTC1 wt is an ER resident protein. (a, b) Representative immunofluorescence images 
of HeLa cells transiently transfected with the indicated constructs and either untreated (control) or 
incubated with cycloheximide (chx, 100 μg/mL), stained with anti-Flag (red) or anti-PDI (green) 
antibodies, as indicated, then analyzed by immunofluorescence. The scale bar represents 10 μm. 
The data shown are representative of at least three independent experiments. (c) Quantification of 
the co-localization of ARTC enzymes with PDI, and vice versa. The column graphs show averaged 
data from three independent experiments with at least 50 cells per experiment (mean±SEM). * 
indicates significantly different from the co-localization coefficient 0, which correspond to 
immunofluorescence of non-transfected cells of the same sample (p < 0.0001). 
The analysis of cells by confocal microscopy revealed that hARTC1 wt co-localized 
with PDI to the same extent in both control and chx-treated cells (Figure 3.5a, 
hARTC1 wt). In contrast, the minimal co-localization of hARTC4, cARTC2.1 wt and 
cARTC2.1 dm with PDI that was seen in control cells, was reduced as a 
consequence of the chx treatment (Figure 3.5a, hARTC4; Figure 3.5b, cARTC2.1 wt, 
cART2.1 dm). Quantification of data confirmed that 55±4% and 6±1% of hARTC1 
wt and cARTC2.1 wt, respectively, co-localized with PDI in transfected, non-treated, 
control cells (Figure 3.5c). However, when the cells were treated with chx, 61±6% 
and 3±0.8% of hARTC1 wt and cARTC2.1 wt, respectively, co-localized with PDI 
(Figure 3.5c). Also, cARTC2.1 dm and hARTC4 showed very little co-localization 
with PDI (16±2% and 19±3%, respectively), as the relative quantification analysis 
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revealed, and their minimal co-localization was reduced after chx treatment 
(11±2% and 3±1%, respectively; Figure 3.5c). 
Under conditions that block new protein synthesis, such as the addition of chx to 
cells, proteins that were not ER-resident would exit the ER compartment and be 
transported to their final destination. This was the case for hARTC4, cARTC2.1 wt 
and cARTC2.1 dm. On the contrary, the treatment with chx had no effect on the 
localization of hARTC1 wt, thus confirming that it was mainly located in the ER 
(Fabrizio, G. et al., 2015b). 
3.2.1.2 Study of endogenous hARTC1 cellular localization in HeLa cells 
The experiments described above using over-expressed proteins revealed an 
unexpected ER cellular localization for hARTC1. The fact that under the same 
experimental conditions cARTC2.1 wt was correctly localized to the plasma 
membrane indicates that the transfected HeLa cells were viable and able to 
transport proteins to their correct destination, and that over-expressed Flag-
tagged proteins could be reliably used to examine cellular localization. However, 
to further exclude the possibility of mis-localization due to hARTC1 wt over-
expression, the cellular location of endogenous hARTC1 was characterized. At 
present, there is no data concerning the cellular localization of endogenous 
hARTC1, and all the available information about its cellular expression was 
obtained with the over-expressed enzyme.  
An antibody, or another probe, is required to examine the localization of 
endogenous proteins. Since no commercial antibody directed against 
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endogenous hARTC1 has yet been tested for immunofluorescence analysis, initial 
experiments were aimed to characterize commercially available antibodies from 
different suppliers. In contrast to the different antibodies tested, that from Abcam 
was the only one revealing an immunofluorescence signal clearly distinguishable 
from the background. Once the best antibody was characterized by 
immunofluorescence, the optimal dilution and blocking conditions were 
determined in order to improve the immunofluorescence signal. The identification 
of the optimal antibody working conditions was of extreme importance since it 
allowed, for the first time, the visualization of endogenous hARTC1 expression by 
confocal microscopy.  
After setting up the optimal antibody working conditions, the co-localization 
between endogenous hARTC1 and the ER protein calnexin was evaluated. Hela 
cells were fixed with 4% PFA, permeabilized and stained with an anti-ARTC1 
antibody and an anti-calnexin antibody.  
 
Modified from Fabrizio, G. et al., 2015b 
Figure 3.6 Endogenous hARTC1 is located in the ER. Representative immunofluorescence 
image of non-transfected HeLa cells stained with anti-hARTC1 (red) or anti-calnexin (green) 
antibodies, as indicated. The scale bar represents 10 μm. The data shown are representative 
of at least three independent experiments. 
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The analysis of cells by confocal microscopy indicated that endogenous hARTC1 
co-localized with the ER marker calnexin (Figure 3.6). 
The immunostaining depicted in Figure 3.6 was evaluated as described earlier to 
quantitate the co-localization between hARTC1 and the calnexin ER marker.  
 
Modified from Fabrizio, G. et al., 2015b 
Figure 3.7 hARTC1 co-localization with the ER marker calnexin. The bars indicate co-
localization of endogenous hARTC1 with calnexin, and vice versa. The data are expressed as 
percent of hARTC1 that co-localized with calnexin and the percent of calnexin co-localizing 
with hARTC1, and were obtained from three independent experiments with at least 50 cells 
per experiment (mean±SEM). * indicates significantly different from the co-localization 
coefficient 0, which correspond to immunofluorescence of non-transfected cells of the same 
sample (p < 0.0001). 
The quantification of the immunofluorescence analysis indicated that 51±2% of 
hARTC1 co-localized with calnexin (Figure 3.7). This value was consistent with the 
data obtained using the transfected cells over-expressing hARTC1 wt (Figure 3.4) 
confirming the main ER localization of the endogenous protein. Altogether, these 
data demonstrated that hARTC1 is a protein primarily localized to the ER, with only 
one fifth of the protein associated with the plasma membrane (Fabrizio, G. et al., 
2015b). This finding casts new light on the cellular location of hARTC1, and 
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plausibly suggested that there may be novel ER-resident substrates for hARTC1-
mediated ADP-ribosylation.    
3.2.2 hARTC1 is the enzyme responsible for GRP78/BiP mono-ADP-ribosylation  
The data presented above describing immunofluorescence analysis of hARTC1 in 
living cells demonstrated that the enzyme has a prevalent intracellular localization, 
and for the first time reported a quantification of the enzyme’s distribution. Since 
some of the protein (~20% c.f. Figure 3.4) is localized to the plasma membrane, 
hARTC1 can catalyze mono-ADP-ribosylation of plasma membrane-associated 
proteins, some of which have been reported (Nemoto, E. et al.,1996; Liu, Z.X. et al., 
1999; Zolkiewska, A. and Moss, J., 1993). However, nothing is known about 
intracellular targets of hARTC1. Due to its substantial intracellular localization, it is 
reasonable to search for proteins that could be mono-ADP-ribosylated by hARTC1 
within cellular organelles. Of note, intracellular ADP-ribosylated proteins are 
known, but the enzyme(s) responsible for the modification still remain to be 
identified. It is possible that hARTC1 is involved in some of these previously 
identified mono-ADP-ribosylation reactions. 
In order to identify intracellular substrates of hARTC1, a strategy was employed 
that took advantage of our previous demonstration that a protein module, named 
Archaeoglobus fulgidus macro domain (mAf1521) which has a high affinity for 
ADP-ribose (Dani, N. et al., 2009). This peptide can function as a bait to isolate 
ADP-ribosylated proteins and, thus, it can be used for the identification of novel 
ADP-ribosylated proteins. This tool was employed in both biochemical and cell 
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biology approaches, allowing identification of novel targets of hARTC1-mediated 
ADP-ribosylation. The setting up of new macro domain-based experiments 
represent an important technological advancement in the study of APD-
ribosylation reactions.  
3.2.2.1 Macro domain-based pull-down assay 
Initial experiments used the macro domain mAf1521 for macro-based GST pull-
down assays, as described by Dani and colleagues (Dani, N. et al., 2009). To verify 
the functionality of this assay, the method was firstly set up by analyzing CHO cells 
transfected with a wild-type ARTC enzyme, or a mutant, inactive form of the same 
enzyme. Considering that no hARTC1 mutant was available, these experiments 
employed cARTC2.1 wt and cARTC2.1 dm. After 24 hours of transfection, cells from 
each transfection condition were lysed and subjected to two-step pull-down with 
the GST-tagged macro domains (see Materials and Methods): the first pull-down 
was performed using the GST-tagged mAf1521/G42E mutant, which does not bind 
ADP-ribosylated proteins. This step allowed removal of protein that was non-
specifically bound to the macro domain module. The supernatant from this first 
step was recovered and underwent a second pull-down with wild-type GST-
mAf1521, to specifically retain ADP-ribosylated proteins. The pulled-down proteins 
obtained following this two-step procedure were separated by 10% SDS-PAGE and 
revealed by colloidal Coomassie blue staining.  
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.8 Macro domain-based pull-down assay coupled to MALDITOF–MS analysis identifies 
GRP78/BiP as a substrate of cARTC2.1 wt. Representative pull-down from CHO cells transfected 
with enzymatically active cARTC2.1. wt or with the enzymatically inactive cARTC2.1 dm. Cell lysates 
(3 mg protein) underwent a non-specific pull-down step using the GST-tagged mAf1521/G42E 
mutant (with abrogated binding of mAf1521 ADP-ribosylated proteins). The unbound material 
underwent a second pull-down with wild-type GST-mAf1521, to specifically retain ADP-
ribosylated proteins. This two-step procedure resulted in separation of specific proteins that were 
revealed by colloidal Coomassie blue staining and identified by MALDI-TOF analysis (NCBI acc. 
number: AAA52614; score: 209; matched peptide no.: 21; sequence coverage: 35%; molecular 
mass: 72 kDa; protein scores ≃65 are significant (p < 0.05). Western Blotting (WB) showed the 
levels of expression of the indicated Flag-tagged proteins, as performed by immunoblotting with 
an anti-Flag antibody. The data shown are representative of at least five independent 
experiments.  
As depicted in Figure 3.8, a specific protein band of ca. 78 kDa was detected in the 
Flag-cARTC2.1 wt-transfected CHO cells pulled-down with GST-tagged mAf1521 
wt. No band was detected in cARTC2.1 dm-transfected cells. As expected, no 
bands were revealed after the incubation with the mutant macro domain, which 
does not bind ADP-ribosylated proteins. To confirm transfection of the cells with 
cARTC2.1 wt and cARTC2.1 dm, Western Blotting was performed, which indicated 
similar levels of expression for both of the transfected proteins (Figure 3.8).  
Having verified the functionality and specificity of the pull-down method, I 
performed similar experiments using CHO cells transfected with either an empty 
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vector, hARTC1 wt or cARTC2.1 wt with the latter being employed as internal 
control. 
 
Modified from Fabrizio, G. et al., 2015b 
Figure 3.9 Macro domain-based pull-down assay coupled to MALDITOF–MS analysis identifies 
GRP78/BiP as a substrate of hARTC1 wt. Representative pull-down from CHO cells transfected 
with an empty vector or with enzymatically active hARTC1 wt or cARTC2.1 wt. Cell lysates (3 mg 
protein) underwent non-specific pull-down step using the GST-tagged mAf1521/G42E mutant 
(with abrogated binding of mAf1521 ADP-ribosylated proteins). The unbound material underwent 
a second pull-down with wild-type GST-mAf1521, to specifically retain ADP-ribosylated proteins. 
This two-step procedure resulted in separation of specific proteins that were revealed by colloidal 
Coomassie blue staining and identified by MALDI-TOF analysis (NCBI acc. number: AAA52614; 
score: 209; matched peptide no.: 21; sequence coverage: 35%; molecular mass: 72 kDa; protein 
scores ≃65 are significant (p < 0.05). Western Blotting (WB) showed the levels of expression of 
the indicated Flag-tagged proteins, as performed by immunoblotting with an anti-Flag antibody. 
The data shown are representative of at least five independent experiments.  
As depicted in Figure 3.9, no band was pulled-down from cells transfected with 
the empty vector alone, whereas a protein band of ca. 78 kDa was detected in 
hARTC1 wt-transfected cells. The transfection of the enzymes was checked with 
Western Blotting (Figure 3.9, WB). The Western Blotting indicated that both 
enzymes were expressed in the CHO cells albeit with a higher level of cARTC2.1.  
The specific band that was pulled-down in cells transfected with the active 
enzymes was then excised from the gel and subjected to identification by MALDI-
TOF–MS analysis. This specific band was identified as the highly conserved ER 
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chaperone protein GRP78/BiP, thus suggesting that catalytically active cARTC2.1 
wt and hARTC1 wt are involved in the previously described ADP-ribosylation of the 
chaperone (Fabrizio, G. et al., 2015b).  
3.2.2.2 Macro domain-based immunofluorescence assay 
Taking advantage of the ability of macro domain Af1521 to specifically bind 
GRP78/BiP in cells transfected with hARTC1 wt and cARTC2.1 wt, it was next 
investigated whether the same macro domain could be used to visualize ADP-
ribosylated proteins by immunofluorescence.  To this end, conditions were set up 
for an immunofluorescence assay using the GST-tagged wild-type (mAf1521) and 
its non-ADP-ribose binding mutant (mAf1521/G42E). Specifically, HeLa cells were 
non-transfected and were fixed with 4% PFA, permeabilized and incubated with 
the wild-type mAf1521 macro domain or the mAf1521/G42E mutant. To detect the 
macro domain bound to ADP-ribosylated proteins an anti-GST antibody was used. 
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.10 The mAf1521 macro module can be used to visualize ADP-
ribosylated proteins. Representative immunofluorescence images of 
non-transfected HeLa cells that were incubated with GST-mAf1521 (a) or 
GST-mAf1521/G42E (b), stained with anti-Flag and anti-GST antibodies, 
as indicated, and analyzed by immunofluorescence. The scale bar 
represents 10 µm. The data shown are representative of at least ten 
independent experiments. 
The analysis of cells by confocal microscopy revealed predominantly nuclear 
staining for control cells incubated with GST-mAf1521 wild-type (Figure 3.10a), 
suggesting that in these cells, under basal condition, nuclear ADP-ribosylation 
could be detected. The specificity of this labelling was confirmed by the lack of cell 
staining when the GST-tagged mAf1521/G42E mutant macro domain was used 
(Figure 3.10b). As expected, there was no detectable Flag staining in non-
transfected cells. Thus, the use of macro domain in immunofluorescence 
represented an efficient method allowing visualization of ADP-ribosylated proteins 
in intact cells (Fabrizio, G. et al., 2015b).  
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Similar experiment was then performed using HeLa cells transiently transfected for 
24 hours with Flag-tagged hARTC1 wt (Figure 3.11a, b), hARTC4 (Figure 3.11c, d), 
cARTC2.1 wt (Figure 3.11e, f) or cARTC2.1 dm (Figure 3.11g, h). For cell staining, an 
anti-Flag antibody was used to detect the over-expressed enzymes while an anti-
GST antibody was used to detected the GST-tagged mAf1521 and, thus, visualize 
ADP-ribosylation.  
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.11 The mAf1521 macro module allows visualization of ADP-ribosylated proteins in cells 
transfected with active ARTCs. Representative immunofluorescence images of HeLa cells 
transiently transfected with the indicated constructs and incubated with GST-mAf1521 (a, c, e, 
g) or GST-mAf1521/G42E (b, d, f, h), stained with anti-Flag and anti-GST antibodies, as indicated, 
and analyzed by immunofluorescence. The scale bar represents 10 µm. The data shown are 
representative of at least ten independent experiments.  
The immunofluorescence images showed clear peri-nuclear staining of hARTC1 wt 
(Figure 3.11a, b; see also Figures 3.2; 3.5; 3.6), whereas a minimal peri-nuclear 
staining was seen for hARTC4 (Figure 3.11c, d). As expected, the staining of 
cARTC2.1 wt and cARTC2.1 dm (Figure 3.11e, f and Figure 3.11g, h, respectively) 
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showed that they were correctly localized to the cell periphery, as previously 
reported (Stilla, A. et al., 2011).  
Additionally, GST-mAf1521 also revealed a peri-nuclear staining in cells transfected 
with enzymatically active hARTC1 wt (Figure 3.11a) and cARTC2.1 wt (Figure 3.11e), 
in line with ADP-ribosylation events occurring within the ER. In contrast, cells 
transfected with the inactive enzymes, hARTC4 and cARTC2.1 dm, showed nuclear 
staining with GST-mAf1521 (Figure 3.11c and Figure 3.11g, respectively), as in 
control cells (Figure 3.10a). Obviously, the mutated mAf1521/G42E peptide that 
cannot bind ADP-ribosylated proteins showed no staining in any of the transfected 
cells (Figure 3.11b, d, f, h), as expected. 
Of note, cARTC2.1 has been well described as a plasma membrane enzyme, as the 
staining with anti-Flag antibody also confirmed (Stilla, A. et al., 2011; Figure 3.5b). 
However, no detectable peripheral staining was observed with GST-mAf1521 in 
cells over-expressing cARTC2.1. This can be explained considering there is not 
sufficient extracellular NAD+ to sustain ADP-ribosylation events in the extracellular 
compartment where cARTC2.1 is mainly localized. It has been previously 
demonstrated, that a peripheral ADP-ribosylation staining can only be detected 
when cells were incubated with NAD+ (Stilla, A. et al., 2011). However, as a GPI-
anchored enzyme, it is transiently present into the ER where it can act as an ART 
(Figures 3.9 and 3.11). 
Altogether, these data provided a technological advance in the study of ADP-
ribosylation by immunofluorescence microscopy. A prominent GST-mAf1521-
dependent peri-nuclear staining of cells was seen upon transfection with the active 
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enzymes hARTC1 wt and cARTC2.1 wt, but not with their inactive counterparts. This 
GST-mAf1521 peri-nuclear staining correlated with hARTC1 wt- and cARTC2.1 wt-
mediated ADP-ribosylation occurring at the ER level (Fabrizio, G. et al., 2015b).  
To further investigate whether this peri-nuclear staining revealed by 
immunofluorescence with GST-mAf1521 in cells over-expressing hARTC1 wt and 
cARTC2.1 wt was due to ADP-ribosylated GRP78/BiP, since it occurred in the same 
organelle where the chaperone is known to reside, immunofluorescence 
experiments were performed using HeLa cells transiently transfected for 24 hours 
with Flag-tagged hARTC1 wt, hARTC4, cARTC2.1 wt and cARTC2.1 dm, as indicated 
(Figure 3.12). Cells were then incubated with GST-mAf1521 (Figure 3.12a, c, e, g) or 
with the inactive mutant GST-mAf1521/G42E (Figure 3.12b, d, f, h) and stained with 
anti-GR78/BiP and anti-GST antibodies, as indicated in the figure. 
188 
 
 
189 
 
 
Modified from Fabrizio, G. et al., 2015b 
Figure 3.12 The mAf1521 macro module staining co-localizes with GRP78/BiP. Representative 
immunofluorescence images of HeLa cells transiently transfected with the indicated constructs, 
incubated with GST-mAf1521 (a, c, e, g) or GST-mAf1521/G42E (b, d, f, h), stained with anti-GST 
and anti-GRP78/BiP antibodies, as indicated, and analyzed by immunofluorescence. The scale 
bar represents 10 µm. The data shown are representative of at least five independent experiments. 
The immunofluorescence analysis showed that in cells over-expressing the active 
enzymes hARTC1 wt and cARTC2.1 wt GST-mAf1521 co-localized with GRP78/BiP 
(Figure 3.12a, e). In contrast, there was no co-localization between GRP78/BiP 
and GST-mAf1521 when the cells were transfected with the inactive enzymes 
hARTC4 or cARTC2.1 dm (Figure 3.12c, g). As expected, GST-mAf1521/G42E did 
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not lead to immunofluorescence with any transfected cells since it does not bind 
ADP-ribose (Figure 3.12b, d, f, h). 
The data described above are consistent with the notion that GRP78/BiP is ADP-
ribosylated as a consequence of either hARTC1 wt or cARTC2.1 wt over-expression 
(Fabrizio, G. et al., 2015b). Of note, cARTC2.1 was physically separated from 
GRP78/BiP (Figure 3.13c), since it is a cell membrane enzyme (Stilla, A. et al., 2011). 
However, it induced GRP78/BiP ADP-ribosylation in line with its action as an 
arginine-specific ART, and with the fact that, as a GPI-anchored protein, it is 
transiently present into the ER. 
Finally, to directly evaluate the co-localization of hARTC1 wt with its target 
GRP78/BiP, immunofluorescence experiments were performed on cells transfected 
with the same constructs (Flag-tagged hARTC1 wt, hARTC4, cARTC2.1 wt and 
cARTC2.1 dm) and then analyzed using an anti-GRP78/BiP antibody in 
combination with an anti-Flag antibody. 
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Taken from Fabrizio, G. et al., 2015b 
Figure 3.13 hARTC1 wt co-localizes with GRP78/BiP. Representative immunofluorescence 
images of HeLa cells transiently transfected with the indicated constructs, stained with anti-
GRP78/BiP or anti-Flag antibodies, as indicated, and analyzed by immunofluorescence. The 
scale bar represents 10 µm. The data shown are representative of at least five independent 
experiments. 
As revealed by immunofluorescence images, hARTC1 wt co-localized with 
GRP78/BiP (Figure 3.13a), consistent with it being an ER-associated enzyme, in 
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contrast to all of the other ARTCs evaluated under the same experimental 
conditions (figure 3.13 b, c, d).  
3.2.2.3 Macro domain-based far-Western Blotting assay 
Taking advantage of the high affinity of the GST-mAf1521 macro domain for ADP-
ribosylated substrates, its suitability as a molecular probe in far-Western Blotting 
was investigated. This is a molecular biological method based on Western Blotting 
but, instead of an antibody to detect the protein(s) of interest, far-Western Blotting 
uses a non-antibody protein able to probe for protein(s) of interest. In this way, 
binding partners of the probe protein may be identified. Different methods can be 
used to visualize the probe protein: radiolabeling, antibody with tag affinity (like 
HIS or Flag), or a protein-specific antibody against the probe protein. However, 
because cell extracts are usually completely denatured due to boiling in detergent 
before gel electrophoresis, this is only a useful approach for detecting interactions 
that do not require the native folded structure of the protein of interest.  
The ability of the GST-mAf1521 macro domain to recognize ADP-ribosylated 
proteins immobilized on nitrocellulose was examined. To this aim, lysates obtained 
from HeLa cells previously transfected with the empty vector (pME.CD8LF), a GPI-
GFP construct, or with Flag-tagged hARTC1 wt, hARTC4, cARTC2.1 wt and 
cARTC2.1 dm, were separated by SDS-PAGE and subsequently transferred to 
nitrocellulose filters. The filter was then probed with GST-mAf1521, using an anti-
GST antibody to reveal it. As shown in Figure 3.14, macro domain labelled 
numerous bands, each of which corresponded to an ADP-ribosylated substrate. 
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.14 GRP78/BiP is ADP-ribosylated by the ARTCs. Representative far-Western Blotting (FAR-
WB, top) with GST-tagged mAf1521 of HeLa cells transfected with the empty vector (control) or 
with the indicated constructs. The solubilized proteins were separated by SDS-PAGE, transferred 
to nitrocellulose filters and incubated with GST-tagged mAf1521. Representative Western Blotting 
(WB, bottom) showing that the indicated band in Far-WB was recognized by a specific anti-
GRP78/BiP antibody. The levels of expression of the indicated Flag-tagged proteins and the actin 
loading control are also shown. The data shown are representative of at least three independent 
experiments. 
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As shown in Figure 3.14, an evident pattern of ADP-ribosylated proteins was 
induced by hARTC1 wt and cARTC2.1 wt over-expression, as they both possessed 
arginine-specific ART activity. In contrast, a very slight protein labeling was 
obtained after the transfection of the inactive enzymes hARTC4 and cARTC2.1 dm, 
that were, indeed, comparable to that of the cells transfected with the empty 
vector (Figure 3.14, Far-WB, control) or with GPI-GFP (Figure 3.14, Far-WB, GPI-
GFP). Analysis of the ADP-ribosylated targets of cells transfected with the 
enzymatically active hARTC1 wt and cARTC2.1 wt, revealed a protein band with the 
predicted molecular weight of GRP78/BiP (Figure 3.14, Far-WB, ADP-ribosylated 
GRP78/BiP).  
A band at the same apparent molecular weight was also recognized by an anti-
GRP78/BiP antibody and, obviously, it was present in all the samples and not just 
in hARTC1 wt- and cARTC2.1 wt-transfected cells, as the chaperone is ubiquitously 
expressed (Figure 3.14, WB).  Moreover, staining with anti-Flag was performed to 
check the expression of the transfected enzymes and actin was used a loading 
control (Figure 3.14, WB). 
Thus, the results presented here demonstrated that the GST-mAf1521 macro 
domain was a powerful tool that was suitable for analysis of ADP-ribosylated 
substrates in far-Western Blotting and, more importantly, confirmed that mono-
ADP-ribosylation of GRP78/BiP was mediated by arginine-specific enzymes of the 
ARTC family (Fabrizio, G. et al., 2015b).  
In order to demonstrate that the band revealed in far-Western Blotting after the 
transfection of active ARTCs was the mono-ADP-ribosylated GRP78/BiP, siRNA-
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mediated knock-down of the chaperone was used. Initially, protocols were 
optimized to find ideal experimental conditions to silence the chaperone, using a 
pool of commercially available siRNA. The major difficulty was to efficiently silence 
one of the most abundant chaperones in the ER, since its silencing resulted in 
extensive cell death. Thus, it was important to find the optimal conditions to have 
the best silencing without inducing extensive cell death. The best result was 
achieved with the “siGENOME Human HSPA5 siRNA reagents” used at 100 nM for 
48 hours, as shown in Figure 3.15. 
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Modified from Fabrizio, G. et al., 2015b 
Figure 3.15 Silencing of GRP78/BiP reduces GRP78/BiP mono-ADP-ribosylation. Representative far-
Western Blotting (FAR-WB) with GST-tagged mAf1521 of both control and GRP78/BiP-silenced 
HeLa cells. The solubilized proteins were separated by SDS-PAGE, transferred to nitrocellulose 
filters, and incubated with GST-tagged mAf1521. Representative Western Blotting (WB) showing 
GRP78/BiP knock-down and the levels of expression of tubulin, that was used as loading control. 
Quantification of the reduction of GRP78/BiP (white bar) and that of GRP78/BiP ADP-ribosylation 
(black bar), expressed as percentage of inhibition. The data shown are representative of at least 
three independent experiments. *: significantly different from the relevant control (p < 0.05). 
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Western Blotting (WB), as depicted in Figure 3.15, showed a 40% reduction of the 
GRP78/BiP chaperone after silencing; as already mentioned, a stronger knock-
down resulted in extensive cell death. However, this knock-down was sufficient to 
cause a reduction of the ADP-ribosylated form of the chaperone of about 65%. 
The demonstration of the reduction of the 78-kDa band revealed by far-WB 
strongly supported the notion that the protein detected by mAf1521 was, indeed, 
GRP78/BiP.  
These data demonstrated that the GST-mAf1521 macro domain and its ability to 
bind ADP-ribosylated proteins with high affinity affords a useful tool for analysis 
of ADP-ribosylation also in far-Western Blotting experiments. Through this novel 
approach it was possible to demonstrate that hARTC1 is involved in the previously 
described GRP78/BiP mono-ADP-ribosylation (Fabrizio, G. et al., 2015b).  
3.3 Summary 
• hARTC1 is located in the ER: both the over-expressed and the endogenous 
protein co-localize with different ER markers in immunofluorescence 
experiments.  
• hARTC1 and cARTC2.1 are synthetize into the ER as GPI-anchor proteins but, 
differently from cARTC2.1, which is mainly located in the plasma membrane, half 
of hARTC1 is ER resident. 
• Macro domain is a powerful tool for the study of APD-ribosylation. Macro 
domain can be used in immunofluorescence allowing visualization of ADP-
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ribosylated proteins in intact cells, and in far-Western Blotting to detect specific 
ADP-ribosylated targets.  
• The prime target of hARTC1-mediated mono-ADP-ribosylation is the 
chaperone GRP78/BiP.  
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Chapter 4 
Study of GRP78/BiP mono-ADP-ribosylation using a catalytically inactive hARTC1 
double mutant and siRNA-mediated knock-down of hARTC1 
4.1 Introduction 
The experiments reported in the previous Chapter demonstrated that hARTC1 wt 
is an enzyme localized in the ER, where it is involved in the mono-ADP-ribosylation 
of the chaperone GRP78/BiP. The experiments described in that Chapter were 
performed using the enzymes cARTC2.1 wt, and its catalytically inactive mutant or 
the enzyme hARTC4 as the negative controls of hARTC1 wt, both for cellular 
localization (cARTC2.1 wt and cARTC2.1 dm are localized to the plasma membrane) 
and activity (cARTC2.1 dm and hARTC4 are inactive enzymes). However, a more 
specific approach is to use a catalytically inactive mutant of hARTC1 wt. This 
validates data obtained with other enzymes, and excludes indirect effects 
mediated by hARTC1 on the ADP-ribosylation of GRP78/BiP. For these reasons, a 
catalytically inactive mutant version of hARTC1 was generated using site-directed 
mutagenesis.  
Another important experimental approach to study GRP78/BiP mono-ADP-
ribosylation by hARTC1 is the use of siRNA-mediated knock-down. Silencing of 
hARTC1 was therefore used to directly demonstrate that hARTC1 was the enzyme 
involved in the modification of the GRP78/BiP.    
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4.2 Results 
4.2.1 Study of expression, localization and activity of hARTC1 double mutant 
hARTC1 has conserved residues corresponding to the R-S-EXE motif of arginine-
specific mono-ADP-ribosyl-transferases (Glowacki, G. et al 2002). In particular, 
glutamate 240 (E240) is considered a key catalytic amino acid, even though 
glutamate 238 (E238) is critical for enzyme function (Takada, T. et al., 1995). 
Mutation of either of these residues has been shown to alter the enzyme’s capacity 
to use arginine as acceptor, supporting the idea that this was the region involved 
in acceptor recognition (Bourgeois, C. et al., 2003). To test how mutations could 
alter the substrate specificity, single point and double point mutant versions of 
hARTC1 were generated. Firstly, experiments to generate a single point hARTC1 
mutant by changing the glutamate 240 to glycine (E240G) were performed. 
Previous work from my laboratory had characterized single point and double point 
(E207G/E209G) mutant isoforms of hamster ARTC2.1 (Stilla, A. et al., 2011). It was 
found that the single point mutated protein still had a partial transferase activity, 
while the double point mutant was completely inactive. In light of these 
observations, a double mutant (E238G/E240G) was generated, in which both of 
the glutamic acid residues of the EXE motif were mutated. Unfortunately, attempts 
to generate the single point mutant hARTC1-E240G failed: no growth on the 
antibiotic plate was seen after bacterial transformation, even though the positive 
and negative control of the experiments confirmed that the reaction was properly 
set up and executed. For the positive control, competent bacteria were 
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transformed with non-digested plasmid DNA and plated on selection media; it 
allows measurement of the efficiency of transformation and served as a standard 
for comparison with other transformations. For the negative control, competent 
bacteria without addition of plasmid were plated on positive selection media and 
no growth was observed. Despite repeated attempts and successful 
transformations procedure, no colony could be observed on the plate 
corresponding to single point mutant hARTC1-E240G. The over-expression of the 
mutant protein could have toxic effects on the bacterial growth. A possible 
explanation could be that the single mutant protein is expressed, but it interferes 
with the normal proliferation and homeostasis of the microorganism, resulting in 
cell death. This toxicity is not exclusive for hARTC1 single point mutant as different 
enzymes of the ART family have already been described to be deleterious for 
bacteria, causing unsuccessful transformations. However, the double point mutant 
(E238G/E240G) of hARTC1 was successfully generated. This double point mutant 
is hereafter referred to as hARTC1 dm. The doubly mutated hARTC1 enzyme was 
characterized in terms of expression, activity and cellular localization. The level of 
expression was evaluated by Western Blotting, catalytic activity was assessed with 
far-Western Blotting and macro domain-based immunofluorescence experiments, 
and the cellular localization of hARTC1 dm was examined using 
immunofluorescence experiments. 
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4.2.1.1 The hARTC1 (E238G/E240G) dm is not able to mediate GRP78/BiP mono-
ADP-ribosylation  
To evaluate hARTC1 dm expression and activity, Western Blotting and far-Western 
Blotting experiments were performed. Specifically, HeLa cells were transfected with 
the empty vector or with hARTC1 wt or hARTC1 dm for 24 hours. Subsequently, 
cells were lysed, their protein content measured and separated by SDS-PAGE, 
transferred to nitrocellulose filters and, then, probed with GST-mAf1521 for far-
Western Blotting or with anti-ARTC1, anti-GRP78/BiP and anti-tubulin antibodies 
for Western Blotting. 
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Modified from Fabrizio, G. et al., 2015b 
Figure 4.1 hARTC1 dm does not induce GRP78/BiP mono-ADP-ribosylation and is therefore 
catalytically inactive. Representative far-Western Blotting (FAR-WB, top) with GST-tagged 
mAf1521 of HeLa cells transfected with an empty vector (control), or with the indicated 
constructs. The solubilised proteins were separated by SDS-PAGE, transferred to 
nitrocellulose filters and incubated with GST-tagged mAf1521. Representative Western 
Blotting (WB, bottom) showing that the indicated band in FAR-WB was recognized by a 
specific anti-GRP78 antibody. The levels of expression of the indicated hARTC1 proteins are 
also shown. Tubulin was used as loading control. The data shown are representative of 
three independent experiments. 
As shown in Figure 4.1, hARTC1 dm transfection levels were comparable to that of 
the wild type protein (Figure 4.1 WB; hARTC1). However, ADP-ribosylated proteins 
detectable in hARTC1 wt-transfected cells were completely absent in hARTC1 dm-
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transfected cells. The lack of band corresponding to GRP78/BiP ADP-ribosylation 
in cells transfected with hARTC1 dm (Figure 4.1 Far-WB; ADP-ribosylated 
GRP78/BiP) indicates that hARTC1 dm was an inactive enzyme.  
As a further examination of the catalytically inactivity of hARTC1 dm, macro 
domain-based immunofluorescence experiments were performed using HeLa 
cells transfected for 24 hours with the Flag-hARTC1 dm. An anti-Flag antibody was 
used to detect the over-expressed enzyme, and an anti-GST antibody was used to 
detect the GST-tagged mAf1521 probe to visualize potential ADP-ribosylation 
(Figure 4.2). 
 
Modified from Fabrizio, G. et al., 2015b 
Figure 4.2 The mAf1521 macro module does not allow visualization of ADP-ribosylated 
proteins in cells transfected with hARTC1 dm. Representative immunofluorescence images of 
HeLa cells were transiently transfected with Flag-hARTC1 dm, fixed and permeabilized, 
incubated with GST-mAf1521 and then stained with anti-Flag and anti-GST antibodies. The 
scale bar indicates 10 µm. The data shown are representative of three independent 
experiments. 
As shown in Figure 4.2, immunofluorescence confirmed that in cells transfected 
with hARTC1 dm only a modest nuclear staining was detectable with GST-mAf1521, 
similar to that of control cells (cf. Figure 3.10a) or that of hARTC4- and cARTC2.1 
dm-transfected cells (cf. Figures 3.11c, g, respectively). Altogether, these 
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experiments demonstrated that the double mutant form of hARTC1 was expressed 
in HeLa cells as an inactive enzyme that could not catalyze ADP-ribosylation 
reactions (Fabrizio, G. et al., 2015b). 
4.2.1.2 The hARTC1 (E238G/E240G) dm is localized to the ER 
The cellular location of hARTC1 dm was examined using immunofluorescence 
experiments. HeLa cells were transfected with hARTC1 dm for 24 hours and stained 
with an anti-Flag antibody to determine the location of the expressed protein. The 
cells were also stained with an anti-GRP78/BiP antibody to show the ER. 
 
Modified from Fabrizio, G. et al., 2015b 
Figure 4.3 hARTC1 dm co-localizes with GRP78/BiP. Representative immunofluorescence images 
of HeLa cells that were transiently transfected with Flag-hARTC1 dm and stained with anti-
GRP78/BiP and anti-Flag antibodies. The scale bar indicates 10 µm. The data shown are 
representative of three independent experiments.  
The analysis of cells by confocal microscopy revealed that, when over-expressed 
in HeLa cells, Flag-hARTC1 dm co-localized with GRP78/BiP (Figure 4.3). Thus, it 
appeared to be an ER-resident enzyme exactly as the wild-type counterpart (cf. 
Figure 3.13a) and in contrast to all of the other ARTCs evaluated under similar 
experimental conditions (cf. Figure 3.13b, c, d). 
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This result demonstrated that hARTC1 dm was expressed and correctly localized 
at the ER compartment albeit catalytically inactive. The results obtained with 
hARTC1 dm further validate previous data shown in this thesis concerning hARTC1 
ER localization and its involvement in GRP78/BiP ADP-ribosylation reaction 
(Fabrizio, G. et al., 2015b).  
4.2.2 Silencing of hARTC1 reduces the level of GRP78/BiP mono-ADP-ribosylation 
Silencing of hARTC1 was used to examine the effect of knocking-down the 
expression of the enzyme and of its consequence for ADP-ribosylation of 
GRP78/BiP. The working hypothesis was that a reduction of hARTC1 expression 
accompanied by lower levels of GRP78/BiP modifications would provide a direct 
demonstration this was the enzyme involved in the chaperone’s mono-ADP-
ribosylation.  
For the silencing of hARTC1 a few commercial tools were available; however, they 
were not yet being tested by the providers. For this study, a set of 4 siRNAs from 
Sigma-Aldrich were initially tested but this tool was not able to silence hARTC1. 
Thus, single siRNA sequences were generated, designing 4 different 
oligonucleotides that were specific for hARTC1. Then I performed different 
protocols to optimize the experimental conditions for the best knock-down, 
including evaluation of different siRNAs combination (single, double, triple or 
quadruple siRNAs), various siRNA transfection reagents (HiPerFect Transfection 
Reagent from Qiagen, Lipofectamine 2000 Transfection Reagent from Thermo 
Fisher Scientific, jetPRIME DNA/siRNA Transfection Reagent form Polyplus), ratio 
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of transfection reagent to siRNA, cell density at transfection, dose-response and 
time-course of silencing (48 hours or 72 hours). The best reduction of hARTC1 was 
achieved with HeLa cells transfected with a pool of three siRNAs (siRNA1ARTC1, 
siRNA2ARTC1 and siRNA4ARTC1, table 2.1.2) used 30 nM each for 48h, transfected 
with jetPRIME reagent. hARTC1 knock-down was analyzed by Western Blotting, 
and the levels of ADP-ribosylated GRP78/BiP by far-Western Blotting.   
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Modified from Fabrizio, G. et al., 2015b 
Figure 4.4 Silencing of hARTC1 reduces the basal level of GRP78/BiP mono-ADP-ribosylation. 
Representative far-Western Blotting (FAR-WB, top) with GST-tagged mAf1521 of both control and 
hARTC1-silenced HeLa cells. The solubilised proteins were separated by SDS-PAGE, transferred to 
nitrocellulose filters, and incubated with GST-tagged mAf1521. Representative Western Blotting 
(WB, bottom) showing hARTC1 knock-down. The anti-ARTC1 antibody revealed at least four major 
bands that would reflect different degrees of glycosylation of hARTC1. The Western Blotting also 
showed the levels of expression of GRP78/BIP and of GAPDH, which was used as loading control. 
The graph (bottom) show the quantification of the reduction of hARTC1 protein expression (white 
bar; relative to control cells set at 100%), and that of ADP-ribosylated GRP78/BiP (black bar; relative 
to control cells set at 100%). The data shown are representative of at least three independent 
experiments. * indicates significantly different from the relevant control (p < 0.05).  
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The Western Blotting shown in Figure 4.4 indicates that the hARTC1 antibody 
revealed the presence of at least four different major bands. This was reported in 
the datasheet of this specific commercial antibody from Sigma-Aldrich (see 
Materials and Methods, Table 2.3). The presence of multiple protein bands was 
consistent with different degrees of glycosylation of the hARTC1 protein, since this 
modification had previously been reported for ecto-ART enzymes (Zolkiewska, A. 
et al., 1992). However, application of hARTC1 siRNA led to reductions in the density 
of all four bands, and quantification of one of them (specifically the one 
corresponding to the indication “hARTC1” near the bottom panel of Figure 3.19) 
demonstrated a reduction of band intensity by 55% (relative to control non-
transfected cells).  
Regarding GRP78/BiP ADP-ribosylation, far-Western Blotting of non-transfected 
HeLa cells revealed a distinct band corresponding in size to GRP78/BiP that could 
only be detected after longer exposure (Figures 3.19, control, and 3.15, control). 
This specific band, however, was reduced by approximately 40% when 
endogenous hARTC1 was knocked-down by siRNA (Figure 3.19).  
Thus, the silencing of hARTC1 was sufficient to inhibit the basal level of ADP-
ribosylated GRP78/BiP. This finding provided a direct demonstration that hARTC1 
was the enzyme responsible for the modification of the chaperone (Fabrizio, G. et 
al., 2015b). 
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4.3 Summary 
• A doubly mutated hARTC1 has been generated using site-directed 
mutagenesis. 
• hARTC1 dm is localized at the ER and is expressed as an inactive enzyme that 
could not generate ADP-ribosylated GRP78/BiP, as evaluated using the macro 
domain in immunofluorescence and far-Western Blotting experiments. 
• The silencing of hARTC1 inhibits the basal levels of GRP78/BiP mono-ADP-
ribosylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
211 
 
Chapter 5 
Expression and activity of hARTC1 are regulated by ER stress but are not involved 
in the UPR  
5.1 Introduction 
The molecular chaperone GRP78/BiP has been reported to undergo intracellular 
mono-ADP-ribosylation, but the enzyme(s) responsible for this modification have 
not been identified so far (Laitusis, A.L. et al., 1999; Ledford, B.E. and Leno, G.H., 
1994). However, due to GRP78/BiP’s ER luminal localization, it was previously 
postulated that, from a topological point of view, an arginine-specific enzyme of 
the ARTC family would be needed to modify the chaperone (Di Girolamo, M. et 
al., 2005, Fabrizio, G. et al., 2015b). Consistent with this hypothesis, the data 
presented in the previous chapters demonstrated that hARTC1 was the enzyme 
involved in this previously described mono-ADP-ribosylation. 
GRP78/BiP is a well-characterized molecular chaperone ubiquitously expressed in 
mammalian cells (Chen, W.T. and Lee, A.S., 2011). It is best known for binding to 
hydrophobic patches on nascent polypeptides within the ER, preventing 
intermediates from aggregating and facilitating the acquisition of proper 
secondary structure of mature proteins (Gardner, B.M. et al., 2013; Zhu, G. and Lee, 
A.S., 2015). Along with its role in protein folding, GRP78/BiP has also been 
demonstrated to be a player in a wide variety of cellular pathways, including ER 
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stress and UPR (Brewer, J.W., 2014; Hetz, C., 2012; Ni, M. and Lee, A.S., 2007; Zhu, 
G. and Lee, A.S., 2015).  
The role of GRP78/BiP, like the other chaperones, during the processing of nascent 
proteins in the ER lumen is dependent on ER luminal factors such as calcium 
concentration, redox homeostasis and oxygen supply (Araki, K. and Nagata, K., 
2011; Gorlach, A. et al., 2006; Ushioda, R. et al., 2016). Physiological or pathological 
conditions that disrupt this fine balance, such as ER calcium depletion, glucose 
deprivation and oxidative stress, perturb the ER homeostasis and lead to 
accumulation of unfolded or misfolded proteins in the ER, causing the ER stress 
(Vincenz-Donnelly, L. and Hipp, M.S., 2017).  
The cellular responses to ER stress are multifaceted and include the activation of 
the UPR pathway, primary aim of which is to sustain cell survival by attenuating 
protein synthesis and restoring cellular homeostasis (Gardner, B.M. et al., 2013; 
Grootjans, J. et al., 2016; Kaufman, R.J., 1999; Welihinda, A.A. et al., 1999). The UPR 
is orchestrated by three ER transmembrane receptors: ATF6, IRE1α and PERK 
(Brewer, J.W., 2014; Hetz, C., 2012; Mori, K., 2000). In resting cells they are all kept 
inactivate through their association with GRP78/BiP (Brewer, J.W., 2014; Hetz, C., 
2012). Upon ER stress, unfolded proteins accumulate in the ER lumen resulting in 
the dissociation of GRP78/BiP from ATF6, IRE1α and PERK, subsequently 
transducing the UPR (Brewer, J.W., 2014; Hetz, C., 2012; Merksamer, P.I. and Papa, 
F.R., 2010; Ron, D. and Walter, P., 2007). UPR activation leads to an adaptive 
increase in folding capacity, exemplified by the induction of different genes, 
including GRP78/BiP (Zhang, K. and Kaufman, R.J., 2008). However, when ER stress 
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is not mitigated, an ER stress-induced cell death ensues (Iurlaro, R. and Munoz-
Pinedo, C., 2016; Logue, S.E. et al., 2013; Sano, R. and Reed, J.C., 2013). Considering 
the key functions of GRP78/BiP in protein folding and in the ER stress response, 
the main focus of this Chapter was the study of the biological role of GRP78/BiP 
mono-ADP-ribosylation in these contexts. 
The mono-ADP-ribosylation of GRP78/BiP has been hypothesized to be a way to 
regulate the availability of the functional chaperone since, when ADP-ribosylated, 
it is in an inactive state (Laitusis, A.L. et al., 1999; Ledford, B.E. and Leno, G.H., 1994). 
Under normal conditions, the levels of ADP-ribosylated GRP78/BiP are reported 
to be low (Laitusis, A.L. et al., 1999). However, during stress conditions, such as 
amino acid starvation or cell treatment with protein synthesis inhibitors, which 
cause a reduction in mRNA translation and protein processing, there is an increase 
in the amount of the modified chaperone. Therefore, it has been suggested that 
this ADP-ribosylation represents a buffering system that allows the rates of protein 
processing to be balanced with those of protein synthesis (Laitusis, A.L. et al., 1999). 
Considering that this study has identified, for the first time, the enzyme involved 
in GRP78/BiP mono-ADP-ribosylation, further experiments analyzed the functional 
role of this modification. Firstly, it was investigated whether cell stresses that are 
well known activators of ER stress and, thus, are reported to induce GRP78/BiP, 
could also modulate hARTC1 and, consequently, affect GRP78/BiP mono-ADP-
ribosylation levels. Secondly, due to GRP78/BiP’s role as a master regulator of the 
UPR, the possible involvement of hARTC1 in this process was examined. 
Specifically, whether and how the manipulation of hARTC1 gene expression 
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affected the three GRP78/BiP-interacting sensors was analyzed. Modulating the 
expression of the enzyme responsible for GRP78/BiP mono-ADP-ribosylation 
allowed an investigation into the functional role of this post-translational 
modification and, plausibly revealed hARTC1 as a new, unexpected player of the 
UPR. 
5.2 Results 
5.2.1 hARTC1 is an ER stress-sensing protein  
Different reports have indicated that GRP78/BiP expression is modulated by 
various stress-inducing agents or by conditions that adversely affect ER functions, 
such as oxidative stress, chemical toxicity, inhibition of the ER calcium-ATPase, 
inhibitors of glycosylation and hypoxia (Beriault, D.R. and Werstucka, G. H., 2013; 
Oslowski, C.M. and Urano, F. 2011). Therefore, it was examined whether these same 
stress conditions were also able to modulate hARTC1 levels, thus implicating a 
hARTC1 in the ER stress response.  
Starting from data available within the published literature, HeLa cells were 
exposed to different stress-evoking treatments already described as GRP78/BiP 
inducers, whilst changes in mRNA transcript and protein levels were analyzed. 
Specifically, HeLa cells were subjected to stress treatments with DTT (2 mM for 2 
hours), thapsigargin (1 μM for 2 hours, and 0.3 μM for 18 and 24 hours), heat shock 
(42°C for 24 hours) and hypoxia (induced by 0.1% O2 for 24 hours; Beriault, D.R. 
and Werstucka, G. H., 2013; Li, W.W et al., 1993; Negroiu, G. et al., 2000).  
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For transcript levels, mRNA was extracted from cells subjected to these stress 
treatments and analysed with (qRT)-PCR, using primers specifically designed for 
ARTC1, GRP78/BiP and GAPDH (employed as internal control; see Table 2.2).  
 
 
Modified from Fabrizio, G. et al., 2015b 
Figure 5.1 hARTC1 and GRP78/BiP mRNA levels are increased by the cell stressors DTT and 
thapsigargin. The graphs show quantification of the levels of (a) endogenous hARTC1 and (b) 
GRP78/BiP mRNA transcripts within HeLa cells exposed to different stress-inducing treatments, 
determined by (qRT)-PCR. The (qRT)-PCR results were normalized to GAPDH mRNA, and then 
reported as arbitrary units relative to the hARTC1 or GRP78/BiP transcript of non-transfected, non-
treated HeLa cells (control, taken as 1.0). Data are presented as mean±SD of three independent 
experiments, each performed in triplicate. * indicates significantly different from control (p < 0.01). 
A significant increase of hARTC1 mRNA levels (Figure 5.1a) was observed as a 
consequence of DTT (3.04±2.76) and thapsigargin (10.73±2.59) treatments, both 
of which are well-characterized treatments for the induction of ER stress and 
GRP78/BiP expression. As expected, GRP78/BiP levels increased in HeLa cells 
treated with DTT (3.82±0.11) and thapsigargin (3.01±0.21), confirming previous 
reports (Laitusis, A.L. et al., 1999).  
GRP78/BiP mRNA levels were increased after 2 hours of treatment with 
thapsigargin (2.90±0.22), with even higher mRNA levels being observed in cells 
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treated for 18 hours (5.21±0.13) that were maintained through to 24 hours 
(4.97±0.11; Figure 5.1b). Conversely, the increase in hARTC1 mRNA was observed 
after 2 hours of treatment with thapsigargin, but had returned to control levels by 
18 hours (1.19±0.87) and 24 hours (0.76±2.30) of treatment (Figure 5.1a).  
When other stress treatments were used (heat shock, hypoxia), little or no changes 
in either hARTC1 (heat shock 1.83±1.21; hypoxia 1.46±0.25) or GRP78/BiP (heat 
shock 0.92±0.41; hypoxia 1.14±0.16) mRNA levels were observed. Despite the fact 
that GRP78/BiP is an HSP70 member, and thus is expected to be affect by heat-
shock, it has already been reported in the literature that GRP78/BiP expression is 
not significantly affected by heat shock conditions, as opposed to the other 
members of the HSP family (Wooden, S.K. and Lee, A.S., 1992).   
Thus, hARTC1 and GRP78/BiP transcripts are modulated by the same stresses, even 
though with different timing (Fabrizio, G. et al., 2015b).  
The (qRT)-PCR results were verified by analyzing the changes in hARTC1 and 
GRP78/BiP protein levels. Specifically, Western Blotting of HeLa cells exposed to 
the same stress conditions was performed. After being lysed, samples were 
separated by SDS-PAGE, transferred to nitrocellulose filters and probed with 
specific antibodies, as described in Materials and Methods.  
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Modified from Fabrizio, G. et al., 2015b 
Figure 5.2 hARTC1 and GRP78/BiP protein levels are increased by the cell stressors DTT and 
thapsigargin. (a) Representative Western Blotting showing endogenous hARTC1 and GRP78/BiP 
levels in cells exposed to different stress-inducing treatments. Tubulin was used a loading control. 
The level of expression of hARTC1 following transfection is also shown and was employed for the 
identification of the hARTC1 protein band of interest. (b and c) Quantification of the protein levels 
of (b) hARTC1 and (c) GRP78/BiP, normalized to tubulin, and relative to those of non-treated cells 
(control, taken as 1.0). Data are presented as mean±SD of three independent experiments, each 
performed in duplicate. * indicates significantly different from the relevant control (p < 0.05). 
The evaluation of both hARTC1 and GRP78/BiP protein levels under the same 
incubation conditions confirmed the mRNA analysis (Figure 5.1a, b). Increased 
levels of hARTC1 and GRP78/BiP were observed as a consequence of the DTT and 
thapsigargin treatments, but not with the other stressors (Figure 5.2). 
Quantification of protein bands demonstrated a significant increase of hARTC1 
(Figure 5.2b) following 2 hours of treatment with the cell stressors DTT (2.55±0.68) 
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and thapsigargin (3.22±1.11). Whereas, increased levels of GRP78/BiP (Figure 5.2c) 
were only observed following long-term treatments with thapsigargin 
(thapsigargin for 18 hours, 1.33±0.18; thapsigargin for 24 hours, 1.56±0.38). In 
contrast to the mRNA expression analysis, for which GRP78/BiP was elevated after 
2 hours of treatments and continued through the 24 hours, higher protein levels 
were evident only after 18 and 24 hours (cf. Figure 5.1 and 5.2).    
Of note, for the stress treatment experiments two different controls (non-treated, 
non-transfected cells) were used: the first was employed for the 2-hour DTT and 
thapsigargin treatments, and the second for the 18- and 24-hours thapsigargin, 
heat-shock and hypoxia treatments (Figure 5.1). With respect to protein levels, it 
seemed that both hARTC1 and GRP78/BiP were time-dependently expressed, as 
shown in Figure 5.2a.  
For hARTC1, as shown in the middle panel of Figure 5.2a, multiple bands were 
visualized, which were consistent with the different degrees of glycosylation of the 
protein (see also Figure 3.19 and related comments). Densitometric analysis was 
only performed on one of these band, i.e. the band that increased after hARTC1 
transfection (indicated by the arrow in the middle panel of Figure 5.2a). To ensure 
the quantification of the same band for all experiments, a sample of hARTC1 
transfected cells was routinely used as marker for the correct band.      
Altogether, the data from mRNA and protein analysis confirmed that under ER 
stress conditions there was a faster expression of hARTC1 than GRP78/BiP. 
Conversely, during the long-term ER stress treatments that caused increased 
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expression of GRP78/BiP, the basal hARTC1 levels were restored (Fabrizio, G. et al., 
2015b). 
Considering that these data demonstrate that hARTC1 was induced by ER stress 
treatments known to modulate GRP78/BiP, the next step was to investigate 
whether these same stress conditions could influence GRP78/BiP mono-ADP-
ribosylation. In order to evaluate the effect on mono-ADP-ribosylation, the macro 
domain-based far-Western Blotting was performed using HeLa cells exposed to 
both short-term and long-term stress conditions. In both cases, cells were lysed, 
separated by SDS-PAGE and subsequently transferred to nitrocellulose filters, as 
described in Materials and Methods. Subsequently, the filters were probed with 
the GST-mAf1521 macro domain, using an anti-GST antibody to reveal its binding 
(Figures 5.3 and 5.4).  
For the short-term stress treatments, GRP78/BiP ADP-ribosylation was analyzed at 
three different time points (20, 60 and 120 minutes; Figure 5.3). Indeed, both DTT 
and thapsigargin were reported to cause acute inhibition of translation, and 10 - 
20 minutes’ treatment was enough to inhibit the synthesis of almost all proteins 
(Brostrom, C.O. and Brostrom, M.A., 1998).  
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Modified from Fabrizio, G. et al., 2015b 
Figure 5.3 ADP-ribosylation of GRP78/BiP is induced by short-term treatment of HeLa cells with 
DTT and thapsigargin. (a) Representative far-Western Blotting (Far-WB) and (b) relative 
quantification of ADP-ribosylated GRP78/BiP in HeLa cells that were either untreated (control) or 
treated for the indicated times with DTT (2 mM) or thapsigargin (1 μM). The indicated band (ADP-
ribosylated GRP78/BiP) was also recognized with an anti-GRP78/BiP specific antibody. Tubulin 
was used as a loading control. Data are representative of at least three independent experiments. 
* indicates significantly different from the relevant control (p < 0.05).  
As depicted in Figure 5.3, increased levels of ADP-ribosylated GRP78/BiP were 
detectable during acute treatments with DTT and thapsigargin. These increased 
levels of ADP-ribosylated GRP78/BiP were evident after 20 minutes of DTT and 
thapsigargin addition, and were maintained for 2 hours (Figure 5.3a, Far-WB). 
Quantification of the relevant band confirmed that there was more than a two-
fold induction of GRP78/BiP ADP-ribosylation during the acute stress treatment 
with DTT (20 minutes, 2.46±0.30; 1 hour, 2.15±0.64), and this was maintained 
through 2 hours (1.90±0.43; Figure 5.3b). Treatment with thapsigargin did not give 
a significant increase of GRP78/BiP ADP-ribosylation after 20 minutes of treatment 
(1.23±0.25), whereas significant increases were detectable after 1 hour (1.48±0.06) 
and 2 hours (1.50±0.45) of treatment (Figure 5.3b). 
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For the long-term stress experiments, ADP-ribosylation of GRP78/BiP was 
analysed in cells exposed to 0.3 μM thapsigargin for 18 and 24 hours. Under these 
stress treatment conditions, the expression of GRP78/BiP has been well reported 
to be induced (Figure 5.2; Li, W.W. et al., 1993).  
 
Modified from Fabrizio, G. et al., 2015b 
Figure 5.4 ADP-ribosylation of GRP78/BiP is not affected by long-term treatment of HeLa cells 
with thapsigargin. Representative far-Western Blotting (Far-WB) and relative quantification of 
ADP-ribosylated GRP78/BiP in HeLa cells that were either untreated (control) or treated for the 
indicated times with thapsigargin (0.3 μM). The indicated band (ADP-ribosylated GRP78/BiP) was 
also recognized with an anti-GRP78/BiP specific antibody. GAPDH was used as a loading control. 
Data are representative of at least three independent experiments. * indicates significantly 
different from the relevant control (p < 0.05).  
The long-term stress treatments with thapsigargin were accompanied by the 
reduction of the ADP-ribosylated form of GRP78/BiP, as evaluated by far-Western 
Blotting with the mAf1521 macro domain (Figure 5.4a, Far-WB). Quantification of 
the relevant band indicated a reduction for the 18-hour thapsigargin treatment 
(0.53±0.10) and for the 24-hour thapsigargin treatment (0.47±0.11; Figure 5.4b). In 
addition, as expected (Figure 5.2), the expression of GRP78/BiP was increased 
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(Figure 5.4a, WB). Thus, the long-term stress treatments increased GRP78/BiP 
expression, but were ineffective in inducing GRP78/BiP ADP-ribosylation.  
Altogether these data demonstrated that established activators of ER stress could 
induce expression of hARTC1 and GRP78/BiP, as well as GRP78/BiP mono-ADP-
ribosylation (Fabrizio, G. et al., 2015b). These findings suggested that induction of 
hARTC1 and the consequent GRP78/BiP mono-ADP-ribosylation could be an early 
cell response to ER stress conditions, thereby indicating a possible role for hARTC1 
in the ER stress response required for cell survival.  
5.2.2 hARTC1 does not trigger the UPR  
The data reported above indicated that hARTC1 mRNA and protein expression was 
rapidly increased after the short-term stress treatments with DTT and thapsigargin. 
In addition to elevated protein levels, these data also indicated an increased 
enzyme activity that resulted in higher GRP78/BiP ADP-ribosylation levels. 
Considering that both DTT and thapsigargin are well-characterized inducers of the 
UPR and that the chaperone GRP78/BiP is a master regulator of this process, the 
putative role of hARTC1 in the UPR was examined.  
To monitor the UPR, the activation of individual UPR signaling pathways, both at 
mRNA and protein levels was evaluated. Firstly, attempts were made to establish 
the experimental conditions to detect the UPR activation by Western Blotting. The 
Western Blotting analysis aimed to monitor PERK pathway, analyzing the 
autophosphorylation of PERK (using an antibody antiphospho-PERK from Abcam), 
the amount of elF2α compared to that of phosphorylated elF2α (using antibodies 
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anti-eIF2α and antiphospho-eIF2α from Cell Signaling), the increase of ATF4 
(using an antibody anti-ATF4 from Santa Cruz Biotechnologies) and that of CHOP 
(using an antibody anti-CHOP from Santa Cruz Biotechnologies). Moreover, ATF6 
pathway was examined by Western Blotting, evaluating the ATF6 cleavage (using 
an antibody anti-ATF6 from Santa Cruz Biotechnologies). All these analyses did 
not allow to measure any UPR activation, even though cells treated with well-
known ER stressors were used as controls for the experiments. However, the three 
UPR signaling pathways were successfully evaluated by (qRT)-PCR using primer 
sequences specifically designed for human XBP1 (used to analyze IRE1α pathway, 
see Chapter 1.8.1.3), ATF4 and CHOP (both used to analyze PERK pathway, see 
Chapter 1.8.1.1). In addition, ATF6 translocation (see Chapter 1.8.1.2) was analyzed 
by immunofluorescence experiments. 
For the evaluation of XBP1, ATF4 and CHOP mRNA transcript levels, cells were 
subjected to the stress treatments described above that were shown to induce 
hARTC1 expression and GRP78/BiP mono-ADP-ribosylation. Thus, 2 mM DTT and 
1 μM thapsigargin were used for short-term stress experiments (20, 60 and 120 
minutes) and 0.3 μM thapsigargin to examine the effects of long-term stress (18 
and 24 hours). 
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Figure 5.5 XBP1, ATF4 and CHOP are expressed upon treatment with DTT and thapsigargin. 
Quantification of the mRNA transcript levels of XBP1 (a), ATF4 (b) or CHOP (c) in HeLa cells 
treated for the indicated time with DTT (2 mM) or thapsigargin (1 μM), determined by (qRT)-
PCR, and normalized to GAPDH mRNA. The data are reported using arbitrary units relative to 
XBP1 (a), ATF4 (b) or CHOP (c) transcript levels in non-treated HeLa cells (taken as 1.0). Data 
are presented as mean±SD of three independent experiments, each performed in triplicate. * 
indicates significantly different from the relative control (p < 0.05). 
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There was a time-dependent increase in mRNA transcript expression for all of the 
three genes analyzed. XBP1, ATF4 and CHOP expression was increased after 20 
minutes of treatment with both DTT and thapsigargin, and their levels showed a 
continued increase at prolonged time treatments (60 and 120 minutes; Figure 5.5). 
With these experiments, the ability to monitor UPR activation via a (qRT)-PCR was 
evaluated. The results in Figure 5.5 indicate that (qRT)-PCR provided a sensitive 
assay for monitoring the expression of key components of cellular UPR caused by 
established forms of short- and long-term stress. After this validation, the next 
investigations were designed to determine whether ARTCs could activate the UPR. 
Indeed, transfection of active ARTCs induced GR78/BiP mono-ADP-ribosylation 
(Figure 3.14), similar to the effect obtained with short-term DTT and thapsigargin 
stress treatments. Thus, as DTT and thapsigargin activated the UPR, ARTCs could 
also have a role in this cellular response.  
To this aim, HeLa cells transfected for 24 hours with either active (hARTC1 wt and 
cARTC2.1 wt) or inactive (hARTC1 dm, hARTC4 and cARTC2.1 dm) ARTCs were 
analyzed by (qRT)-PCR for XBP1, ATF4 and CHOP mRNA transcript levels. Non-
transfected HeLa cells, and cell transfected with a GPI-GFP construct used as a 
further control, were also analyzed. 
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Figure 5.6 XBP1, ATF4 and CHOP mRNA transcripts are increased after transfection of 
ARTCs. Quantification of the mRNA transcript levels of XBP1 (a), ATF4 (b) or CHOP (c) in 
HeLa cells transfected with the indicated constructs, determined by (qRT)-PCR, and 
normalized to GAPDH mRNA. The data are reported using arbitrary units relative to XBP1 
(a), ATF4 (b) or CHOP (c) transcript of non-transfected HeLa cells (taken as 1.0). Data are 
presented as mean±SD of three independent experiments, each performed in triplicate. 
* indicates significantly different from the relative control (p < 0.05). 
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As shown in Figure 5.6, increased levels of XBP1, ATF4 and CHOP mRNA transcripts 
were detectable in all the transfected samples. As compared to control cells, 
transfection of active (hARTC1 wt and cARTC2.1 wt) or inactive (hARTC1 dm, 
hARTC4 and cARTC2.1 dm) enzymes caused increased XBP1, ATF4 and CHOP 
mRNA levels (Figure 5.6). However, the transfection of a GPI-GFP construct had 
similar effects (Figure 5.6). These findings suggested that the activation of the UPR 
signaling pathways examined was not specifically caused by active ARTCs and their 
consequent GRP78/BiP mono-ADP-ribosylation, but was due to the transfection 
of exogenous proteins that passed into the lumen of the ER.   
Furthermore, the effect of silencing hARTC1 (achieved as described in Chapter 
4.2.2 and checked by Western Blotting) on the UPR signaling pathways was 
determined by (qRT)-PCR. Thus, XBP1, ATF4 and CHOP mRNA levels were 
measured in non-transfected HeLa cells and those of cells treated with the 
transfection reagent only (i.e. mock transfection) or cells silenced for hARTC1. 
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Figure 5.7 XBP1, ATF4 and CHOP mRNA transcripts are increased after 
mock transfection or silencing of hARTC1. Quantification of the levels of 
XBP1 (a), ATF4 (b) or CHOP (c) transcripts in mock- or siRNA-transfected 
HeLa cells, determined by (qRT)-PCR, and normalized to GAPDH mRNA. 
The data are reported using arbitrary units relative to XBP1 (a), ATF4 (b) 
or CHOP (c) transcript of non-transfected HeLa cells (taken as 1.0). Data 
are mean±SD of three independent experiments, each performed in 
triplicate. * indicates significantly different from the relative control (p < 
0.05). 
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Similarly to the transfection experiments (Figure 5.6), a significant increase of XBP1 
and CHOP mRNA levels were detected in both mock-transfected and hARTC1-
silenced cells (Figure 5.7a, c). ATF4 mRNA levels were, instead, comparable to that 
of control cells (Figure 5.7b). Even though the increase of XBP1 and CHOP were 
significantly different from control cells, it seemed they were caused by the 
transfection reagent/procedure, as they were also elevated in mock-transfected 
cells. These findings further excluded a possible role for hARTC1 in the UPR.  
Finally, to monitor the ATF6 branch of the UPR, the translocation of this protein to 
the nucleus via the Golgi apparatus was determined by performing 
immunofluorescence experiments. Firstly, non-transfected HeLa cells, and cells 
treated with 0.3 μM thapsigargin for 24 hours, were analyzed for nuclear ATF6 
localization, to evaluate whether a treatment known to induce the UPR allowed 
visualization of this translocation.  
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Figure 5.8 ATF6 translocates to the nucleus after thapsigargin treatment. (a, b) Representative 
immunofluorescence images of non-transfected HeLa cells either untreated (control) or 
treated with thapsigargin 0.3 μM for 24 hours (thapsigargin). Cells were sta ined with an 
antibody anti-ATF6 (red), nuclei were stained with DRAQ5, then analyzed by 
immunofluorescence. The scale bar represents 10 μm. The data shown are representative of at 
least three independent experiments. (c) Quantification of ATF6 nuclear localization, 
expressed as percentages of total cells analyzed. The data shown are means±SD of three 
independent experiments. * indicates significantly different from the control (p < 0.01). 
Treatment of cells with thapsigargin caused a significant translocation of ATF6 into 
the nucleus (56%; Figure 5.8). ATF6 translocation was then evaluated in HeLa cells 
that were left untreated or were transfected for 24 hours with a GPI-GFP construct 
or with the ARTCs (hARTC1 wt, cARTC2.1 wt and cARTC2.1 dm).  
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Figure 5.9 ATF6 translocates to the nucleus after ARTCs transfection. 
Quantification of ATF6 nuclear localization of non-transfected HeLa cells 
(control) or cells transfected for 24 hours with the indicated constructs, 
expressed as percentages of total cells analyzed. The data shown are 
means±SD of three independent experiments. * indicates significantly 
different from the control (p < 0.01). 
As shown in the Figure 5.9, upon transfection with any of the constructs it was 
possible to detect a nuclear ATF6 localization. Quantification of ATF6 nuclear 
localization, expressed as percentage of the total cells analyzed, confirmed that, 
as compared to non-transfected control cells, ATF6 nuclear translocation was 
detectable in almost all the transfected samples (Figure 5.9). Therefore, it was 
possible that the over-expression of exogenous proteins, independently from their 
activity (as it was also associated to GPI-GFP transfection), caused the ATF6 nuclear 
translocation. 
Considering the high percentage of transfected cells that displayed nuclear ATF6 
translocation, the temporal kinetics of the translocation was investigated. ATF6 
translocation of HeLa cells transfected for 6, 9 and 12 hours with GPI-GFP or with 
the ARTCs (hARTC1 wt, cARTC2.1 wt and cARTC2.1 dm) was determined. 
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Figure 5.10 ATF6 translocates to the nucleus within 6 hours post transfection with ARTCs. 
Quantification of ATF6 nuclear localization of non-transfected HeLa cells (control) or cells 
transfected for 6, 9 and 12 hours with the indicated constructs, expressed as percentages of total 
cells analyzed. The data shown are means±SD of three independent experiments. * indicates 
significantly different from the control (p < 0.01). 
As shown in Figure 5.10, quantification of data confirmed that nuclear ATF6 
translocation occurred within occurred within 6 hours of transfection, and was 
maintained through to 24 hours (Figure 5.10). Considering that the same 
percentage of cells displaying ATF6 translocation was obtained after the 
transfection of any of the exogenous proteins indicated in Figure 5.10, it is 
reasonable to conclude than none of them had a direct effect on the ATF6 branch 
of the UPR.    
Altogether, these data indicate that hARTC1 has no direct role in the UPR pathway.  
Increased expression of mRNA for the UPR branches analyzed was obtained after 
the transfection of all exogenous proteins that passed through the ER, and there 
was no evidence of a change in mRNA expression specifically linked to ARTC 
transfection or silencing. It is possible that the ADP-ribosylation of GRP78/BiP and 
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its role as a regulator of the availability of the functional chaperone are involved 
in a different pathway than in the UPR.  
5.3 Summary 
• Short-term cells stress treatments with DTT or thapsigargin increase hARTC1 
mRNA and protein levels. 
• Short-term cells stress treatments with DTT or thapsigargin induce GRP78/BiP 
ADP-ribosylation. 
• Western Blotting does not reveal as a useful approach for monitoring UPR 
activity. UPR signaling pathways have been successfully evaluated using (qRT)-
PCR or immunofluorescence experiments. 
• hARTC1, and its activity as GRP78/BiP mono-ART, does not trigger UPR. Indeed, 
the activation of the UPR signaling pathways is due to the transfection of GPI-
anchored proteins that passed into the lumen of the ER and not specifically 
caused by active ARTCs.  
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Chapter 6 
Study of the biological role of hARTC1 
6.1 Introduction 
The data reported in Chapters 3, 4 and 5 demonstrated that hARTC1 is able to 
catalyze the mono-ADP-ribosylation of GRP78/BiP and that the enzyme can act 
as an ER-stress sensor. Indeed, hARTC1 expression is rapidly increased by well-
known ER stresses, such as DTT and thapsigargin. Moreover, these same stresses 
are able to induce hARTC1-mediated GRP78/BiP mono-ADP-ribosylation.  
GRP78/BiP is a central regulator of the ER stress response as it interacts and binds 
to the three ER transmembrane signaling molecules ATF6, IRE1α and PERK, 
keeping them inactive (Brewer, J.W., 2014; Hetz, C., 2012). During ER stress, 
GRP78/BiP is released from these three protein sensors allowing them to become 
functional and initiate the UPR to restore the ER homeostasis (Zhang, K. and 
Kaufman, R.J., 2008). However, under severe and prolonged ER stress, the UPR 
activates unique pathways that lead to cell death through apoptosis or autophagy 
(Iurlaro, R. and Munoz-Pinedo, C., 2016; Logue, S.E. et al., 2013; Sano, R. and Reed, 
J.C., 2013). Thus, GRP78/BiP has a crucial role in controlling the balance between 
cell viability and apoptosis through its ability to maintain the ER stress sensors and 
the pro-apoptotic machineries in their inactive state.  
Therefore, considering that hARTC1 is able to catalyze the mono-ADP-ribosylation 
of GRP78/BiP, the role of hARTC1 was examined for cellular functions that are 
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regulated by GRP78/BiP, including cell survival, cell death and cancer. Indeed, the 
pro-survival role of GRP78/BiP is a characteristic of cancer cells that are constantly 
subjected to chronic ER stress because of the tumor microenvironment, 
characterized by nutrient deprivation, acidosis and severe hypoxia (Justus, C.R. et 
al., 2015; Luo, B. and Lee, A.S., 2013; Wang, M. et al., 2009). In cancer cells the UPR 
is often activated in order to sustain cell survival and GRP78/BiP is over-expressed 
in a wide variety of cancer cells including breast, lung, prostate and ovarian 
cancers, melanoma and glioma cells (Lee, A.S., 2014; Wang, M. et al., 2009; see 
also Chapter 1.8.3). Of note, recent reports also demonstrated a linkage between 
hARTC1 and cancer, suggesting that hARTC1 can play a role in invasion, 
proliferation and apoptosis processes in colon carcinoma (Tang, Y. et al., 2015; 
Xiao, M. et al., 2013; Xu, J.X. et al., 2017; Yang, L. et al., 2016). Moreover, hARTC1 
has been associated with glioma; indeed, it has been reported that hARTC1 
expression in glioma tissues is higher than in normal, control brain tissues and that 
this hARTC1 upregulation could be associated with the aggressiveness of glioma 
(Li, Z. et al., 2016).  
6.2 Results 
6.2.1 Study of hARTC1 expression and GRP78/BiP mono-ADP-ribosylation level in 
ovarian cancer cell lines  
To investigate a possible role of hARTC1 in cancer, initial experiments evaluated 
hARTC1 expression levels in different cancer cell lines (ovary, melanoma, breast, 
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prostate). Subsequently, attention was focused on ovarian cancer cells, as ovarian 
cancer is one of the most common cancers in women worldwide (estimated 
number of new cases in 2017: 1,3%; 
https://seer.cancer.gov/statfacts/html/cervix.html) and, internationally, it 
represents the eighth leading cause of cancer death among women (Ginsburg, O. 
et al., 2017; Torre, L.A. et al. 2017). Currently, the most common front-line 
treatment uses primary surgery followed by chemotherapy or chemoradiotherapy 
(the external beam or brachytherapy plus cisplatin are used in the UK). However, 
this combined therapy is not always sufficient to avoid the disease returning. 
Therefore, it is of interest explore more effective treatment options for this type of 
cancer. In recent years, significant research efforts have been made to find new, 
effective anticancer therapy for ovarian cancer, especially using molecularly-
targeted therapy. One of these strategies is focused on the use of PARP inhibitors; 
to date different PARP inhibitors are under clinical trials for the therapy of patients 
with ovarian tumors and three of them (Olaparib, Rucaparib and Niraparib) has 
already been approved by FDA (Balasubramaniam, S. et al., 2017; Brown, J.S. et al., 
2016; Brown, J.S. et al., 2017; Dulaney, C. et al., 2017; Scott, L.J., 2017; Kim, G., et al., 
2015). Thus, ADP-ribosylation reactions have turned out to be an important target 
for tumor therapy. The inhibition of ART activity is emerging as a potentially 
important strategy for ovarian cancer treatment. In addition to the most 
extensively studied role of the ARTDs in this type of cancer, it would be interesting 
investigate the role of the ARTCs in this context.  
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The following ovarian cancer cell lines were chosen for the study: A2780, IGROV-
1, OVCAR-3, OVCAR-5, SKOV-3, OVCA-432, CAOV-3. hARTC1 and GRP78/BiP 
mRNA levels were evaluated with (qRT)-PCR using primers specifically designed 
for ARTC1, GRP78/BiP and GAPDH (employed as internal control; see Table 2.2). 
 
Figure 6.1 hARTC1 and GRP78/BiP mRNA levels in ovarian cancer cell lines. The graphs show 
quantification of the levels of (a) endogenous hARTC1 and (b) GRP78/BiP mRNA transcripts of 
different ovarian cancer cell lines, determined by (qRT)-PCR. The (qRT)-PCR results were 
normalized to GAPDH mRNA, and then reported as arbitrary units relative to HeLa cells (taken 
as 1.0). Data are presented as mean±SD of three independent experiments, each performed in 
triplicate. The D'Agostino and Pearson omnibus normality test was used to check the uniform 
distribution of the values. All data passed the normality requirements.  
To compare each cell line, I reported the (qRT)-PCR data as fold induction relative 
to HeLa cells, which were used for all my previous experiments (Figure 6.1). All the 
ovarian cell lines showed increased levels of hARTC1 mRNA as compared to HeLa 
cells (Figure 6.1a). Specifically, A2780, IGROV-1 and OVCAR-5 were associated with 
10-fold, or more, higher expression compared to HeLa cells (A2780, 8.97±0.92; 
IGROV-1, 14.16±1.81; OVCAR-5, 19.63±1.12; Figure 6.1a). The other ovarian cancer 
cell lines had a more modest expression of hARTC1 mRNA compared to HeLa cells 
(OVCAR-3, 5.03±1.81; SKOV-3, 2.81±1.40; OVCA-432, 3.16±1.17; CAOV-3, 
4.96±2.43; Figure 6.1a).  
GRP78/BiP mRNA levels within the ovarian cancer cell lines showed similar levels 
as compared to HeLa (Figure 6.1b). Among all the cell lines analyzed, the highest 
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mRNA levels were detected in SKOV-3 cells, which showed a 2-fold induction of 
GRP78/BiP transcript (1.84±0.35; Figure 6.1b).  
Then, hARTC1 protein levels were analyzed in the same cell lines. For this aim, 
Western Blotting was performed using cell lysates that were separated by SDS-
PAGE, transferred to nitrocellulose filters and probed with specific antibodies 
against hARTC1, GRP78/BiP and GAPDH (used as loading control; see Table 2.3). 
hARTC1 wt- and hARTC1 dm-transfected cells were also analyzed and used as 
control for the band of interest (thereby ensuring that the band used for the 
quantification was the same of all the other previous experiments).  
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Figure 6.2 hARTC1 and GRP78/BiP protein levels in ovarian cancer cell lines. (a) Representative 
Western Blotting (WB) of ovarian cancer cell lines and HeLa cells transfected with hARTC1 wt or 
hARTC1 dm, showing endogenous hARTC1, GRP78/BiP and GAPDH levels. (b and c) 
Quantification of the protein levels of (b) hARTC1 and (c) GRP78/BiP, normalized to GAPDH, 
and relative to those of HeLa cells (taken as 1.0). Data are means±SD of at least five independent 
experiments. The D'Agostino and Pearson omnibus normality test was used to check the 
uniform distribution of the values; all data passed the normality requirements.  
As expected, multiple bands were visualized using the anti-ARTC1 antibody (Figure 
6.2a, middle panel). These bands are consistent with the different degrees of 
glycosylation of the protein (see also Figure 3.19, Figure 5.2 and comments relating 
to these figures). Densitometric analysis was performed using the band 
corresponding to that induced by hARTC1 transfection (indicated by the arrow in 
the middle panel of Figure 6.2a). The highest hARTC1 protein level was detectable 
in OVCAR-5 cells, in line with the mRNA data (cf. Figures 6.1 and 6.2a). The other 
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cell lines had similar hARTC1 protein levels, even if the various bands recognized 
by the anti-ARTC1 antibody were differently modulated (Figure 6.2a, b). The 
quantification of GRP78/BiP protein levels showed similar levels between all the 
cell lines and also compared to HeLa cells (Figure 6.2b). In conclusion, the ovarian 
cancer cell lines analyzed had similar GRP78/BiP and hARTC1 levels; however, 
hARTC1 seemed to be differently glycosylated in each cell line.  
A correlation between hARTC1 and GRP78/BiP mRNA and protein levels for all the 
ovarian cancer cell lines analyzed is shown in Figure 6.3.   
 
Figure 6.3 hARTC1 and GRP78/BiP mRNA and protein levels in ovarian cancer cell lines. (a) 
hARTC1 mRNA (black bars) and protein (white bars) levels normalized to GAPDH mRNA or 
protein levels, and relative to those of HeLa cells (taken as 1.0). (b) GRP78/BiP mRNA (black 
bars) and protein (white bars) levels normalized to GAPDH mRNA or protein levels, and 
relative to those of HeLa cells (taken as 1.0). Data are means±SD of at least five independent 
experiments.  
 
The level of GRP78/BiP mono-ADP-ribosylation in these ovarian cancer cell lines 
was investigated. For this aim, the macro domain-based far-Western Blotting 
technique was performed using cells lysates that were separated by SDS-PAGE, 
transferred to nitrocellulose filters and then probed with GST-mAf1521, using an 
anti-GST antibody to reveal it.  
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Figure 6.4 GRP78/BiP mono-ADP-ribosylation profile of ovarian cancer cell lines. Representative 
far-Western Blotting (FAR-WB) with GST-tagged mAf1521 of ovarian cancer cell lines. The 
indicated band (ADP-ribosylated GRP78) was also recognized with an anti-GRP78 specific 
antibody. The Western Blotting (WB) also showed the levels of expression of GRP78/BiP and of 
GAPDH, used as loading control. Data are representative of at least three independent 
experiments.  
As depicted in Figure 6.4, some of the ovarian cell lines showed a protein band 
following incubation with the anti-GST antibody at the molecular weight of 
GRP78/BiP that was also recognized by an anti-GRP78/BiP antibody. As reported 
above, GRP78/BiP protein level, normalized to GAPDH, were similar between all 
the cell lines (cf Figures 6.2 and Figure 6.4). On the contrary, the levels of ADP-
ribosylated GRP78 varied and, compared to HeLa, the highest levels were found 
in A2780, OVCAR-5 and SKOV-3 cell lines (Figure 6.4). Considering that GRP78/BiP 
protein levels were confirmed to be similar between all the cell lines, one possibility 
could be that the lower levels of GRP78/BiP ADP-ribosylation in some of the cell 
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lines depended on the presence of mutation(s) in the consensus site(s) for ADP-
ribosylation of the chaperone.  
To search for the presence of mutation(s), GRP78/BiP DNA sequencing analysis 
was performed for all the ovarian cell lines used. Firstly, an appropriate pair of 
primers were designed that specifically matched with the nucleotide sequence of 
the chaperone, flanking both the identified mutation sites of ADP-ribosylation: the 
arginine (R) residues 470 and 492 (see Table 2.2; Chambers, J.E. et al., 2012). Then, 
the DNA was extracted from the cell lysates and subjected to PCR amplification 
using these specific primers. The PCR products were subsequently purified and 
sequenced. Sequence results were visualized using a specific software (see 
Chapter 2.2.4.15) and were compared to the NCBI reference sequences of the gene 
of interest “human Grp78/Bip”.  
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Figure 6.5 Ovarian cancer cell lines do not contain mutations within their GRP78/BiP mono-ADP-
ribosylation sites. Analysis of the DNA sequences spanning the identified mono-ADP-ribosylation 
sites of Grp78/BiP for (a) A2780, (b) IGROV-1, (c) OVCAR-3, (d) OVCAR-5, (e) SKOV-3, (f) OVCA-
432, (g) CAOV-3 and (h) HeLa cell lines. The sites of ADP-ribosylation correspond to the nucleotidic 
triplet AGA and CGT. Sequence results were visualized using the FinchTV software.  
 
The identified amino acid sites of ADP-ribosylation are both localized in the 
substrate-binding domain of the chaperone and R470 is encoded by the 
corresponding nucleotidic triplet AGA, whereas R492 by the triplet CGT 
(Chambers, J.E. et al., 2012). The analysis of the purified Grp78/Bip nucleotide 
sequences from ovarian cancer cell lines demonstrated that none of them had any 
mutation in either of these ADP-ribosylation sites, since each cell lines had the 
AGA and CGT triplets in the positions corresponding to these amino acids residues 
(Figure 6.5). Thus, the different ADP-ribosylated GRP78/BiP levels were not 
associated with the mutation of the identified ADP-ribosylation sites. Further 
investigations are needed to understand the reasons for the different ADP-
ribosylated states of GRP78/BiP within the ovarian cancer cell lines analyzed. 
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6.2.2 hARTC1 over-expression in HeLa cells inhibits cell proliferation 
GRP78/BiP has a central role in the ER stress response, as it can activate both pro-
survival and pro-death signaling; promoting cell survival when the cell can resolve 
the stress, or cell death when the stress is greater/chronic and the cell fails to 
restore ER homeostasis. Generally, ER stress-associated cell death occurs through 
apoptosis. However also other types of cell death have been observed (Hitomi, J. 
et al., 2004; Nakagawa, T. et al., 2000; Ullman, E. et al., 2008; Wu, J. and Kaufman, 
R.J., 2006). 
Some members of the ARTCs (ARTC2.1 and ARTC2.2) have already been reported 
to have a role in the apoptotic process. Particularly, mouse ARTC2s, expressed on 
peripheral T cells, induced P2X7 activation by ADP-ribosylation and led to cell 
death by apoptosis (Adriouch, S. et al., 2001; Seman, M. et al., 2003). P2X7 is a 
direct target of ARTC2-mediated ADP-ribosylation and, once activated, results in 
T cell apoptosis (Adriouch, S. et al., 2001; Seman, M. et al., 2003). Here, it was 
investigated whether hARTC1 was also implicated in cell death.  
Initial experiments used cytometric analysis with annexin-V/propidium iodide (PI) 
double staining in order to discriminate between necrosis and apoptosis. When 
cells undergo apoptosis, they expose phosphatidylserine (PS) on their surface and, 
as the apoptotic process progresses, cell membrane integrity is eventually lost. 
Thus, in the early stages of apoptosis cells maintain plasma membrane integrity, 
whereas those cells in the late stages of apoptosis, or are already dead, do not. 
Annexin-V is a calcium-dependent phospholipid binding protein with high affinity 
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for PS that binds to cells with exposed PS. PI is a fluorescent dye that intercalates 
into double-stranded nucleic acid. It is excluded from viable cells, but can enter 
into dead or dying cells with ruptured plasma membranes. Thus, viable cells with 
intact membranes exclude PI, whereas membranes of dead and damaged cells are 
permeable to PI. Cells that stain negative for both Annexin-V and PI are alive and 
not undergoing measurable apoptosis. Cells that stain positive for Annexin-V and 
negative for PI are undergoing apoptosis. Cells that stain positive for both 
Annexin-V and PI are in the end stage of apoptosis. Cells that stain positive for PI 
and negative for Annexin-V are undergoing necrosis. 
For analysis, HeLa cells were left untreated (control) or were treated with the 
transfection reagent only (mock transfection) or with hARTC1 wt and its 
catalytically inactive mutant hARTC1 dm. Moreover, as a further positive control, 
HeLa cells were treated with puromycin, a well-known inducer of apoptosis. Cell 
death was evaluated after 24, 48 and 72 hours following transfection or treatment 
with puromycin. 
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Figure 6.6 Characterization of hARTC1-induced cell death. Flow cytometric analysis of annexin-V 
and propidium iodide double staining of HeLa cells transiently transfected with the indicated 
constructs or treated with puromycin (10 μg/mL) for 24h (a), 48h (b) and 72h (c). The results are 
presented as percentage values (%). The data shown are representative of at least two independent 
experiments.  
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As depicted in Figure 6.6a, cells transfected for 24 hours with either hARTC1 wt or 
hARTC1 dm showed the same percentage of living cells, as well as the same 
percentage of apoptosis (including early and late apoptosis) and the same 
abundant percentage of necrosis. Mock-transfected cells were quite similar to 
control cells, whereas puromycin treated cells were prevalently apoptotic, as 
expected. After 48 hours of transfection, control and mock-transfected cells still 
continuing being similar. Puromycin-treated cells showed predominant apoptosis 
at each of the time points analyzed (Figure 6.6b). On the contrary, hARTC1 wt- and 
hARTC1 dm-transfected cells showed an increase in the apoptotic process (Figure 
6.6b). Finally, 72 hours after transfection the situation was almost the same of that 
of 48 hours (Figure 6.6c). 
Altogether these data indicated that both necrosis and apoptotic cell death were 
associated with hARTC1 transfection. After 24 hours of transfection the percentage 
of necrosis and apoptosis were quite similar. Whereas, after 48 and 72 hours of 
transfection the apoptotic cell death was mainly detectable. However, 
independently from the type of cell death revealed, this seemed to be an effect 
due to the transfection of the ARTCs, but not associated with their ADP-
ribosylation activity, as it was also registered in hARTC1 dm-transfected cells that, 
as an inactive enzyme, was demonstrated to not be able to catalyze ADP-
ribosylation (see Chapters 3 and 4). 
Cell viability assays were performed using the Trypan Blue exclusion test, analyzing 
whether the over-expression of hARTC1 wt and that of the inactive hARTC1 dm 
affected cell viability. Specifically, non-transfected (control) HeLa cells, cells treated 
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with the transfection reagent only (mock transfection), or cells transfected with 
either hARTC1 wt or with the inactive hARTC1 dm were analyzed. After 24 hours of 
transfection, cells were stained with Trypan Blue, a molecule that is cell membrane 
impermeable and, therefore, only enters cells with compromised membranes. 
Upon entry into the cell, Trypan Blue binds to intracellular proteins thereby 
rendering the cells a bluish color. Thus, it allowed direct identification and 
enumeration of live (unstained) and dead (blue) cells in a given population. Cell 
viability was expressed as the percentage of dead cells within a population (see 
Chapter 2.2.2.2). 
 
Figure 6.7 hARTC1 induces cell death. Cell mortality determined by Trypan Blue exclusion assay of 
HeLa cells transiently transfected with the indicated constructs, or with no vector (mock). The data 
represent means ±SD of at least ten independent experiments. *: indicates significantly different 
from the control (p < 0.01). #: indicates significantly different from mock (p < 0.05). The Unpaired 
Student’s t-tests was performed for statistical analysis. 
As indicated in Figure 6.7, transfection of the active hARTC1 (hARTC1 wt) enzyme 
induced significant cell death (27±6.9%) as compared to control samples (control, 
7±1.5%; mock, 12±1.5%). This was not the case of the catalytically inactive hARTC1 
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dm, for which the increase of cell mortality was not statistically significant as 
compared to control samples (control or mock) or to hARTC1 wt (17±6.8%; Figure 
6.7). 
The number of percentage of dead cells was calculated as the number of stained 
(blue) cells over the number of total (stained and unstained) cells. A closer analysis 
of these data indicated that the number of dead cells was the same for all the 
samples, whereas the number of living cells varied among them. Indeed, there was 
a reduction of total cells number in hARTC1 wt transfected cells. The transfection 
of hARTC1 wt, but not that of hARTC1 dm, was associated to a 50% of reduction 
of living cells This reduction is most likely caused by the inhibition of cells 
proliferation (Figure 6.8).   
 
Figure 6.8 hARTC1 reduces the number of living cells. The number of dead (blue) and living 
(white) cells was determined by Trypan Blue exclusion assay of HeLa cells transiently 
transfected with the indicated constructs. The results are presented as number of cells/mL. 
The data shown are representative of at least ten independent experiments. *: indicates 
significantly different from the control (p < 0.01). #: indicates significantly different from 
mock (p < 0.05). The Unpaired Student’s t-tests was performed for statistical analysis. 
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Considering that hARTC1 transfection did not cause an increase of dead cells, but 
affected the number of living cells, as evaluated by Trypan Blue exclusion assay, 
the possible role of hARTC1 wt and that of its catalytically inactive mutant hARTC1 
dm in cell proliferation was investigated. 
To this aim, cell proliferation was measured using non-transfected (control) HeLa 
cells, cells treated with the transfection reagent only (mock transfection), or 
transfected with either hARTC1 wt or hARTC1 dm. Cell proliferation was analyzed 
by direct counting of the cells every 24 hours for 3 days, thus, also verifying a 
possible time-dependent role. Data were reported by comparison with control 
cells counted at the same time taken as 1.0 (see Chapter 2.2.2.1). 
 
Figure 6.9 hARTC1 inhibits cell proliferation. Cell proliferation was measured by direct counting of 
HeLa cells transiently transfected with the indicated constructs for 24h, 48h and 72h. The results 
are normalized to control cells, with control cell numbers taken as 1.0. The data represent mean±SD 
of at least five independent experiments. * indicates significantly different from the control (p < 
0.01). # indicates significantly different from hARTC1 dm (p < 0.05).  
As shown in Figure 6.9, a 50% inhibition of cell proliferation was detectable 24 
hours after transfection with hARTC1 wt, as compared to control cells (control and 
mock), or to hARTC1 dm over-expressing cells. A similar reduction in cell 
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proliferation was also revealed after 48 and 72 hours of transfection, but this was 
not statistically significant as compared to hARTC1 dm over-expressing cells. 
Therefore, transfection of hARTC1 wt, but not that of its catalytically inactive mutant 
hARTC1 dm, inhibited HeLa cell proliferation at 24 hours from transfection.  
Overall, hARTC1 transfection caused a modest induction in cell death, but this was 
not dependent on the enzyme catalytic activity, as similar effects were seen 
following hARTC1 dm transfection. However, hARTC1 inhibits cell proliferation and, 
interestingly, this was dependent on the enzyme catalytic activity, at least in the 
short-term. This finding suggests that mono-ADP-ribosylation hARTC1-mediated 
can have a role in cell proliferation.  
6.3 Summary 
• The ovarian cancer cell lines analyzed do not contain mutation(s) in the 
identified ADP-ribosylation sites of GRP78/BiP. Further investigations are 
needed to understand the reasons for the different ADP-ribosylated GRP78/BiP 
levels detected in these ovarian cancer cell lines. 
• Over-expression of hARTC1 inhibits cell proliferation.  
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Chapter 7 
 ARTD10 recruits GAPDH into cytosolic cell bodies 
7.1 Introduction 
Mono-ADP-ribosylation has been identified as a PTM involved in various cellular 
functions, including cell cycle regulation, apoptosis, metabolism, signal 
transduction, cell proliferation and cancer (Butepage, M. et al., 2015; Fabrizio, G. et 
al.2015a; Feijs, K.L. et al., 2013). Among the different ARTD enzymes with a role in 
cell proliferation, ARTD10 has been one of the most investigated (Verheugd, P. et 
al., 2013; Yu, M. et al., 2005). ARTD10 was the first ARTD to be characterized as a 
mono-ART and it has been demonstrated to be a highly dynamic protein, with a 
cytosolic localization under basal conditions, but able to shuttle between the 
cytoplasm and the nucleus (Kleine, H. et al., 2012). ARTD10 forms “bodies” that can 
be primarily detected in the cytoplasm. These bodies are able to move and tend 
to fuse over time, while also forming de novo and disappearing (Kleine, H. et al., 
2012). 
Different reports indicate that ARTD10 plays important roles in the regulation of 
several cellular processes, including the control of cell proliferation and of NF-κB 
signaling (Carter-O’Connell, I. et al., 2016; Kaufmann, M. et al., 2015; Venkannagari, 
H. et al., 2016). ARTD10 was initially isolated as a partner of the oncoprotein c-Myc, 
potentially underpinning why its overexpression interfered with cell proliferation 
(Yu, M. et al., 2005). Although it remains unknown which protein(s) are mono-
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ADP-ribosylated by ARTD10 to mediate this growth inhibitory phenotype, a 
candidate is GSK3β, which is known to regulate cell proliferation and whose kinase 
activity is inhibited once it is modified by ARTD10 (Feijs, K.L. et al., 2013b; Wu, D. 
and Pan, W., 2010). Moreover, ARTD10 has been described as a regulator of the 
NF-kB signaling pathway, which also plays a role in cell proliferation in addition to 
its essential functions in immune and inflammatory responses (Verheugd, P. et al., 
2013). By mono-ADP-ribosylating the NF-kB essential modulator NEMO, ARTD10 
inhibits its poly-ubiquitination and its downstream signal pathway, thus causing a 
reduced activation of NF-κB target genes (Verheugd, P. et al., 2013). Interestingly, 
the catalytic activity of ARTD10 was strictly required to inhibit cell proliferation, as 
only wild type ARTD10, but not the catalytically inactive ARTD10-G888W mutant, 
was able to mediate this function (Herzog, N. et al., 2013).  
Recently, in our laboratory, the glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was identified as a novel substrate of ARTD10 (Mayo, E. et al., manuscript 
in preparation; title: ARTD10 induces ADP-ribosylation of GAPDH, and recruits 
GAPDH into cytosolic membrane-free cell bodies; list of authors: Mayo, E., Fabrizio, 
G., Scarpa, E.S., Stilla, A., Dani, N., Chiacchiera, F., Kleine, H., Attanasio, F., Luscher, 
B., Di Girolamo, M.). GAPDH is a 37 kDa glycolytic enzyme involved in controlling 
the energy production. GAPDH functions are important for different cellular 
pathways that affect cell structure, gene expression, signal transduction thereby 
linking metabolic activity to various cellular processes, including cell survival and 
proliferation (Zhang, J.Y. et al., 2015). Importantly, glucose metabolism has been 
reported to have a central role in both cell proliferation and carcinogenesis as the 
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majority of human tumors have high levels of GAPDH expression (Colell, A. et al., 
2009; Guo, C. et al., 2013; Zhang, J.Y. et al., 2015). The activity of GAPDH has been 
described to be tightly regulated at both transcriptional and post-translational 
levels. ADP-ribosylation represents one of the PTMs that have been previously 
reported to regulate GAPDH activity. GAPDH was already known to be a substrate 
of poly-ADP-ribosylation by ARTD1, which elicited large cellular energy deficits and 
accelerated cell death (Du, X. et al., 2003; Seidler, N.W., 2013). Our experiments 
provide evidence that ARTD10 is involved in the mono-ADP-ribosylation of 
GAPDH.  
7.2 Results 
7.2.1 ARTD10 interacts and co-localizes with GAPDH in cytosolic cell bodies 
The Luscher’s group described the existence of ARTD10-dependent bodies (Kleine, 
H. et al., 2012). We have confirmed the formation of cell bodies in cells 
overexpressing ARTD10. Interestingly, using electron microscopy experiments we 
have observed that these bodies were membrane-free (Mayo, E. et al., manuscript 
in preparation; title: ARTD10 induces ADP-ribosylation of GAPDH, and recruits 
GAPDH into cytosolic membrane-free cell bodies; list of authors: Mayo, E., Fabrizio, 
G., Scarpa, E.S., Stilla, A., Dani, N., Chiacchiera, F., Kleine, H., Attanasio, F., Luscher, 
B., Di Girolamo, M.). Moreover, previous data obtained using immunoprecipitation 
experiments and MALDI-TOF-MS analysis demonstrated that GAPDH was an 
ARTD10 interactor. In this context, immunofluorescence experiments were 
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performed to verify whether the formation of cell bodies was a specific 
consequence of ARTD10 mono-ART activity, thus excluding that other active 
ARTDs (i.e. ARTD15 and ARTD16) could also form them. The localization of GAPDH 
within these cytosolic cell bodies was also analyzed. 
Immunofluorescence experiments were performed using HeLa cells transiently 
transfected with HA-tagged ARTD10 wild-type (referred to as ARTD10), HA-tagged 
catalytically inactive mutant ARTD10 G888W (referred to as ARTD10-G888W), HA-
tagged ARTD16 (referred to as ARTD16), or with FLAG-tagged ARTD15 (referred to 
as ARTD15). After fixation with 4% PFA and incubation with IF blocking solution 
(see Chapter 2.1.4, Table 2.4), the transfected cells were stained with anti-HA or 
anti-FLAG antibodies to visualize the over-expressed proteins and with an anti-
GAPDH antibody to check GAPDH distribution. 
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Figure 7.1 GAPDH co-localizes with ARTD10-positive bodies in ARTD10-transfected cells. The 
panels show representative immunofluorescence images of HeLa cells transiently transfected 
with HA-tagged ARTD10, ARTD10-G888W, ARTD16 or with FLAG-tagged ARTD15, stained with 
anti-HA (green) or anti-FLAG (green) and anti-GAPDH (red) antibodies, as indicated. The scale 
bars represent 10 μm. The data shown are representative of at least three independent 
experiments.  
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The analysis of cells using confocal microscopy revealed that upon transfection 
with the full-length enzyme, ARTD10 mainly localized to the cytosol and 
concentrated in punctate structures that resembled protein aggregates (Figure 7.1; 
ARTD10). Interestingly, GAPDH was also recruited into these cytoplasmic cell 
bodies, where it co-localized with ARTD10 (Figure 7.1; ARTD10). Of note, the 
catalytically inactive ARTD10-G888W was also able to induce the formation of cell 
bodies; however, only a minimal co-localization with GAPDH could be visualized 
(Figure 7.1; ARTD10-G888W). Indeed, quantification analysis confirmed that 
45±2% of GAPDH co-localized with ARTD10-positive cell bodies in ARTD10-
transfected cells, while only 19±3% of GAPDH co-localized with catalytically 
inactive ARTD10-G888W-positive cell bodies. ARTD15- and ARTD16-transfected 
cells did not form cytoplasmic bodies and the enzymes did not co-localize with 
GAPDH (Figure 7.1; ARTD16; ARTD15). Thus, ARTD10 transfection was able to 
induce formation of cell bodies, independently from the catalytic activity. The 
formation of these cell bodies was specific for ARTD10 as the other ARTDs did not 
cause cell bodies to form. ARTD10 and GAPDH co-localize into these cytoplasmic 
cell bodies. Since minimal co-localization was detected in ARTD10-G888W 
transfected cells the ability to recruit GAPDH in the cytosolic bodies is, at least in 
part, dependent on the catalytic activity of ARTD10. 
To further verify the presence of a direct binding between GAPDH and ARTD10, 
immunoprecipitation experiments were performed using different HA-tagged 
enzymes, and the precipitated material was probed for GAPDH. HeLa cells were 
transfected with catalytically active, and catalytically inactive, HA-ARTD10. Cells 
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were also transfected with HA-ARTD16, which was used as a negative control, 
considering it was shown to not form cell bodies when over-expressed in HeLa 
cells and to not co-localize with GAPDH (Figure 7.1, ARTD16). Following 
transfection and lysate collection, samples were incubated with an anti-HA 
antibody, then separated by SDS-PAGE and analyzed by Western Blotting using 
antibodies raised against GAPDH or the HA-tag. 
 
Figure 7.2 ARTD10 interacts with GAPDH. Quantification of 
GAPDH immunoprecipitation in HeLa cells transiently 
transfected with HA-tagged ARTD10, ARTD10-G888W and 
ARTD16, expressed as percentage of control, which 
correspond to the total amount of GAPDH 
(supernatant+resin). Data are representative of two 
independent experiments. 
As shown in figure 7.2, GAPDH was co-immunoprecipitated with endogenous 
ARTD10. Moreover, the quantification of the immunoprecipitated GAPDH 
indicated that the catalytically inactive ARTD10-G888W could also bind GAPDH, 
although to a lower extent compared to the catalytically active enzyme (Figure 
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7.2). No detectable GAPDH was co-immunoprecipitated by ARTD16 under the 
same experimental conditions (Figure 7.2). Thus, these data exclude the possibility 
of a non-specific interaction and indicated that ARTD10 and GAPDH can interact 
and they are part of the same complex.  
Altogether, these data demonstrate that the catalytic activity of ARTD10 is not 
strictly required for formation of cell bodies, consistent with other reports 
suggesting that different ARTD10 domains are important for their formation (Forst, 
A.H. et al., 2013; Kleine, H. et al., 2012). These other domains could also be essential 
for the interaction with GAPDH and its recruitment in the cytosolic bodies. 
However, the catalytic activity appeared to be important for maintaining GAPDH 
in the cytosolic bodies, as a more prominent GAPDH recruitment was detected 
after ARTD10 transfection (45%), in contrast to that of the catalytically inactive 
ARTD10-G888W (19%). Further studies will be crucial in understanding how these 
structures, and ARTD10-mediated mono-ADP-ribosylation of GAPDH, are 
regulated and how they are involved in different of cell functions, including cell 
proliferation. 
7.3 Summary 
• ARTD10 transfection induces formation of cytosolic cell bodies. 
• GAPDH co-localizes with ARTD10 in these cytosolic cell bodies. 
• ARTD10 catalytic activity is important for GAPDH recruitment into the cytosolic 
cell bodies. 
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Chapter 8 
Final discussion  
The present study investigated mono-ADP-ribosylation reactions, mainly exploring 
hARTC1-mediated mono-ADP-ribosylation, its cellular target(s) and the possible 
role in different cellular processes. Moreover, some aspects of the interaction 
between the mono-ART ARTD10, and its target GAPDH, were also investigated.  
ADP-ribosylation is a reversible PTM comprising the transfer of single or multiple 
ADP-ribose moieties from NAD+ to a substrate, forming a mono- or poly-ADP-
ribosylated protein. The reaction is catalyzed by different classes of enzymes, 
including ARTCs, ARTDs and some members of the sirtuin family. ARTCs 
encompass extracellular membrane-bound or secreted proteins that modify other 
membrane-bound proteins or secreted factors (Glowacki, G. et al., 2002; Koch-
Nolte, F. et al., 2008). Rat (r), mouse (m) and human (h) ARTCs have been well 
studied and characterized. Human ARTC family is composed of only four 
functional members, which are either active mono-ARTs (hARTC1, hARTC5) or 
inactive proteins (hARTC3, hARTC4). The gene encoding for ARTC2, which is 
duplicated in mouse and rat, is instead a pseudogene in humans (Koch-Nolte, F. 
et al., 1997; Prochazka, M., et al., 1991; Haag, F. et al., 1994). All ARTCs are ecto-
enzymes anchored to the cell membrane; the only exception is hARTC5, which 
lacks the signal sequence typical of GPI-anchored membrane proteins and, thus, 
is a secreted enzyme (Glowacki, G. et al., 2002; Okazaki, I.J. and Moss, J., 1999; 
Stilla, A. et al., 2011).  
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Together with ARTC2, ARTC1 has been the most studied member of the ARTC 
family in rodents. Different ARTC1 substrates have been identified, including 
soluble or plasma-membrane-associated protein targets such as integrin α7 and 
various cell surface molecules (LFA-1, CD45, CD43 and CD44), suggesting ARTC1 
involvement in different cellular processes (Paone, G. et al., 2002; Seman, M. et al., 
2003; Zolkiewska, A. and Moss, J., 1993). Despite the numerous mono-ADP-
ribosylated substrates identified in rodents, few information is available about 
ARTC1 in humans. The human defensin HNP-1 has been described as a target of 
hARTC1-mediated mono-ADP-ribosylation (Paone, G. et al., 2002). Once ADP-
ribosylated, HNP-1 functions results altered, as it loses its antimicrobial and 
cytotoxic activities (Paone, G. et al., 2002). ADP-ribosylated HNP-1 has been found, 
in vivo, in bronchoalveolar lavage fluids of smoker patients, supporting the idea 
that the modified form is produced during the inflammatory response when it 
loses its antimicrobial activity (Paone, G. et al., 2002). Thus, hARTC1 has been 
proposed to have a regulatory role in airway inflammation (Paone, G. et al., 2002). 
More recently, hARTC1 has been linked to cancer, suggesting its potential role in 
invasion, proliferation, aggressiveness and apoptosis processes (Li, Z. et al., 2016; 
Tang, Y. et al., 2015; Xiao, M. et al., 2013; Xu, J.X. et al., 2017; Yang, L. et al., 2016). 
Despite the substantial progress made with regard to hARTC1-mediated mono-
ADP-ribosylation in humans, its biological role is not well characterized. Therefore, 
one of the aim of this study was to investigate mono-ADP-ribosylation reactions 
mediated by hARTC1, searching for new possible substrate(s) of mono-ADP-
ribosylation and their potential functional role(s).       
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The experiments carried out in the first part of the present study demonstrated 
that hARTC1 is mainly located in the ER. Both the over-expressed and the 
endogenous protein localized to a tubular membrane network consistent with the 
ER, as they co-localized with typical ER marker proteins such as calnexin, 
calreticulin, PDI and GRP78/BiP (Figures 3.2; 3.5; 3.6; 3.13). The use of other ARTCs 
with known cellular localization (e.g. cARTC2.1 wt and dm, described by Stilla, A. 
et al. as plasma membrane enzymes) provided a control of these experiments 
(Stilla, A. et al., 2011; Figures 3.2; 3.5; 3.6; 3.13). Importantly, the ER localization of 
hARTC1 was not affected by cycloheximide. Indeed, cycloheximide treatment 
blocks new protein synthesis and, thus, proteins that are not ER-resident exit the 
ER compartment reaching their final destination. The results obtained here 
demonstrated that this was the case for hARTC4, cARTC2.1 wt and cARTC2.1 dm 
(Figure 3.5a, b). On the contrary, the treatment with cycloheximide had no effect 
on the localization of hARTC1 (Figure 3.5a), thus confirming to be ER localized. As 
a further validation of the ER localization, quantifications of the percentage of co-
localization between the ARTCs and the different cellular markers were performed 
in several independent experiments, supporting the finding that hARTC1 is an ER 
localized protein (Figures 3.4; 3.5c; 3.7). This finding was unexpected since ARTC1 
has always been hypothesized to be an ecto-enzyme, based on various 
observations. Indeed, ARTC1 sequence contains a stretch of hydrophobic amino 
acids that is a typical feature of GPI-anchored membrane proteins (Glowacki, G. et 
al., 2002). Moreover, numerous plasma membrane-associated proteins have been 
identified as targets of ARTC1-mediated mono-ADP-ribosylation (Paone, G. et al., 
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2002; Seman, M. et al., 2003; Zolkiewska, A. and Moss, J., 1993). Finally, its closest 
homolog ARTC2 has been well-described as a plasma membrane-localized 
enzyme (Koch-Nolte, F. et al., 1999; Stilla, A. et al., 2011). The only observation that 
counteracts this hypothesis comes from a report by Soman G. et al (1984) asserting 
that ARTC1 can have an intracellular localization. Indeed, in this paper it was 
reported that in rabbit skeletal muscle, 70% of the ARTC1 activity is intracellularly 
localized, anchored to the membrane of the sarcoplasmic reticulum (Soman, G. et 
al., 1984). In line with this description about ARTC1 activity in the sarcoplasmic 
reticulum, the results reported here demonstrated the intracellular localization of 
hARTC1 providing, for the first time, a quantification of the enzyme’s distribution. 
The experiments of the present study demonstrated that some of the enzyme 
(~20% c.f. Figure 3.4) is localized to the plasma membrane, where it may catalyze 
mono-ADP-ribosylation of some of the previously reported plasma membrane-
associated proteins. However, the majority of the enzyme was found to be 
localized to the ER (~50% c.f. Figures 3.4; 3.5; 3.7), where it may be involved in the 
mono-ADP-ribosylation of new and undiscovered intracellular targets. Indeed, 
there is a large number of intracellular proteins that have been demonstrated to 
undergo mono-ADP-ribosylation, but for which the enzyme(s) responsible for the 
modification still remains to be identified. Interestingly, most of these mono-ADP-
ribosylated targets have been reported to have a role in cell signaling and 
metabolism, and the enzymatic activities involved in their modifications have been 
shown to be both cytosolic and membrane associated. Thus, it is plausible that 
hARTC1 could be involved in some of these previously described intracellular 
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mono-ADP-ribosylation reactions. To verify this hypothesis, new cellular target(s) 
of hARTC1 were investigated.  
The approaches adopted for substrates analysis were based on the use of Af1521 
macro domain, a protein module that we have been previously demonstrated to 
have high affinity for ADP-ribosylated proteins and has been successfully used to 
pull down ADP-ribosylated proteins (Dani, N. et al., 2011). In the work described 
here, the macro domain-based pull-down assay demonstrated that the over-
expression of either arginine-specific hARTC1 wt or cARTC2.1 wt led to GRP78/BiP 
mono-ADP-ribosylation (Figures 3.8; 3.9). GRP78/BiP mono-ADP-ribosylation was 
already known, but the physiological relevance of this modification (as it regulated 
the availability of the functional chaperone), and the enzyme(s) involved have not 
yet been characterized (Laitusis, A.L. et al., 1999).  
In the study reported here, new macro domain-based assays were set up utilizing 
the high affinity of Af1521 macro domain for ADP-ribosylated targets. Specifically, 
the innovative approaches were the application of macro domain in 
immunofluorescence and far-Western Blotting experiments. These new macro 
domain-based assays confirm that GRP78/BiP is a target of hARTC1, highlighting 
the technological importance of this tool in the study of APD-ribosylation 
reactions.  
The use of macro domain in immunofluorescence assays represents a novel 
method that allowed, for the first time, the visualization of ADP-ribosylated 
proteins in living cells. With this approach, in cells under basal conditions only 
nuclear ADP-ribosylation was detected (Figure 3.10a). The use of a double mutant 
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form of the macro domain, which has been shown to not bind ADP-ribosylated 
proteins, provided a suitable negative control (Figure 3.10b). However, in cells 
over-expressing hARTC1 it was possible to detect a peri-nuclear staining of ADP-
ribosylated that co-localized with GRP78/BiP, making it highly likely that this 
modification occurred in living cells. Furthermore, these studies demonstrated that 
the ADP-ribosylation was catalyzed by active ARTCs, as it was only observed in 
cells transfected with cARTC2.1 wt, but not in those transfected with the inactive 
enzymes cARTC2.1 dm, hARTC4 and hARTC1 dm (Figures 3.11a, c, e, g; 3.12a, c, e, 
g; 3.13; 4.2). An unexpected finding was that the macro domain nuclear staining 
was not detectable when cells overexpressed the active ARTCs (Figures 3.11a, e; 
3.12a, e). A possible explanation is that when an active enzyme is overexpressed, 
it consumes most of the cellular NAD, which is therefore not available for nuclear 
reactions mediated by the endogenous enzyme(s).  
As a further demonstration that hARTC1 contributes to GRP78/BiP mono-ADP-
ribosylation, the use of macro-domain-based far-Western Blotting allowed direct 
visualization of ADP-ribosylated proteins in cells transfected with the active ARTCs. 
Among the numerous protein bands that correspond to different ADP-ribosylated 
targets, a protein band with the molecular weight of GRP78/BiP was visualized only 
in cells transfected with the enzymatically active cARTC2.1 wt and hARTC1 wt, but 
not in cARTC2.1 dm-, hARTC4- or hARTC1 dm-transfected cells (Figures 3.14; 4.1). 
The same band was also recognized by an anti-GRP78/BiP antibody (Figures 3.14; 
3.15; 4.1) and, as further confirmation that it corresponded to the ADP-ribosylated 
form of the chaperone, it was reduced by 65% in cells where GRP78/BiP expression 
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was silenced (Figure 3.15). Moreover, silencing hARTC1 also reduced the basal level 
of ADP-ribosylated GRP78/BiP by 40% (Figure 4.4). As a proof for the specificity 
of the reaction, a doubly mutated hARTC1 (hARTC1 dm) was generated. When 
overexpressed in HeLa cells, the mutant protein was correctly expressed and 
localized to the ER with a similar distribution to hARTC1 wt protein, colocalizing 
with GRP78/BiP (Figure 4.3). However, hARTC1 dm, although over-expressed at 
comparable levels to hARTC1 wt (Figure 4.1), was not able to catalyze ADP-
ribosylation reactions, as no band corresponding to GRP78/BiP could be visualized 
using the macro domain-based far-Western Blotting assay (Figure 4.1) and only a 
modest nuclear staining was detectable with the macro domain-based 
immunofluorescence experiments, similar to control and to hARTC4- and 
cARTC2.1 dm-transfected cells (Figure 4.2).  
Altogether, these data demonstrate that hARTC1 is an intracellular enzyme, is 
mainly located in the ER, and is responsible for GRP78/BiP mono-ADP-
ribosylation. This modification has been known for some time, and it has been 
described as a way to regulate the availability of the functional chaperone (Laitusis, 
A.L. et al., 1999; Ledford, B.E. and Leno, G.H., 1994). Indeed, when GRP78/BiP is 
ADP-ribosylated it is in an inactive state and this modification occurs in response 
to nutritional stress and to environmental conditions that can result in reduced 
protein synthesis, and thus in a reduced flux of proteins into the ER (Laitusis, A.L. 
et al., 1999). Therefore, it has been hypothesized that GRP78/BiP mono-ADP-
ribosylation could be a system for balancing the rate of protein processing with 
those of protein synthesis. (Laitusis, A.L. et al., 1999; Ledford, B.E. and Leno, G.H., 
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1994). The identification of the enzyme responsible for GRP78/BiP mono-ADP-
ribosylation is of extreme interest since it allows to study the regulation of the 
activity of an important ER chaperone such as GRP78/BiP. 
Indeed, GRP78/BiP is an ER-resident protein with multiple essential roles that are 
crucial for contribution to quality control for protein homeostasis in the ER. 
Efficient GRP78/BiP functions rely on numerous factors such as calcium 
concentration, redox homeostasis and oxygen supply (Araki, K. and Nagata, K., 
2011; Gorlach, A. et al., 2006; Ushioda, R. et al., 2016). Under conditions that perturb 
the ER homeostasis, such as ER calcium depletion, glucose deprivation and 
oxidative stress, cells trigger the ER stress response to cope with this imbalance, 
activating the UPR (Vincenz-Donnelly, L. and Hipp, M.S., 2017). The UPR aims to 
restore ER homeostasis by temporarily attenuating new proteins translation, 
increasing the expression of proteins involved in protein folding and maturation, 
such as chaperones and foldases, inducing the degradation of misfolded proteins 
through the ER-associated degradation (ERAD) complex (Gardner, B.M. et al., 2013; 
Grootjans, J. et al., 2016; Kaufman, R.J., 1999; Strzyz, P., 2016; Welihinda, A.A. et al., 
1999; Zhang, K. and Kaufman, R.J., 2008). If this fails, ER activates the death 
signaling pathways (Iurlaro, R. and Munoz-Pinedo, C., 2016; Logue, S.E. et al., 2013; 
Sano, R. and Reed, J.C., 2013). 
Different stress-inducing agents or conditions that adversely affect the ER 
functions such as oxidative stress, chemical toxicity, inhibition of the ER calcium-
ATPase, inhibitors of glycosylation and hypoxia have been reported to modulate 
GRP78/BiP expression (Beriaulta, D.R. and Werstucka, G. H., 2013; Oslowski, C.M. 
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and Urano, F. 2011; Toth, M.E. et al., 2015). The present study shows that the same 
stress treatments reported to stimulate GRP78/BiP expression can also induce 
hARTC1 expression and activity, and consequently, the ADP-ribosylation of the 
chaperone. Indeed, both mRNA and protein analysis revealed that hARTC1 
expression was rapidly induced by short term treatments of cells with the stressors 
DTT and thapsigargin, but not with hypoxia or heat shock (Figures 5.1; 5.2). This 
activation, in turn, resulted in increased levels of ADP-ribosylated GRP78/BiP 
(Figure 5.3). Of note, it is possible that the increased levels of modified GRP78/BiP 
were underestimated, considering that this is a reversible reaction, and, therefore, 
the modified GRP78/BiP might have become the substrate of a specific hydrolase 
that could have regenerated the non-modified form.  
Both DTT and thapsigargin are well-characterized inducers of ER stress, as they 
affect correct protein folding. In contrast, neither hypoxia nor heat-shock have 
been demonstrated to affect translation. Specifically, treatment with DTT results in 
the ER retention of newly synthesized proteins that cannot fold correctly as they 
cannot form disulfide bonds, whereas the treatment with thapsigargin inhibits the 
ER calcium-ATPase, thereby causing depletion of the ER calcium, which is 
associated with a slowed rate of protein processing (Taniyama, Y. et al., 1991; 
Thastrup, O., 1990). DTT and thapsigargin have been reported to inhibit translation 
with rapid timing: 10 minutes treatments are sufficient to inhibit the synthesis of 
almost all proteins (Brostrom, C.O. and Brostrom, M.A., 1998). However, cells can 
adapt to this translational inhibition. During longer-term exposure to stress 
treatments protein translation is recovered (Brostrom, C.O. and Brostrom, M.A., 
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1998). The results of the present study demonstrated that, as a consequence of 
longer-term exposure stress treatments, GRP78/BiP is expressed at high levels and 
its mono-ADP-ribosylated form is not present (Figure 5.4). The induction of 
GRP78/BiP expression required a minimum of 2 hours, and plateaued within 12–
18 hours, depending on the cell type (Brostrom, C.O. and Brostrom, M.A., 1998). 
These increased levels of GRP78/BiP, and of other chaperones, enhance the ER 
protein folding capability. Thus, GRP78/BiP is a central mediator of both acute 
inhibition of translation initiation and its subsequent recovery. The results obtained 
in this study are broadly consistent with the previously reported observations 
showing that the ADP-ribosylated form of GRP78/BiP accumulated when the 
protein flow through the ER was decreased (Laitusis, A.L. et al., 1999). Indeed, when 
the protein flow through the ER was decreased the cells do not require the 
chaperone activity as a facilitator of the folding of newly synthesized proteins. The 
ER stressors DTT and thapsigargin initially depress protein synthesis, rendering 
GRP78/BiP unnecessary. However, when translation is restored, as during longer 
term exposure to chemical disruptors, GRP78/BiP activity is required. A reversible 
PTM such as mono-ADP-ribosylation could allow the rapid regulation of the 
activity of GRP78/BiP, based on the needs of the cell. In line with these 
considerations, Chambers and colleagues suggested that cells can quickly adapt 
to fluctuations in the load of unfolding protein by shifting the amount of 
GRP78/BiP between active state, and a latent ADP-ribosylated pool (Chambers, 
J.E. et al., 2012). Indeed, when ADP-ribosylated, GRP78/BiP is inactive with respect 
to binding polypeptides. This was demonstrated by experiments showing that 
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mutations that mimic the negative charge of ADP-ribose can destabilize the 
chaperone binding to its substrate without affecting its ability to hydrolyze or 
exchange nucleotides (Chambers, J.E. et al., 2012). Thus, the ADP-ribosylation of 
GRP78/BiP has been proposed to be a way to inactivate the chaperone, avoiding 
its degradation and allowing the cell to rapidly reactivate it through de-
ribosylation (Chambers, J.E. et al., 2012).  
GRP78/BiP is a master regulator of the UPR as it is directly associated with the 
three UPR signaling proteins ATF6, IRE1α and PERK (Brewer, J.W., 2014; Hetz, C., 
2012; Mori, K., 2000). In resting cells, the three UPR sensors are kept inactivate 
through their association with GRP78/BiP (Brewer, J.W., 2014; Hetz, C., 2012). When 
unfolded proteins accumulate in the ER lumen, for example during ER stress 
GRP78/BiP is reported to bind to misfolded proteins resulting in its dissociation 
from ATF6, IRE1α and PERK that become functional, thereby transducing the UPR 
(Brewer, J.W., 2014; Hetz, C., 2012; Merksamer, P.I. and Papa, F.R., 2010; Ron, D. 
and Walter, P., 2007). Since DTT and thapsigargin are well-characterized inducers 
of the UPR it is possible that the increased levels of ADP-ribosylated GRP78/BiP 
and of hARTC1 detected during cellular treatments with these stresses are 
associated with the release of the three UPR chaperone interactors. If this is the 
case, then ADP-ribosylation of GRP78/BiP could also be regarded as a facilitator 
of the UPR. For the study described here, the evaluation of UPR activation was 
approached with different techniques. Although evaluation by protein analysis 
failed, both (qRT)-PCR and immunofluorescence experiments have proven to be 
functional UPR assays. However, whilst the experiments confirmed that the ER 
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stressors DTT and thapsigargin are UPR inducers (Figure 5.5), no correlation 
between GRP78/BiP mono-ADP-ribosylation hARTC1-mediated and UPR 
activation was detected, since hARTC1 transfection did not trigger the UPR (Figures 
5.6; 5.7; 8.1).  
 
Figure 8.1 Schematic representation of GRP78/BiP mono-ADP-ribosylation mediated by 
hARTC1 occurring at the ER level. 
As no correlation with the UPR was found, other possible roles of hARTC1-
mediated mono-ADP-ribosylation were investigated, considering the different 
cellular functions that are regulated by GRP78/BiP such as cell survival, cell death 
and cancer. GRP78/BiP has been described as a disease-associated protein, whose 
expression may serve as a useful biomarker for pathology mechanisms. Indeed, 
different reports demonstrated it possess distinct functions in addition to that of 
being a chaperone residing in the ER, as it can be actively translocated to other 
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cellular locations and assume novel functions controlling signaling, proliferation, 
invasion, apoptosis, inflammation and immunity (Lee, A.S., 2014). Among these 
functions, it has been linked to cancer progression and therapeutic resistance, 
demonstrating it is over-expressed in a wide variety of cancer cells including 
breast, lung, prostate and ovarian cancers, melanoma and glioma cells (Lee, A.S., 
2014 and reference therein; Wang, M. et al., 2009). Recently, hARTC1 has also been 
associated with cancer, suggesting it can play a role in invasion, proliferation, 
aggressiveness and apoptosis processes (Li, Z. et al., 2016; Tang, Y. et al., 2015; 
Xiao, M. et al., 2013; Xu, J.X. et al., 2017; Yang, L. et al., 2016). In the study reported 
here different ovarian cancer cell lines were examined, analyzing hARTC1 
expression and GRP78/BiP mono-ADP-ribosylation. Ovarian cancer is one of the 
most common types of cancer among women, representing the eighth leading 
cause of cancer death (Ginsburg, O. et al., 2017; Torre, L.A. et al. 2017). The most 
common front-line treatment uses primary surgery followed by chemotherapy or 
chemoradiotherapy. However, this combined therapy is not always sufficient to 
avoid the disease returning. Thus, more effective treatment options are being 
explored, especially using molecularly-targeted therapy. One possibility is the use 
of PARP inhibitors, which represent a good strategy in the management of ovarian 
cancer. Currently, different trials with PARP inhibitors are in progress, and three of 
them (Olaparib, Rucaparib and Niraparib) have already been approved by FDA for 
the therapy of patients with ovarian tumors (Balasubramaniam, S. et al., 2017; 
Brown, J.S. et al., 2016; Brown, J.S. et al., 2017; Dulaney, C. et al., 2017; Scott, L.J., 
2017; Kim, G., et al., 2015). Thus, ADP-ribosylation reactions have turned out to be 
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important for tumors: the inhibition of ART activity is emerging as a potentially 
important strategy for ovarian cancer treatment. In addition to the most 
extensively studied role of the ARTD1 in this type of cancer, it is interesting 
investigate the role of the ARTCs in this context. Studying the mono-ADP-
ribosylation of target proteins with a well-documented role in cancer progression, 
such as GRP78/BiP, would be extremely useful for understanding how this 
modification affects protein function(s) in this context.   
The various ovarian cancer cell lines chosen for this study were screened for 
hARTC1 and GRP78/BiP, showing comparable mRNA and protein levels, without 
any significant difference (Figures 6.1; 6.2). However, using the macro domain-
based far-Western Blotting assay, different levels of GRP78/BiP ADP-ribosylation 
were detected (Figure 6.4). One possible explanation for the lack of significant 
variation of GRP78/BiP ADP-ribosylation is that GRP78/BiP has mutation(s) in its 
identified ADP-ribosylation sites and, thus, cannot be modified. Specifically, the 
amino acid sites of ADP-ribosylation are the arginine (R) residues 470 and 492, 
both localized in the substrate-binding domain of the chaperone (Chambers, J.E. 
et al., 2012). However, the sequencing analysis did not show the presence of 
altered nucleotides, as all the sequence relative to the analyzed cell lines were 
perfectly overlapped with the corresponding NCBI sequence of human Grp78/BiP 
(Figure 6.5). Thus, the different levels of GRP78/BiP ADP-ribosylation revealed by 
the far-Western Blotting assay are not associated with the mutation of the ADP-
ribosylation sites. Further investigations are needed to understand the reasons the 
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different ADP-ribosylation states of GRP78/BiP in the ovarian cancer cell lines 
analyzed. 
Interestingly, hARTC1-mediated mono-ADP-ribosylation has been demonstrated 
to have a role in cell proliferation. The experiments carried out in the last part of 
this study show that the over-expression of hARTC1 wt, but not that of its 
catalytically inactive mutant hARTC1 dm, have no effect of cell viability, but can 
affect cell proliferation, resulting in 50% inhibition during the first 24h of 
transfection (Figures 6.7; 6.8; 6.9).  
In Summary: the collected results demonstrate that hARTC1 is an enzyme mainly 
localized to the ER, in contrast to the previously characterized ARTC proteins. 
There, hARTC1 is involved in the mono-ADP-ribosylation of GRP78/BiP, whose 
modification has been proposed to serve as a rapid regulation of the chaperone 
activity. In line with this hypothesis, hARTC1 was activated during the short-term 
treatment with ER stressors, resulting in acute ADP-ribosylation of GRP78/BiP 
paralleling translational inhibition. Indeed, protein synthesis depression caused by 
ER stress treatments is a condition which makes GRP78/BiP unnecessary; however, 
when translation is restored and unfolded protein accumulates in the ER, 
GRP78/BiP activity is required. A reversible, post-translational modification, such 
as mono-ADP-ribosylation, allows the rapid regulation of the activity of GRP78/BiP 
based on the needs of the cell. These findings identify hARTC1 as a novel, 
previously unsuspected, player in GRP78/BiP-mediated ER stress responses (Figure 
8.1). The mono-ADP-ribosylation of the chaperone does not result in the release 
of GRP78/BiP interactors ATF6, IRE1α and PERK, since hARTC1 over-expression did 
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not trigger the UPR. However, hARTC1 over-expression inhibited cell proliferation, 
thus linking hARTC1-mediated mono-ADP-ribosylation to this process. The over-
expression of hARTC1 and the consequent GRP78/BiP mono-ADP-ribosylation 
resulted in the accumulation of the inactive, mono-ADP-ribosylated form of the 
chaperone that is therefore not available for assisting protein synthesis. It could 
be hypothesized that this situation causes an inhibition of cell proliferation that is 
maintained until the cells can restore the pool of active GRP78/BiP, through its de-
ribosylation or new chaperone synthesis, as confirmed by the fact that cell 
proliferation re-start after 48 hours of transfection. To evaluate all these 
hypotheses further investigations are required. However, these findings open new 
insights into mono-ADP-ribosylation reactions and how they regulate the 
biological activity of proteins with key role in central processes such as ER stress 
response, cell proliferation and cancer.  
In addition to hARTC1 mono-ADP-ribosylation, a section of this study focused on 
mono-ART ARTD10, which was the subject of a research project carried out in our 
laboratory. ARTD10 is a 150 kDa enzyme belonging to the ARTDs, characterized 
as a mono-ART (Kleine, H. et al., 2008). Different reports linked ARTD10 to cell 
proliferation and identified various target of ARTD10 with a potential role in this 
process (Carter-O’Connell, I. et al., 2016; Kaufmann, M. et al., 2015; Venkannagari, 
H. et al., 2016; Verheugd, P. et al., 2013; Yu, M. et al., 2005). However, it remains 
unknown which protein(s) are mono-ADP-ribosylated by ARTD10 to mediate the 
growth inhibitory phenotype (Yu, M. et al., 2005). Previous and not yet published 
data of our laboratory identified GAPDH as a novel substrate of ARTD10 (Mayo, E. 
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et al., manuscript in preparation; title: ARTD10 induces ADP-ribosylation of 
GAPDH, and recruits GAPDH into cytosolic membrane-free cell bodies; list of 
authors: Mayo, E., Fabrizio, G., Scarpa, E.S., Stilla, A., Dani, N., Chiacchiera, F., Kleine, 
H., Attanasio, F., Luscher, B., Di Girolamo, M.). Specifically, we reported that 
ARTD10 interacts with and mono-ADP-ribosylates the glycolytic enzyme GAPDH 
and this modification occurs in membrane-free cytosolic cell bodies (Mayo, E. et 
al., manuscript in preparation; title: ARTD10 induces ADP-ribosylation of GAPDH, 
and recruits GAPDH into cytosolic membrane-free cell bodies; list of authors: 
Mayo, E., Fabrizio, G., Scarpa, E.S., Stilla, A., Dani, N., Chiacchiera, F., Kleine, H., 
Attanasio, F., Luscher, B., Di Girolamo, M.). Indeed, the experiments reported in 
this study confirmed that the transfection of ARTD10 induce the formation of cell 
bodies in which GAPDH co-localizes with ARTD10 (Figure 7.1). The presence of 
these cell bodies was independent from the catalytic activity of ARTD10, as also 
the catalytically inactive ARTD10-G888W was able to induce their formation (Figure 
7.1). However, ARTD10 catalytic activity was essential for recruiting GAPDH into 
these cell bodies (Figures 7.1; 7.2). These observations are in agreement with the 
previous description of ARTD10 as a predominantly cytosolic enzyme under basal 
conditions, able to form discrete and dynamic “bodies” in the cytoplasm (Kleine, 
H., et al., 2012). Moreover, the catalytic activity of ARTD10 has been reported to be 
strictly required to inhibit cell proliferation, as only ARTD10 but not the catalytically 
inactive ARTD10-G888W mutant is able to mediate this function (Herzog, N. et al., 
2013). However, despite these important data about ARTD10 as the enzyme that 
modifies and recruits GAPDH into cytosolic bodies, further studies are necessary 
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to evaluate if, and how, mono-ADP-ribosylation mediated by ARTD10 has any 
effect on GAPDH glycolytic activity.  
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List of abbreviations 
AAD Allergic airway disease 
AC Adenylyl cyclase  
ADP Adenosine diphosphate 
AHR Aryl hydrocarbon receptor 
AHRR  AHR repressor 
AKT Serine/threonine-protein kinase 
ALS Amyotrophic lateral sclerosis 
AMD Automodification domain 
ANOVA One-way analysis of variance 
APLF Aprataxin and PNKP like factor 
ARD Ankyrin repeat domain 
ARF6 ADP-ribosylation factor 6  
Arg Arginine 
ARH ADP-ribosyl-hydrolase 
ARNT AHR nuclear translocator 
ART ADP-ribosyl-transferase 
ARTC ADP-ribosyl-transferase clostridia toxin-like 
ARTD ADP-ribosyl-transferase diphtheria toxin-like 
Asp Aspartate 
ATF6 Activating transcription factor 6  
ATP Adenosine triphosphate 
ATTC American Type Culture Collection 
BAG1 BCL2 associated athanogene 1 
BAL B-aggressive lymphoma 
BALF Bronchoalveolar lavage fluids 
BBAP B-lymphoma and BAL-associated protein 
281 
 
BFA Brefeldin A 
BiP Immunoglobulin heavy chain-binding protein 
BRCA1 Breast cancer type 1 susceptibility protein 
BRCT BRCA1 carboxy-terminal  
bZIP Basic leucine zipper 
c Cricetinae 
C/EBP CCAAT-enhancer-binding protein 
CBD  Central binding domain 
CD Cluster of Differentiation 
cDNA Complementary DNA 
CF Cystic fibrosis 
CFTR CF transmembrane conductance regulator  
CHFR Checkpoint with FHA and RING finger 
CHO cells Chinese hamster ovary cells 
CHOP C/EBP homologous protein 
Chx Cycloheximide 
CoaSt6 Collaborator of Stat6 
Cripto-1 Teratocarcinoma-derived growth factor 1 
CtBP1/BARS BFA-induced ADP-ribosylated substrate 
DAC Deacetylase 
DLBCL Diffuse large B-cell lymphoma  
dm Double mutant 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DRAG Dinitrogenase reductase activating glycohydrolase 
DRAT Dinitrogenase reductase ADP-ribosyl-transferase 
ECL Enhanced chemiluminescence 
EF-2 Elongation factor 2 
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EGCG (-)-epigallocatechin gallate 
elF2α Eukaryotic translation initiation factor 2 α 
EMBL European Molecular Biology Laboratory 
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERK Extracellular signal-regulated kinase 
FAR-WB Far-Western Blotting 
FCM Flow cytometry 
FDA Food and Drug Administration 
FGF-2 Fibroblast growth factor 2 
FGFR Fibroblast growth factor receptor 
FMNS Fondazione Mario Negri Sud 
GADD34 DNA damage inducible gene 34  
GAPDH Glyceraldehyde 3 phosphate dehydrogenase 
GDH Glutamate dehydrogenase 
Glu Glutamic acid 
GnRHR Gonadotropin-releasing hormone receptor  
GPCRs G-protein coupled receptors  
GPI Glycosylphosphatidylinisotol 
GRD Glycine-rich domain 
GRP78 Glucose-regulated protein 78 kDa 
GSK3β Glycogen synthase kinase 3 beta 
GST Glutathione S-transferase 
h Human 
HDAC Histone deacetylase 
HeLa cells Human cervical cancer cells 
Hep-G2 cells Human hepatoma G2 cells 
HIV Human immunodeficiency virus 
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HL-60 cells Human promyelocytic leukemia cells 
HNC cell lines Head and neck cancer cell lines 
HNP-1 Human neutrophil peptide 1 
HPS Histidine-proline-serine 
HRP Horseradish peroxidase 
HSP70 Heat shock family of stress proteins 70 kDa 
HSPA5 Heat shock protein family A member 5  
IF Immunofluorescence 
IFN Interferon 
Ig Immunoglobulin  
IL Interleukin 
IRAP Insulin-responsive aminopeptidase 
IRE1α Inositol-requiring enzyme 1α 
IRF1 Interferon response factor 1 
ISGs Interferon-stimulated genes 
JNK2 Jun N-terminal kinase 2 
Kapβ1 karyopherin-β1/importin-β1 
kDa Kilodalton 
LC-MS/MS Liquid chromatography tandem-MS 
LFA-1 Lymphocyte-function-associated antigen 1 
LPS Lipopolysaccharide 
LSCM Laser scanning confocal microscopy  
m Mouse 
MAb159 Mouse monoclonal IgG antibody 
MALDITOF-MS Matrix-assisted laser desorption/ionization time-of-flight-MS  
MDR Multidrug resistance 
MIBG Meta-iodobenzylguanidine  
MLV Murine leukemia virus 
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mRNA Messenger RNA 
MS Mass spectrometry 
MTJ-1 Murine tumor cell DnaJ-like protein-1 
MVP Major vault protein 
MVP-ID Major-vault particle interaction domain 
NAD Nicotinamide adenine dinucleotide 
NCBI National Center for Biotechnology Information 
NEMO NF-κB essential modulator 
NES Nuclear export sequence 
NF-κB Nuclear Factor-κappaB  
NLS Nuclear localization signal 
NMU cells Rat mammary adenocarcinoma cells 
NuMA Nuclear mitotic apparatus protein 
O-A-ADP-ribose O-acetyl-ADP-ribose 
OD Optical density 
PAR Poly-ADP-ribose 
PAR-4/PAWR Prostate apoptosis response 4 
PARG Poly-ADP-ribose-glycohydrolase 
PARP Poly-ADP-ribose-polymerase 
PBZ Poly-ADP-ribose binding zinc-finger 
PCNA Proliferating cell nuclear antigen 
PDGF Platelet-derived growth factor 
PDI Protein disulfide isomerase 
PEPCK Phosphoenolpyruvate carboxykinase 
PERK PKR-like ER kinase  
PI Propidium iodide 
PI3K Phosphoinositide 3-kinase 
PJ34 N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N dimethylacetamide HCl 
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PKR Double-stranded RNA-dependent protein kinase 
PLC Phospholipase C  
PNKP  Polynucleotide kinase/phosphatase 
PRD PARP regulatory domain 
PS Phosphatidylserine 
PTM Post-translational modification 
r Rat  
Ran Ras-related nuclear protein 
RAP80 Receptor-associated protein 80 
RNA Ribonucleic acid 
RNP Ribonucleoprotein 
Rpm Revolutions per minute 
RRM RNA-binding/recognition motif 
S1P Site-1 protease  
S2P Site-2 protease 
SAM Sterile alpha motif 
SAP SAF/Acinus/PIAS-DNA-binding domain 
SD Standard deviation 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEB Staphylococcal enterotoxin B 
SEM Standard error of the mean 
SGs Stress-granules 
siRNA Small interfering RNA  
Sirtuin or SIRT Silent information regulator SIR2-like protein 
SMCs Smooth muscle cells 
SOD1 Superoxide dismutase 
STAT1β Signal transducer and activator of transcription 1 isoform β 
STAT6 Signal Transducer and Activator of Transcription 6 
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SubA Sub AB subunit A 
SubAB Subtilase cytotoxin 
TAB182 Tankyrase-binding protein 182 kDa 
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TEP1 Telomerase-associated protein 
TiPARP TCDD-inducible PARP 
Tm Melting temperature 
TMD Trans-membrane domain 
TNF Tumor necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
TRF1 Telomeric repeat binding factor 1 
UIM Ubiquitin interaction motif 
UPR Unfolded protein response 
v/v Volume/volume 
VEEV Venezuelan equine encephalitis virus 
VIT Vault protein inter-alpha-trypsin 
vWA Von Willebrand type A 
w/v Weight/volume 
WB Western Blotting 
WGA Wheat germ agglutinin 
wt Wild-type 
XBP1 X-box binding protein 1 
XBP1s Spliced XBP1 
XRCC1 X-ray cross complementing group 1 protein 
ZAP/ZC3HAV1 Zinc-finger Antiviral Protein 
ZF Zinc finger 
ZF/THP Zinc finger/TiPARP homologous domain 
α2M* Alpha-2-macroglobulin 
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(qRT)-PCR Quantitative real-time Polymerase Chain Reaction  
53BP1 p53 binding protein 1 
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